



UNIVERSITY OF HELSINKI



<https://helda.helsinki.fi>

Helda

Endovascular Metal Devices for the Treatment of Cerebrovascular Diseases

Zhu, Yueqi

Wiley Blackwell

2019-02-22

Zhu, Y, Zhang, H, Zhang, Y, Wu, H, Wei, L, Zhou, G, Zhang, Y, Deng, L, Cheng, Y, Li, M, Almeida Santos, H & Cui, W 2019, 'Endovascular Metal Devices for the Treatment of Cerebrovascular Diseases', *Advanced Materials*, vol. 31, no. 8, 1805452. <https://doi.org/10.1002/adma.201805452>

<http://hdl.handle.net/10138/327347>

10.1002/adma.201805452

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Advanced Materials

Endovascular Metal Devices for the Treatment of Cerebrovascular Diseases --Manuscript Draft--

Manuscript Number:	adma.201805452R1
Full Title:	Endovascular Metal Devices for the Treatment of Cerebrovascular Diseases
Article Type:	Review
Section/Category:	
Keywords:	Cerebrovascular disease; metal-based stents; biodegradable; flexible endovascular devices; drug elution
Corresponding Author:	Helder Santos, D.Sc. (Chem. Eng.) University of Helsinki Helsinki, Helsinki FINLAND
Additional Information:	
Question	Response
Please submit a plain text version of your cover letter here.	<p>Helsinki, 21 August 2018, Dr. Jos Lenders Advanced Materials, Editor</p> <p>Dear Dr. Jos,</p> <p>Please, find enclosed our revised manuscript entitled "Endovascular Metal Devices for the Treatment of Cerebrovascular Diseases" (Review, No. adma.201805452), which we hope to be considered for publication in AM.</p> <p>I would like to thank the reviewer for the very valuable and detailed comments on our manuscript. We have revised the manuscript according to the reviewer's comments, and made major revisions to the main text.</p> <p>Please, find the modified and revised parts marked with yellow color in the revised manuscript file. However, some grammar modifications have not been marked in the manuscript. We have also replied to all the questions of the reviewer, and responded to each point of the comments. These have been revised and improved along the comments.</p> <p>In additional, we have requested permissions to reproduce all the figures, except the ones we have drawn ourselves.</p> <p>We sincerely hope that our questions satisfy the reviewer's concerns.</p> <p>We believe that the readership of Advanced Materials will find this review useful and interesting, and look forward to your final approval of its publication.</p> <p>Thank You in advanced for your kind consideration!</p> <p>Sincerely, Hélder Santos</p> <hr/> <p>Associate Professor (tenure-track; Pharm. Nanotechnol.), Head of Division Head of the Division of Pharmaceutical Chemistry and Technology Head of the Nanomedicines and Biomedical Engineering Group Head of the Preclinical Drug Formulation and Analysis Group</p>

	<p>Director of Doctoral Programme in Drug Research, University of Helsinki</p> <p>Drug Research Program, Faculty of Pharmacy, University of Helsinki, Finland & Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Finland @: helder.santos@helsinki.fi</p>
Do you or any of your co-authors have a conflict of interest to declare?	No. The authors declare no conflict of interest.
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Helsinki
Corresponding Author's Secondary Institution:	
First Author:	Yueqi Zhu
First Author Secondary Information:	
Order of Authors:	Yueqi Zhu
	Hongbo Zhang
	Yiran Zhang
	Huayin Wu
	Liming Wei
	Gen Zhou
	Yuezhou Zhang
	Lianfu Deng
	Yingsheng Cheng
	Minghua Li
	Helder Santos, D.Sc. (Chem. Eng.)
	Wenguo Cui
Order of Authors Secondary Information:	
Abstract:	<p>Cerebrovascular disease involves various medical disorders that obstruct brain blood vessels or deteriorate cerebral circulation, resulting in ischemic or hemorrhagic stroke. Platinum coils with or without biological modification have become routine embolization devices in the cerebral aneurysm sac to reduce the risk of bleeding. Many intracranial stents, flow diverters and stent retrievers have been invented with uniquely designed structures. To accelerate the translation of these devices into clinical usage, an in-depth understanding of the mechanical and material performance of these metal-based devices is critical. However, considering the more distal location and tortuous anatomic characteristics of cerebral arteries, present devices still risk failing to arrive at target lesions. Consequently, more flexible endovascular devices and novel designs are under urgent demand to overcome the deficiencies of existing devices. Herein, we discuss the pros and cons of the current structural designs when these devices are applied to the treatment of diseases ranging broadly from hemorrhages to ischemic strokes, in order to encourage further development of such kind of devices and investigation of their use in the clinic. Moreover, novel biodegradable materials and drug elution techniques, and the design, safety and efficacy of personalized devices for further clinical applications in cerebral vasculature are discussed.</p>

1 DOI: 10.1002/adma. ((please add manuscript number))

2
3 **Article type:** ((Review))

4
5 **Endovascular Metal Devices for the Treatment**
6
7
8 **of Cerebrovascular Diseases**
9

10 *Yueqi Zhu[#], Hongbo Zhang[#], Yiran Zhang[#], Huayin Wu, Liming Wei, Gen Zhou,*

11
12 *Yuezhou Zhang, Lianfu Deng, Yingsheng Cheng*, Minghua Li*, Hélder A. Santos*,*

13
14 *Wenguo Cui**
15
16
17

18 Dr. Y. Zhu, Y. Zhang, L. Wei, G. Zhou, Prof. Y. Cheng and Prof. M. Li
19 Department of Radiology; Shanghai Jiao Tong University Affiliated Sixth People's
20 Hospital; No. 600, Yishan Road; Shanghai, 200233, P.R.China
21 Email: chengyingshengradio@hotmail.com, liminghuaradio@hotmail.com
22
23

24 Dr H. Zhang, Prof. L. Deng and Prof. W. Cui
25 Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases,
26 Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao
27 Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025,
28 P.R.China.
29 Email: wgcui80@hotmail.com
30
31
32

33 Dr H. Zhang and Y. Zhang
34 Department of Pharmaceutical Sciences Laboratory, Åbo Akademi University, FI-
35 00520, Finland.
36 Turku Center for Biotechnology, University of Turku and Åbo Akademi University,
37 FI-00520, Finland.
38
39

40 H. Wu
41 Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard
42 University, Cambridge MA 02138, USA
43
44

45 Prof. H. Santos
46 Drug Research Program, Division of Pharmaceutical Chemistry and Technology,
47 Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
48 Email: helder.santos@helsinki.fi
49
50

51 [#] These authors contributed equally to this work.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Cerebrovascular disease involves various medical disorders that obstruct brain blood vessels or deteriorate cerebral circulation, resulting in ischemic or hemorrhagic stroke. **Platinum** coils with or without biological modification have become routine embolization devices in the cerebral aneurysm sac to reduce the risk of bleeding. **Many** intracranial stents, flow diverters and stent retrievers have been invented with uniquely designed structures. To accelerate the translation of these devices into clinical usage, an in-depth understanding of the mechanical and material performance of these metal-based devices is critical. However, considering the more distal location and tortuous anatomic characteristics of cerebral arteries, present devices still risk failing to arrive at target lesions. Consequently, more flexible endovascular devices and novel designs are under urgent demand to overcome the deficiencies of existing devices. Herein, we discuss the pros and cons of the current structural designs when these devices are applied to **the treatment of diseases ranging broadly from hemorrhages to ischemic strokes, in order to encourage further development of such kind of devices and investigation of their use in the clinic.** Moreover, novel biodegradable materials and drug elution techniques, and the design, safety and efficacy of personalized devices for further clinical applications in cerebral vasculature are discussed.

Keywords: Cerebrovascular disease; metal-based stents; biodegradable; flexible endovascular devices; drug elution.

1. Introduction

Cerebrovascular diseases have been ranked the second leading cause of death after ischemic heart disease in a recent analysis of the burden of 135 diseases^[1]. In 2015, cerebrovascular diseases accounted for 6.2 million deaths worldwide, or 11.1 % of all deaths^[2]. Cerebrovascular diseases can damage the brain by causing changes to its blood supply, thereby depriving brain cells of the oxygen they need for survival. The pathological basis for stroke is disturbance of cerebral blood circulation, which may either be ischemic or hemorrhagic in nature. Approximately 85% of strokes are ischemic in nature, leading to infarction of the tissue supplied by the occluded vessel^[3]. Hemorrhagic stroke is mostly caused by hypertension, intracranial aneurysms due to widening and weakening of an artery, and vascular malformations such as tangled vessels. Although they account for only 13% of total strokes^[4], hemorrhagic strokes are responsible for about 40% of all stroke mortality^[5]. In the past, open surgery might be the only option for cerebrovascular diseases and was mainly considered for hemorrhage related diseases but rarely applied in acute or chronic ischemic stroke due to the high risk of mortality and morbidity from this operation.

In 1971, Serbinenko pioneered endovascular therapy by using a detachable balloon to occlude a traumatic carotid cavernous fistula^[6]. Another milestone was marked by Guglielmi's report of the neurointerventional approach for cerebrovascular disease treatment in 1991^[7]. Later on, this proof-of-concept was further commercialized into an electrolytically detachable platinum coil apparatus (GDC, Boston Scientific). At present, endovascular treatment is of utmost importance for cerebrovascular diseases due to its minimal invasiveness and largely satisfactory outcomes. The success of endovascular treatment relies heavily on the device applied since any deficiency in the device can cause serious consequences in the clinic. Compared with peripheral vascular devices, the devices used in the cerebral vasculature possess unique requirements as

1
2
3 follows: first, the materials used **must be approved for endovascular implantation** and
4
5 should not cause any bio-toxicity to neuro cells; second, the devices are required to
6
7 have excellent flexibility and mechanical performance to avoid any hemorrhaging or
8
9 ischemic complications during their delivery or release. Cerebral devices are often
10
11 introduced from the femoral artery and passed through the aortic and cervical arteries
12
13 before entering the brain vasculature; therefore, flexibility is often the first
14
15 consideration when developing a new cerebral device. Moreover, the diameter of
16
17 intracranial arteries is only several millimeters wide and these arteries often pass
18
19 through the bone channel at the skull base to form an extremely tortuous path. Although
20
21 many metal alloys, ceramics and biopolymer materials have been approved for
22
23 implantation in a human body, only a few metals or metal alloys meet the requirements
24
25 of cerebrovascular devices, including platinum, nitinol alloy, Co alloy and 316L
26
27 stainless alloy [8]. Besides liquid embolic agents such as **ethylene vinyl alcohol**
28
29 **copolymer (Onyx)**, almost all intracranial implanted devices used in clinical settings
30
31 are metal-based. Thus, the development of intracranial devices has mainly focused on
32
33 designing novel structures.
34
35
36
37
38

39 Intracranial implanted metal devices are roughly categorized into four sub-types:
40
41 embolic devices (coils), stents, flow diverting devices and stent retrievers. As embolic
42
43 devices are mostly used for aneurysm embolization, which requires excellent flexibility,
44
45 the coils are typically made of platinum and their alloys are usually precontoured into
46
47 a 2D or 3D shape to reduce the risk of aneurysm rupture during embolization^[9]. For
48
49 devices that need to provide intraluminal support, including stents, flow diverters or
50
51 stent retrievers, a high compression rate is often needed to achieve a smaller profile for
52
53 smooth delivery and good mechanical radial force is demanded to adapt to tortuous
54
55 vessel wall after releasement. **(Figure 1)** Such devices are mainly made of nitinol, Co
56
57 and 316L stainless alloys. Shape memory nitinol alloys with self-expanding properties
58
59
60
61
62
63
64
65

can be delivered via standard catheter delivery systems, while Co and 316L stainless alloys cannot expand by themselves thus need a balloon catheter to dilate.

In this review, we provide an overview of metal device usage as a minimally invasive treatment option for cerebrovascular diseases and discuss the advantages and disadvantages of their structural designs when they are applied in diseases ranging from aneurysms and acute stroke to chronic cerebral vascular stenosis.




Figure 1. Diagram for metal devices used to treat cerebral vascular diseases^[10].

2. Coil devices

2.1 Overview

Coils with either detachable or free designs were the first devices made of metal alloys to be used in clinical settings to treat cerebrovascular diseases. The most

1
2
3 commonly used metals are, in order of increasing hardness, nitinol, platinum, nickel,
4
5 iridium, and tungsten; these metals all have a proven record for patient safety and their
6
7 alloys can be used to tune the mechanical properties. To create coils for aneurysm sac
8
9 embolization, metal stock wires are precontoured into a 2D or 3D shape. In 1991, the
10
11 first reported electrolytically detachable coils by Guglielmi (GDC, Boston Scientific)
12
13 were platinum coils^[7]; however, a platinum (92%)/tungsten (8%) alloy has since
14
15 become the most popular material for coil design. Platinum-based materials are used in
16
17 a variety of medical applications, because the chemical, physical and mechanical
18
19 stability of platinum and its alloys make them ideal for permanent implantation in the
20
21 body. They are inert and do not corrode in physiological environments or cause allergic
22
23 reactions, unlike other metals such as nickel and copper. Since coils used in brain
24
25 vasculature are tiny (a few millimeters wide) and have complicated multi-dimensional
26
27 structures, only platinum and its alloys meet the requirements. Platinum rods or wires
28
29 can be produced in sizes ranging from 0.125" (3.175 mm) in diameter all the way down
30
31 to 0.001" (0.0254 mm)^[11], while other metal alloys, such as Nitinol alloy, cannot be
32
33 made into such tiny diameters while maintaining a similar mechanical strength. Another
34
35 benefit of platinum is its radiopacity; being clearly visible in X-ray images is useful for
36
37 coil insertion, adjustment or detachment during operation. Intracranial platinum coils
38
39 are mainly used for embolization of cerebrovascular diseases such as aneurysms and
40
41 arteriovenous fistulas. Because of the fragile nature of vessel walls under disease
42
43 conditions and the tortuous shape of brain arteries, the embolic system must be soft and
44
45 flexible enough to conform to the size and shape of the aneurysm sac yet minimize
46
47 increases in intraluminal pressure to avoid aneurysm rupture. Meanwhile, the coil
48
49 device should also have enough stiffness, acceptable packing density and a reasonable
50
51 three-dimensional architecture to resist stress caused by blood flow, which may cause
52
53 recanalization after embolism. Furthermore, the surface of the coil device should resist
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 to clotting within the aneurysm sac during the initial adjustment period and have good
4
5 biocompatibility for permanent implantation.
6

7
8 The platinum coil's configuration determines its ability to form a basket in the
9
10 aneurysm sac and its packability, which can be predicted from its primary, secondary
11
12 and tertiary structures. The primary structure is the "stock" wire with a diameter (D_1)
13
14 that is usually between 0.00175 and 0.003 inch. It is wound around a mandrel to create
15
16 the coiled secondary structure, which may vary in size along its length. The secondary
17
18 structure diameter, D_2 , can range from approximately 0.010 inch to 0.015 inch^[8b].
19
20 Finally, the secondary structure can be shaped into tertiary configurations, such as
21
22 helices, spheres, and complex or irregular 3D structures, described by a particular loop
23
24 diameter (D_3) and length (L).
25
26

27
28 In the clinic, the coil stiffness and configuration are two fundamental considerations
29
30 for coil selection from among the commercially available systems. During an
31
32 embolization procedure, coils will be inserted until the aneurysm sac is sufficiently
33
34 occluded; operators choose specific stiffnesses and configurations of coils to perform
35
36 framing, packing and wind up. Stiffness is a critical determinant of a coil's mechanical
37
38 strength and is directly related to the material properties as well as the coil structure.
39
40 The metal strength is described by the shear modulus (G) of the stock wire (Equation
41
42 1), defined as the ratio of the shear stress to the shear strain^[8b], which describes the
43
44 coefficient of elasticity under a shearing force. A thinner stock wire diameter (D_1) will
45
46 make a softer coil while the secondary structure diameter (D_2) and the spacing between
47
48 turns influence both stiffness and packing. Lastly, the tertiary parameters (D_3 and L)
49
50 are key determinants of the entire system's effective stiffness and commercial products
51
52 are often differentiated at this level. Since a softer coil will demonstrate improved
53
54 placement in an aneurysm, the coils are typically sold as "soft," "supersoft" and
55
56
57
58 "ultrasoft".
59
60
61
62
63
64
65


$$k = \frac{D_1^4 G}{8D_2^3 n} = \text{Stiffness} \propto \frac{D_1 G}{D_2 n}.$$

Equation 1. Coil stiffness equation

Complex or spherical coils with a 3D structure are the most frequently selected as the first coil to construct a frame to allow further insertion of embolization coils. The 3D framing coils can be divided into stable and unstable shapes. A 3D coil with a stable shape will keep its precontoured shape inside the aneurysm sac to allow more coils to be inserted in the future. Commercially available examples of such coils include the Guglielmi detachable coil (GDC) 3D (Stryker), Orbit (Codman Neurovascular), Micrus Presidio (Codman Neurovascular) and Target 360 (Stryker) coils. A 3D coil with an unstable shape has better flexibility and its precontoured 3D shape can be adjusted to irregular sacs, as demonstrated by products such as Cosmos (MicroVention/Terumo, Inc.; Aliso Viejo, Calif), Axium (Covidien/ev3) and Target nano 360 (Stryker) coils. The Target Nano (Stryker), Delta Plush (Codman Neurovascular) and Axium Prime (Covidien/ev3) are 2D coils with a helical shape that are primarily used for embolization. Some ultrasoft coils with small diameters are specifically designed to perform embolization as the last or finishing coil, such as the VFC (MicroVention/Terumo), Target Nano (Stryker) and Axium Prime (Covidien/ev3). Meanwhile, many kinds of modified coils have been developed to improve embolism outcomes by promoting blood coagulation or by enabling increased packing densities; these include polyglycolic acid (PGA)-core coils, polylactic-co-glycolic acid (PLGA) coated coils, coils with PGLA or nylon fibers attached or expandable hydrogel coils, which are also called “bioactive coils”^[8b] (**Figure 2**) (**Table 1**).

To perform an embolism treatment, a coil is delivered through the lumen of a microcatheter to the target lesion via a push wire. There are many kinds of microcatheters that can be used for coil system delivery. Typically, they have inner lumen diameters between 0.015-0.027 inches. However, a larger lumen diameter of

1
2
3 microcatheter does not always mean that the coil will pass through more smoothly. In
4 fact, a mis-matched bigger catheter lumen is likely to cause the pre-shaped coil to
5 buckle, therefore preventing the pushing force from being transmitted along its axis.
6
7
8
9 **This may increase friction between the coil and the catheter wall, and cause**
10 **uncontrollable coiling within the aneurysm.** Presently available coils use three types of
11 detachment methods: 1) electrolytic detachment; 2) hydraulic detachment and 3)
12 mechanical detachment. The principle of electrolytic detachment, which was first
13 applied by Guglielmi, is to use an electric current to melt the metallic connection
14 between the coil and the delivery wire to achieve coil detachment. The primary
15 advantage of this detachment method is that the metal connection between coil and the
16 push wire makes it firm. However, sometimes electrolytic detachment may require
17 repeated attempts, so the detachment time can range from a few seconds to several
18 minutes. Moreover, detachment of the Guglielmi coil resulted in gas generation and
19 increased risk of clot formation^[12]. Hydraulic detachment and mechanical detachment
20 are newer methods and are superior to electrolytic detachment because there is no metal
21 at the connection between the coil and the push wire, which may not increase the
22 stiffness of the whole coil system. More importantly, the more consistent seconds-long
23 detachment time and success rate are improvements over electrolytic detachment.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



1
2
3 **Figure 2.** *Structure design of platinum coils. Two-dimensional and three-dimensional*
4 *platinum coils can be applied for aneurysm sac embolism (a) and a typical three-*
5 *dimensional platinum coil (b) configuration from a primary (1°) to secondary (2°) to*
6 *tertiary (3°) structure (c).*
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Detailed information and parameters of metal devices used in clinic for the treatment of cerebral aneurysms

Types	Commercial name	Company	Material	Sub-type	Microfilaments	Braid wire diameter	Radiopaque/Marker	Porosity (Pore size/mm ²)	Retrievability	Method of release	Indications	Occlusion rate
Bare coils	Orbit Detachable Coil System	Codman Neurovascular	Bare platinum	Complex fill, complex standard, mini complex fill, 3D/helical fill, tight distal loop helical technology	-	-	Radiopaque/proximal marker	NA	Y	Hydraulic detachment	IAs, AVMs and AVFs; peripheral embolization	79% ^[13]
	Orbit Galaxy Detachable Coil System	Codman Neurovascular	Platinum	ORBIT GALAXY Frame, 3D/Fill and XTRASOFT® helical coils	-	-	Radiopaque/proximal marker	NA	Y	Hydraulic detachment	IAs, AVMs and AVFs; peripheral embolization	74% ^[14]
	Micrus Endovascular Microcoil System	Codman Neurovascular	Platinum	Micrusphere coil	3D	-	Radiopaque/proximal marker	NA	Y	Mechanical detachment using resistive heating	IAs, AVMs and AVFs; peripheral embolization	83.2% ^[15]
	Axium Detachable Coils	Covidien/ev3	Platinum	Axium™ 3D, Axium™ 3D/Helical,	-	-	Radiopaque/proximal marker	NA	Y	Mechanical detachment	IAs, AVMs and AVF	NA
	MicroPlex® Coil System	MicroVentio n/Terumo	platinum	Cosmos® Coils, Complex Platinum Coils, VFC® Versatile Range Fill, HyperSoft® 3D Complex Coils, Helical Platinum Coils, HyperSoft® Helical Coils	-	-	Radiopaque/proximal marker	NA	Y	V Electrolytic detachment (0.75 seconds)	IAs, AVMs and AVF	NA
	MicroPlex® Advanced Coil System	MicroVentio n/Terumo	platinum	Cosmos® Advanced Coils, VFC® Versatile Range Fill Advanced Coils, 3D/HyperSoft® 3D Advanced Complex Coils, HyperSoft® Advanced Helical Coils	-	-	Radiopaque/proximal marker	NA	Y	V Electrolytic detachment (0.75 seconds)	IAs, AVMs and AVF	NA
	GDC 360° Detachable Coils	Stryker Neurovascular	platinum	GDC 3D, GDC 360, GDC Standard, GDC Soft, GDC Soft, SR, GDC UltraSoft	-	-	Radiopaque/proximal marker	NA	Y	Electrolytic detachment	IAs and neurovascular abnormalities	other 63.2% ^[16]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

	Target Detachable Coils	Stryker Neurovascular	316LVM stainless steel	Target® XL, Target® 3D, Target® 360 and Target® Nano coils	3D/helical	-	Radiopaque/proximal marker	NA	Y	Electrolytic detachment (InZone detachment)	Obstruct blood flow in the neurovascular and peripheral vessels	90% ^[17]
	Penumbra Coil 400	Penumbra, Inc.	Stretch resistant bare platinum	Complex standard, soft, J-soft, curve extra soft	3D/helical	-	Radiopaque/proximal marker	NA	Y	mechanical detachment	IAs, AVMs and AVF, peripheral vasculature	56% ^[18]
	Hydrogel Advanced Coated Coils	MicroVentio n Terumo	Platinum and polymeric hydrogel	HydroCoil®, HydroSoft®, HydroFrame® and HydroFill®	3D/helical	-	Radiopaque/proximal marker	NA	Y	Electrolytic detachment (0.75 seconds)	IAs, AVMs and AVF	77.8% ^[19]
	Matrix coil	Stryker Neurovascular	Platinum and PLGA coating	Matrix 1 coil; Matrix 2 coil	3D/helical	-	Radiopaque/proximal marker	NA	Y	Electrolytic detachment	IAs and other neurovascular abnormalities	86.7% ^[20]
	Nexus coil	Covidien/ev3	PGLA microfilament and Platinum	Nexus™ Tetrus 3D, Nexus™ Morpheus 3D, Nexus™ Multi Diameter Helix CSR™, Nexus™ supersoft and soft CSR™	3D/helical	-	Radiopaque/proximal marker	NA	Y	Mechanical detachment	IAs, AVMs and AVF	48 % ^[21]
Bioactive coils	Axium MicroFX	Covidien/ev3	PGLA, nylon fiber and Platinum	Axium™ PGLA 3D, Axium™ Helix, Axium™ nylon Helix coil	3D/helical	-	Radiopaque/proximal marker	NA	Y	Mechanical detachment	IAs, AVMs and AVF	90.6% ^[22]
	Micrus Endovascular Microcoil System	Codman Neurovascular	PGA running through the lumen of the primary platinum wind	Cerecyte								59% ^[23]
	Micrus Endovascular Microcoil System	Codman Neurovascular	Stretch-resistant PGA element and Platinum	Micrusphere, Presidio, and Cashmere three-dimensional framing coils; Deltaplus, deltamaxx filling and finishing Coils;	3D/helical	-	Radiopaque/proximal marker	NA	Y	Mechanical detachment using resistive heating	IAs, AVMs and AVFs; embolization of peripheral vasculature	83.2% ^[15]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Ultipaq and Helipaq two-
dimensional filling coils

AVF, arteriovenous fistula; AVM, arteriovenous malformation; GDC, Guglielmi Detachable Coil; PGA, polyglycolic acid; PLGA, polylactic-co-glycolic acid.

2.2 Typical coils

2.2.1 *Axium*TM coils

The *Axium*TM detachable coil system consists of a tertiary structure coil and a delivery system. The coil is constructed of a platinum/tungsten alloy primary line, a polypropylene core wire and a 316L stainless detachable zone. The coil system sizes range from the largest (25 mm) to the smallest (1.5 mm) available 3D helices. The coil design aims to balance the softness of a size “10” serial coil with the stability and volume of an “18” serial coil. All *Axium*TM coils are mechanically detached by a simple push movement that separates the link from coils’ body without any cables, boxes or batteries. This detachment method is fast and facilitates precise coil placement, both of which are especially important when treating a ruptured aneurysm.

*Axium*TM coils include bare platinum coils, PGLA microfilament coils, and nylon microfilament coils in stiffnesses from soft to super soft. In most coil sizes, various 2D helix shapes and 3D tertiary shapes are available for clinical selection. The 3D *Axium*TM has large loops which can change packing direction when they touch the aneurysm wall; this design makes the coil adapt well to irregular sacs and provides good mechanical stability for subsequent insertion of 2D coils. The *Axium*TM Prime (Super Soft) coil (44% thinner primary wire, 38% thinner stretch-resistant strands) is four times softer than the routine *Axium* bare coils, enabling the coils to better conform to the aneurysm shape and fill in open spaces. *Axium*TM MicroFXTM coils have additional overlapped nylon or PGLA microfilaments between coil loops, which are both procoagulant materials that prompt thrombosis inside the aneurysm sac to further reduce the risk of aneurysm bleeding or recurrence [22, 24]. PLGA is a bio-absorbable material and nylon is a more durable but non-absorbable material, so the overlapped design creates a more structurally sound lattice effect.

2.2.2 Target[®] coils

The Target[®] detachable coil is a new generation bare coil from the Stryker Company; it is an update from the first generation GDC coil. The Target[®] coil has a laser-ablated detachment zone that uses 82% less metal and can be detached more quickly than GDC (around 30 seconds compared with minutes). Less metal between the coil and push wire makes the connection zone shorter and softer, which minimizes microcatheter kickback and enhances stability during coiling.

The Target[®] detachable coil family includes Target[®] XL, Target[®] 3D, Target[®] 360 and Target[®] Nano coils. The Target[®] XL and 3D are used for regular embolization; the 360 is designed especially for frame building and Nano coils are optimized to be the last coil during embolization^[25]. The first 1.5 loops of the Target[®] 360° coil are 25% smaller than the specified secondary coil diameter, which allows the first few loops to roll freely within the aneurysm sac to adhere to the outer wall and leave an open center, making it suitable for further filling and neck coverage using concentric coils^[26]. The Nano[™] detachable coil is softer than most coils with a diameter <2mm and 2 times softer than normal Target ultrasoft coils. It is constructed by using a smaller primary wire and the most flexible delivery wire. The increased conformability of Nano[™] coils is designed to treat challenging, small aneurysms or residual spaces after coiling^[27]. The Nano[™] coils come in two shapes, Target[®] 360 Nano[™] coils and Target[®] Helical Nano[™] coils, with minimal sizes of only 1 mm × 2 cm and 2mm x 1cm, respectively.

2.2.3 Hydrogel Coils

Hydrogel coils were developed to improve packing density by using an expansible hydrogel that is more effective at filling the aneurysm lumen compared to bare platinum coils. Examples of hydrogel coils include the HydroCoil[®] Embolic system, the HydroSoft[®] and HydroFrame[®] Advanced Embolic coils and the HydroFill[®] Advanced Embolic coil.

The HydroCoil[®] Embolic System is the first generation of hydrogel coils. The device has a platinum coil base with a synthetic, polymeric hydrogel attached to the surface. The hydrogel swells to a nine-fold increase in volume in a physiological environment^[28].

The initial diameter of these devices is approximately 0.010 inches, which is compatible with the 0.017 inch inner diameter of microcatheters. The hydrogel coating will significantly expand after only 5 minutes, thus the HydroCoil needs to be deployed or retracted back into the microcatheter within this period of time. In blood, the hydrogel material reaches its maximum size, approximately 0.035 inches in diameter, in 20 minutes.

1
2 HydroSoft® and HydroFrame® Advanced Embolic Coils belong to the new generation
3 of the HydroCoil® Embolic System. Both of these coils have a hydrogel core inside
4 an outer platinum coil. Due to a 2D helical shape and ultra-soft stiffness, the HydroSoft®
5 coil seeks out small spaces and delivers hydrogel at the aneurysm neck to improve
6 aneurysm sac occlusion and reduce aneurysm recurrence rates as compared to bare
7 platinum coils^[29]. HydroFrame® has variable diameter loops to facilitate the formation
8 of a frame in irregularly shaped aneurysms^[30]. Hydrogel coils at the aneurysm neck are
9 more likely to increase the neck coverage than bare coils. In addition, the expanded
10 hydrogel can provide extra scaffolding to facilitate neointima formation across the neck
11 to prompt histological healing. As a result of the new design, the second-generation
12 coils need no prepping or steaming before usage and have an extended 30-minute
13 working time. Both kinds of new coil systems are compatible with 0.0165" to 0.021"
14 inner diameter microcatheters.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 The HydroFill® Advanced Embolic coil is designed for volumetric filling of aneurysm
32 sac and can reduce intra-aneurysm flow using fewer coils than bare coils^[31]. In
33 experimental aneurysms created to test the occlusion effect of HydroFill, the hydrogel
34 material swelled through the platinum coil and expanded the diameter by 20%,
35 increasing volumetric occlusion compared with a bare platinum coil^[32]. Similar to bare
36 platinum coils, HydroSoft® and HydroFrame®, a HydroFill® coil does not need to be
37 steamed prior to working and has a reasonable 10-30 minute working time for coil
38 insertion and adjustment.

49 **2.3 Clinical applications**

50
51
52 Metal coils are always the first choice in the clinic for endovascular embolization
53 of aneurysm sacs because they reduce the risk of subarachnoid hemorrhaging caused
54 by a ruptured aneurysm, a serious complication that results in a nearly 50% mortality
55 rate clinically. Comparing and analyzing the performance of different types of coils is
56
57
58
59
60
61
62
63
64
65

1
2 necessary to rationalize the choice of devices for better treatment outcomes and to
3
4 reduce complications. Meanwhile, other devices such as balloons and stents are also
5
6 widely used in conjunction with coils to facilitate and increase the coil packing rate,
7
8 reduce coil herniation and maintain parent artery patency. A thorough understanding of
9
10 the feasibility, efficacy and safety of these assisting techniques may guide the
11
12 practitioner in their treatment approach during clinical application.
13
14

15 ***2.3.1 Endovascular coiling for cerebral aneurysm***

16
17
18 The development of coils with very controlled detachment systems is crucial for their
19
20 widespread use in endovascular treatments^[7, 33]. Despite the fact that coils have also
21
22 been used successfully for cerebrovascular diseases such as direct arteriovenous fistulas,
23
24 dural arteriovenous fistulas and arteriovenous malformations, coils are most widely
25
26 used for aneurysm embolization in the clinic. The International Subarachnoid
27
28 Aneurysm Trial (ISAT) revealed that endovascular coiling treatment has a more
29
30 favorable early survival advantage as well as lower morbidity and mortality rates **than**
31
32 **surgical clipping**, which tries to cut off blood flow to the aneurysm by inserting a metal
33
34 clip **at the aneurysm neck**^[34]. Large studies from single or multiple centers showed
35
36 acceptable mortality ($\approx 2\%$) and morbidity rates (between 4% and 9%) after coiling
37
38 treatments, most of which were related to thromboembolic complications and
39
40 intraoperative rupture^[35]. Due to the development of noninvasive imaging techniques,
41
42 increasing numbers of intracranial aneurysms diagnosed before rupture are able to
43
44 receive coiling treatments. In the first prospective multicenter study, Analysis of
45
46 Treatment by Endovascular approach of Nonruptured Aneurysms (ATENA), a total of
47
48 739 coiled unruptured aneurysms yielded a technique success rate of 95.7%, technical
49
50 adverse event rate of 15.4%, 1-month morbidity rate of 1.7% and 1-month mortality
51
52 rate of 1.4%^[36]. The results of the prospective ISUIA study also indicate a better
53
54 outcome associated with coiled aneurysms^[37]. Thus, coiling for aneurysms, whether
55
56 ruptured or unruptured, is a feasible and effective **treatment option**.
57
58
59
60
61
62
63
64
65

1
2 With the development of more flexible, shaped and bio-material coated coils,
3
4 endovascular coiling treatment outcomes are consistently improving. The final
5
6 treatment outcome may depend on many factors including coil size, stiffness,
7
8 configuration, surface modification techniques and most importantly, the doctor's
9
10 experience with the principles of coil selection. Packing density, defined as the ratio of
11
12 the inserted coil volume to the total aneurysm volume, can also affect aneurysm
13
14 recurrence rate observed during angiographic follow up. To achieve a higher packing
15
16 density, the inserted coil volume, which is dependent on both coil thickness and length,
17
18 must be increased. Theoretically, thicker coils should have a higher packing density
19
20 than thinner ones of the same length^[38].

23 24 **2.3.2 Treatment outcomes using modified coils**

25
26
27 Many modified coils have been developed to increase the coil packing rate, clot
28
29 formation or inflammatory response within the aneurysm sac to promote mechanical or
30
31 histological healing of an aneurysm. Typical surface-modified coils include the
32
33 HydroCoils, Axium MicroFX, Micrus Cerecyte and Matrix coils. Modification
34
35 techniques include coating with a hydrogel or PGLA, or microfiber attachment.
36
37 Applying these techniques on bare coils can reduce the risk of aneurysm recurrence,
38
39 rebleeding, and the need for retreatment.
40
41

42
43 The HydroCoil embolic system obviously improves the packing rate in the aneurysm
44
45 lumen, 72% as compared to 32% with standard platinum coils^[39]. In the HydroCoil for
46
47 Endovascular Aneurysm Occlusion (HEAL) Study, the recurrence rate after coiling was
48
49 0% when HydroCoil represented $\geq 75\%$ of the total coil length compared with a
50
51 recurrence rate of 23% when $< 75\%$ of the length was HydroCoil ($P = .035$). Similarly,
52
53 when the final coil inserted was a HydroCoil, the recurrence rate was 11%,
54
55 considerably lower than the 29% recurrence rate when the final coil was a bare platinum coil (P
56
57 $= 0.047$)^[40]. These data suggest that HydroCoil can increase the coil packing rate to both
58
59
60
61
62
63
64
65

1
2 the aneurysm sac and the aneurysm neck to reduce recurrence. However, some concerns
3 remain when using HydroCoil at the aneurysm neck as the swelled hydrogel may
4 herniate into the parent artery and result in stenosis or occlusion. Even so, the further
5 randomized HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS)
6 trial revealed that using hydrogel coils gave an absolute 7.0% reduction in the
7 proportion of major aneurysm recurrence at 18 months after treatment (28% vs. 36%
8 for the control patients), which indicated hydrogel coils were more effective than bare
9 coils. Possible reasons for the reduction may be that hydrogel coils reduce the number
10 of coils necessary, and thus, the procedure time. In patients with recently ruptured
11 aneurysms, the hydrogel group had 8.6% fewer major angiographic recurrences than
12 the control group, suggesting improved adverse primary outcomes^[41]. The German
13 Randomized Endovascular Aneurysm Trial (GREAT) was conducted to compare
14 HydroSoft/HydroFrame coils with standard platinum coils and the results also indicated
15 higher packing densities with hydrogel coils while complication and angiographic
16 occlusion rates were the same for both two groups^[30, 42]. In the Axiom MicroFX for
17 Endovascular Repair of IntraCranial Aneurysm (AMERICA) study, 100 aneurysms
18 were treated with Axiom MicroFX Coils. The total technical success was 99%, and
19 90.6% of the aneurysms with follow-up data had Raymond grade I (complete) or II
20 (residual neck only) occlusion^[22, 43].

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Despite indications that hydrogel coils and nylon or PGLA microfilament coils should yield more favorable treatment outcomes than bare platinum coils, clinical trials have so far revealed results to the contrary. Kang et al. found that even though the mean coil volume deployed and packing density were notably higher when PGLA coils (Matrix coil, Boston Scientific) were used, the incidence of recanalization was the same as for bare coils^[44]. Similar results were also observed for Cerecyte (Micrus Endovascular, San Jose, CA, USA) coils during a 6-month angiographic follow-up^[23]. Moreover, meta-analysis on the current use of bioactive coils does not indicate any

1 overall benefit over the standard platinum coils^[45]. We believe that reasons for these
2
3 disappointing results may include: 1) only a few randomized clinical trials have been
4
5 conducted on this topic, and bias arises from the fact that aneurysms treated using
6
7 bioactive coils are mostly complex aneurysms, such as wide-necked, large, giant or
8
9 dissecting aneurysms, which are more challenging to treat than typical cases; 2) no
10
11 principle of selection for bioactive or bare coils was strictly defined and followed by
12
13 the different studies; and 3) as with bare coils, the experience level of the operators can
14
15 greatly influence the final occlusion rate of the aneurysms.
16
17
18
19

20 ***2.3.3 Balloon remodeling technical for aneurysm coiling***

21
22 For complicated cerebral aneurysms, such as wide-necked, large or giant aneurysms,
23
24 simple coil embolization often runs a risk of low coil packing rate and incomplete neck
25
26 occlusion, which is likely to result in residual neck/sac or aneurysm recanalization. An
27
28 increased packing density is the key to increasing the healing rate of complicated
29
30 cerebral aneurysms. Balloon deployment in the parent artery increases metal packing
31
32 density to avoid recanalization caused by blood flow and can also help seal or remodel
33
34 the aneurysm neck shape to prevent coil protrusion or herniation back into the parent
35
36 artery.
37
38
39

40
41 The balloon remodeling technique entails the temporary inflation of a balloon
42
43 catheter during the coiling procedure. The balloon is placed in front of the aneurysm
44
45 neck to prevent protrusion and herniation back into the parent artery and is removed at
46
47 the end of the procedure so no device is left in the vessel^[46]. The most popular balloon
48
49 catheters for remodeling are currently the HyperGlide™/HyperForm™, which are
50
51 compatible with a 0.010-inch microguidewire, and the Transform™ and the Scepter™,
52
53 which are both compatible with a 0.014-inch microguidewire. The Scepter balloon
54
55 catheter allows the placement of a stent (LVIS JR stent) by inserting the stent through
56
57 the catheter lumen after withdrawing the guide wire^[47]. Another advantage of the
58
59
60
61
62
63
64
65

1
2 balloon remodeling technique is that the balloon can be used as a rescue tool to
3
4 temporarily occlude the parent artery if the aneurysm ruptures during coiling.
5

6
7 In the Clinical and Anatomic Results in the Treatment of Ruptured Intracranial
8
9 Aneurysms (CLARITY) study, two options for treating ruptured aneurysms,
10
11 conventional coil embolization or balloon remodeling coiling, were found to have
12
13 similar levels of safety as determined by perioperative complications and clinical
14
15 outcomes^[48]. The rates of treatment-related complications, thromboembolic events,
16
17 intraoperative rupture, and early rebleeding were not significantly different between the
18
19 two groups. Furthermore, the cumulative morbidity and mortality rates were similar
20
21 (3.8% in the remodeling group vs. 5.1% in the coil embolization group). For unruptured
22
23 aneurysms, the ATENA study found that the overall complication rate was 11.7% for
24
25 balloon remodeling coiling and 10.8% for standard coiling. Interestingly,
26
27 thromboembolic events occurred slightly more often in the standard coiling group than
28
29 in the balloon remodeling coiling group (6.2% vs. 5.4%, respectively)^[49]. This was also
30
31 reported in the meta-analysis by Shapiro et al^[50]. We estimate that the balloon
32
33 remodeling technique may make coiling in aneurysm sacs smoother and significantly
34
35 simplify the interventional manipulation, as ischemic complications are always
36
37 believed to be proportional to the total procedure time.
38
39
40
41
42
43
44

45 **3. Stent devices**

46 **3.1 Overview**

47
48
49 The tortuous course of the cerebrovasculature, especially at the siphon segment of
50
51 the internal carotid artery, can form relatively sharp spatial angles. On one hand, these
52
53 anatomic features require higher flexibility in the stent delivery system to arrive at the
54
55 target lesion site, but on the other hand, they also need enough radial force provided by
56
57
58
59
60
61
62
63
64
65

1
2 the stent to adapt to the complex arterial wall shape after release. In addition to their
3
4 typical use in the treatment of stenosis, stent assisted coiling (SAC) is an effective
5
6 combination technique to stabilize coils inside the aneurysmal sac. So far, most
7
8 clinically-available intracranial stents are bare metal stents that are made of materials
9
10 including nickel-titanium alloys (nitinol), cobalt-based alloys and medical-grade
11
12 stainless-steel alloys. A nitinol alloy is used to manufacture self-expandable stents
13
14 while cobalt-based alloys and stainless-steel alloys are used for balloon expandable
15
16 stents. Cobalt-based alloys have superior mechanical performance, such as a larger
17
18 radial force, than stainless steel.
19
20

21
22 Stent cell structures can be generally divided into three types of designs: open cell
23
24 stents, closed cell stents and half-open cell stents. Each cell in a closed cell stent is fully
25
26 enclosed by struts while open cell stents have some open-ended cells. Usually, open
27
28 cell designs are differentiated from closed cell designs based on the number and
29
30 arrangement of bridge connectors. A braided stent, such as the LVIS stent
31
32 (Microvention), is a typical closed cell stent design. Its advantages include a high
33
34 compression rate to reduce the stent profile and provide uniform radial force or dilation
35
36 against the vessel wall, however, it also comes with increased risk of stent migration
37
38 and reduced flexibility, high stent shortening rate, and difficult positioning during
39
40 deployment^[51]. Closed cell stents can also be made by laser cutting, such as Enterprise
41
42 stent (Cordis), although such designs do not have as high a compression rate. In order
43
44 to maintain sufficient flexibility, the thickness of stent struts must be reduced, which
45
46 often indicates a sacrifice of stent radial force. Because of its design, a closed-cell stent
47
48 has limited flexibility to conform to curved or irregular anatomies, which may cause
49
50 the stent to flatten or kink, resulting in incomplete stent apposition and running the risk
51
52 of higher thromboembolic complication rates^[52]. Most open or half open cell stents are
53
54 made by laser cutting. Open cell stents provide better conformability to curved vessel
55
56 walls because they are more flexible, which is beneficial for cerebrovascular
57
58
59
60
61
62
63
64
65

1
2 applications However, its struts can kink in curved vessels during deployment to cause
3
4 acute in-stent thrombosis or long term in-stent re-stenosis. The Neuroform stent
5
6 (Boston Scientific) and the Winspan stent (Boston Scientific) are common open cell
7
8 stents.
9

10
11 The delivery system is also very important, especially when the stent is used in
12
13 cerebrovascular systems, as the flexibility of the whole stent system depends largely on
14
15 the delivery system. A self-expandable nitinol alloy stent only needs a microcatheter or
16
17 delivery sheath, while cobalt-based alloy or stainless steel stents are compressed around
18
19 a balloon catheter and expanded during balloon dilation. The catheter delivery system
20
21 is more flexible than a balloon catheter. Thus, most intracranial stents use this method
22
23 to increase the chances of successfully arriving at the target: a catheter is first navigated
24
25 to the lesion and then the stent is delivered within the catheter lumen. (**Figure 3**) (**Table**
26
27 **2**)
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




Figure 3. Typical stents used in *clinical treatment* of cerebral aneurysms and intracranial atherosclerotic stenosis^[53].

Table 2. Detailed characteristics and parameters of stents used in cerebrovascular

Stent Name	Company	Material	Sub-type	Microfilaments	Diameter/mm	Length/mm	Radiopaque/Marker	Retrievable	Method of release	Compatible microcatheter/delivery system (inch)	Target vessel diameter/mm	Indications	Technique success rate
Neuroform^[54]	Stryker Neurovascular	Nitinol alloy	Neuroform 1,2,3, EZ,Atlas	Opened cell	2.5-4.5	15-30	4 radiopaque markers on proximal & distal ends	N	Self-expandable	0.027	2.0-4.5	Stent assisted coiling for wide-necked aneurysm	Deployment success rate: 79.0-85.7%; $\geq 90\%$ immediate occlusion: 73-81.3%
Wingspan^[55]	Stryker Neurovascular	Nitinol alloy	NA	Opened cell	2.5-4.5	9-20	4 radiopaque markers on proximal & distal ends	N	Self-expandable	0.031-0.042	2.0-4.5	Cerebral arteriosclerotic vascular disease	Deployment success rate:94.6-99.0%; 30-days and 1-year primary end point events (any stroke or death and ipsilateral ischemic stroke afterward):5.0-14.7% and 7.3-20.0%
Enterprise^[54a, 56]	Codman Neurovascular	Nitinol alloy	With distal tip No distal tip	Closed cell	4.5	14-37	4 radiopaque markers on proximal & distal ends/Radiopaque delivery wire marker	Resheathable from its 63%~85% deployment	Self-expandable	0.021	2.0 – 4.0	Stent assisted coiling for wide-necked aneurysm	Deployment success rate: 93.9-97.0%; $\geq 90\%$ immediate occlusion: 76.0-87.3%), Atherosclerotic stenosis (Deployment success rate:100.0%; 30-days primary end point events (any stroke or death and ipsilateral ischemic stroke afterward):3.3-10%
Leo^[57]	Balt	Nitinol alloy	Leo plus, Leo plus baby	Braided	3.5-5.5	12-75	Two longitudinal radio-opaque platinum wires	Resheathable up to its 90% deployment	Self-expandable	0.03-0.04	1.5-3.1 3.1-6.5	Stent assisted coiling for wide-necked aneurysm	Deployment success rate: 96.2-100%; $\geq 90\%$ immediate occlusion:75.0-100%
Solitaire AB^[58]	Covidien/ev3	Nitinol alloy	-	Closed cell	4-6	15-30	3 or 4 radiopaque markers on distal end and 1 on proximal end	100% retrievable	Self-expandable	0.021-0.027	2.2-6.0	Stent assisted coiling for wide-necked aneurysm	Deployment success rate: 95.9-100%; complete immediate occlusion: 48.7-59%)

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

LVIS [59]	Microvention	Nitinol alloy	LVIS and LVIS JR	Braided	3.5-5.5	17-33	4 radiopaque distal/proximal markers/ 2 radiopaque strands	Resheathable to its 80% deployment	Self-expandable	0.017-0.021	2.0-5.0	Stent assisted coiling for wide-necked aneurysm	Deployment success rate:96.8-100%; complete immediate occlusion:50.0-73.0%
Apollo [60]	MicroPort	Stainless Steel	-	Open-cell	2.5-4.0	8-23	Radiolucent/2 radiopaque markers on balloon catheter	NA	Balloon expandable	0.037-0.040	2.5-4.0	Cerebral arteriosclerotic vascular disease	Deployment success rate: 91.7%; 30-days and 1-year primary end point events (any stroke or death and ipsilateral ischemic stroke afterward):97.8% and 11.0%
Willis [10c, 61]	MicroPort	cobalt-chromium alloy	-	Open-cell	3.5-5.0	7-16	radiopaque stent body/2 radiopaque markers on balloon catheter	NA	Balloon expandable	0.045-0.050	3.5-4.5	Complicated intracranial aneurysms	Technical success for treating distal ICA and VA aneurysms can reach 97.6%; aneurysm occlusion rate 78.1%-87%

3.2 Typical stents

3.2.1 *Neuroform™ stent*

The Neuroform™ stent (Boston Scientific/Stryker) is a nitinol self-expanding intracranial device designed to prevent coil protrusion during stent-assisted coiling of intracranial wide-necked aneurysms. The open-cell design provides good flexibility and conformability. Importantly, this architecture can be expanded segmentally to promote stent anchoring and stability during coiling. The first three generations of Neuroform™ stents were pre-loaded on an enhanced stent delivery wire and sheath system, but were not flexible enough to be accessibly navigated in the tortuous brain vasculature. To improve flexibility, the Neuroform™ stent system has further undergone multiple iterations including the Neuroform™ 2, Neuroform™ 2 Treo, Neuroform™ 3, Neuroform™ EZ® and Neuroform™ Atlas stents.

The Neuroform EZ® Stent System has a 19 mm distal radiopaque tip with similar tip softness as the micro guidewire used in clinic, and it has a 45 degree pre-shape to aid in navigation. The Neuroform EZ® Stent is pre-loaded on a 0.027 inch microcatheter delivery system. The stent delivery wire is a 185 cm stainless steel, with its diameter tapers from 0.018 inch to approximately 0.010 inch at the distal tip to increase flexibility and pushability. The Neuroform™ EZ® Stent System has a simplified delivery system that can be handled by single operator and does not require delivery system exchange like the Neuroform™ 3 stent system does. The deployment failure rate of the Neuroform™ stent is only 2.3%^[62], which indicates that it is safe and effective for SAC applications. However, a delayed self-expansion phenomenon has been reported^[63] during a stent-assisted coiling procedure for a ruptured intracranial aneurysm, possibly due to the stent unfolding inside the sheath before deployment. Alternatively, failure to mechanically expand can also occur the moment the stent comes out from the sheath. Although this phenomenon is rare and not predictable,

1
2 interventionists should keep it in mind, especially for small parent arteries or any other
3
4 factors that increase the risk of unstable stent deployment. The Neuroform™ Atlas stent
5
6 is a new generation of stent with a mixed architecture of open and closed cells. The
7
8 closed cells at its proximal ends can facilitate re-cross of the microcatheter with its
9
10 lumen. Open cells designs in other segments promise more reliable stent opening at
11
12 sharp bends of the parent artery resulting in good wall apposition. Meanwhile,
13
14 alternating 8 cell and 12 structure elements can improve stent flexibility. The
15
16 Neuroform™ Atlas stent is delivered and deployed by 0.017-inch inner lumen
17
18 microcatheter and should be capable of assisting aneurysm embolism in distal, smaller
19
20 or even more tortuous vessel lumens^[64]. However, because the stent strut thickness is
21
22 greatly reduced, users should monitor it for weakness of radial force and potential lower
23
24 metal coverage rate (defined as the ratio of the surface area covered by metal to the
25
26 total surface area) in the aneurysm neck, which results in a higher risk of aneurysm
27
28 recanalization.
29
30

31 32 33 **3.2.2 Wingspan™ stent**

34
35
36 The Wingspan™ stent system (Stryker Neurovascular, Kalamazoo, Michigan) and
37
38 Gateway™ percutaneous transluminal angioplasty (PTA) balloon catheter (Stryker
39
40 Neurovascular, Kalamazoo, Michigan) were approved by the FDA in 2005 for patients
41
42 with severe intracranial atherosclerotic stenosis ($\geq 50\%$) for whom antiplatelet therapy
43
44 was not effective. To use the stent system, the Gateway™ PTA balloon catheter is first
45
46 inflated to dilate the stenotic artery, and is then followed by placement of Wingspan™
47
48 stent within the target vessel to maintain its patency after dilation^[65]. The distal tip of
49
50 Wingspan™ inner shaft is spindle-shaped, which is helpful for it to cross the target
51
52 lesion and draw it back within the deployed stent. The delivery line is covered with
53
54 hydrophilic material, while its taper changes from 2.4 F (0.8mm) distally to 3.2 F
55
56 (1.07mm) proximally to increase flexibility and safety. However, negative results about
57
58 its clinical application were reported by the Stenting vs. Aggressive Medical
59
60

1
2 Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS)
3
4 trial^[66]. Thus, additional caution should be paid to its safety and the following criteria
5
6 should be met before its intracranial insertion, according to the FDA Humanitarian
7
8 Device Exemption documentation^[67] for the Wingspan stent system: 1) patients should
9
10 have had two or more strokes even under aggressive medical management; 2) the most
11
12 recent stroke occurred more than seven days prior to planned treatment with Wingspan;
13
14 3) patients should have 70–99% stenosis due to atherosclerosis of the intracranial artery
15
16 related to the recurrent strokes; and 4) patients have made good recovery from previous
17
18 strokes and have a modified Rankin score of 3 or less prior to Wingspan treatment.
19
20 Moreover, the Wingspan stent should not be used for patients for whom the treatment
21
22 of stroke has an onset of symptoms within seven days or less of treatment, or for the
23
24 treatment of transient ischemic attacks (TIAs)^[66].

25 26 27 28 29 **3.2.3 EnterpriseTM stent**

30
31 The EnterpriseTM stent (Codman & Shurtleff) is a closed-cell, self-expanding stent
32
33 with flared ends. This design enhances stent apposition to the vessel wall, so it is
34
35 appropriate for the treatment of wide-necked intracranial aneurysms and stent-assisted
36
37 coiling procedures. The EnterpriseTM stent received FDA approval for clinical usage in
38
39 2007. So far, the Enterprise stent has been further developed into the Enterprise® 2
40
41 vascular reconstruction device. The Enterprise® 2 is more radiopaque, making it more
42
43 easily observed under fluoroscopes. The Enterprise stent system can be introduced by
44
45 a standard microcatheter and recaptured or redeployed if $\leq 70\%$ is deployed. The flared
46
47 end of the Enterprise stent promotes wall apposition and conformability, as well as
48
49 facilitates re-access through stent. The closed-cell design improves its ability to maintain
50
51 the coil in the aneurysm and prevent it from protruding into the parent artery. Many
52
53 studies indicate that the Enterprise stent can safely treat wide-necked aneurysms^{[53k, 62,}
54
55 ^{68]}, but some reports mentioning post-procedure migration^[69] of an intracranial Enterprise
56
57 stent should also be taken into account^[69]. The delayed migration may be caused by the
58
59
60
61
62
63
64
65

1
2 lubricated polymer, the closed-cell design, differences in outward radial force between
3
4 the flared end and the stent body, or particular anatomic scenarios of posterior
5
6 circulation.
7

8 9 **3.2.4 Leo stent**

10
11 The Leo stent (Balt, Montmorency, France) was the first braided, retrievable, and
12 self-expanding stent developed for the treatment of intracranial wide-neck aneurysms.
13
14 The Leo stent body is composed of twisted nitinol wires for high radial force and
15 continuous surface coverage, and two platinum markers for visualization of both the
16 stent diameter and its length. To date, the Leo stent has two product lines: Leo plus stent
17 and Leo plus baby stent. The Leo plus stent consists of 16 braided wires to form dense
18 mesh cells to provide good coil support. The Leo plus stent is pre-loaded onto its own
19 delivery wire. Also, it is resheathable up to 90% of its deployment length, and thus, can
20 be easily repositioned. Two helical markers running down the entire body of Leo plus
21 stent make the full stent visible under fluoroscopy. The end of the stent is a rounded
22 short flare similar to the Enterprise stent, which ensures smooth wall apposition and
23 easy navigation. The Leo plus baby stent is also a self-expanding and braided stent with
24 radiopaque markers on its two ends, but it has three additional radiopaque tantalum
25 threads in the body. The Leo plus baby stent is compatible with a low profile
26 microcatheter (0.017 inch) that allows the stent to gain access to vessels down to a
27 diameter of 2 mm. However, in wider arterial lumens, the braided structure design
28 decreases radial force compared to the Neurform Atlas stent and it is not suitable for
29 deployment in tortuous arteries.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **3.2.5 Solitaire AB stent**

52
53 The Solitaire stent (EV3) is the only nitinol and self-expanding stent designed
54 with an open slit along the axis and closed cells that is fully retrievable for stent-assisted
55 coiling of wide-neck aneurysms and for retrieving clots from occluded blood vessels in
56
57
58
59
60
61
62
63
64
65

1 the brain. This stent is delivered through a standard 0.021 or 0.027 inch microcatheter
2 using a 0.016 inch pushwire. The Solitaire stent allows for multiple retrievals and
3
4 adjustment after full deployment, just like detachable coil manipulation. It can be
5
6 electrolytically detached after deployment. When not detached, Solitaire stent can be
7
8 safely held or placed without risk of migration during coil placement or balloon use.
9
10 There are 3 or 4 radiopaque markers on the distal end of the stent and one marker on
11
12 the proximal end for increased visibility. The overlapping curled design increases stent
13
14 softness and allows the stent to expand in larger vessels and compress in smaller vessels
15
16 during deployment. There is a non-working length between the working length and the
17
18 proximal marker to facilitate stent retrieval, but this design makes the microcatheter re-
19
20 cross the stent lumen or double stent overlapping deployment becomes difficult. A
21
22 0.021-inch microcatheter is suitable for a stent with 4 mm diameter and 0.027-inch for
23
24 a stent with a 6 mm diameter. The overlapping, highly flexible and retrievable structure
25
26 are reasons why the Solitaire stent has been applied to a diverse range of stent
27
28 techniques. Besides the normal single-stent assisted coiling technique, Y-stenting and
29
30 Kiss-stenting coiling techniques are also frequently employed using the Solitaire stent.
31
32 One general limitation of the Solitaire stent is its low metal coverage rate, which makes
33
34 it difficult to prevent coil protrusion and aneurysm neck healing^[58c, 70].
35
36
37
38
39
40

41 **3.2.6 LVIS stent**

42 The LVIS stent (Microvention) is a self-expandable, 16-wire, low-profile nitinol
43
44 braid stent that can be visualized under fluoroscopy. It is intended for use in SAC
45
46 procedures for the treatment of wide-necked and dissecting aneurysms^[71]. It has a
47
48 smaller than average cell size (0.9 mm) and approximately 23% metal coverage, which
49
50 is much higher than normal coil-assist stents, which average between 6-8% metal
51
52 coverage. The increased metal coverage provides better protection against coil
53
54 protrusion and flow diversion of the parent artery to accelerate thrombosis in the
55
56 aneurysm sac. Furthermore, the LVIS stent consists of 4 radiopaque markers on each
57
58
59
60
61
62
63
64
65

1
2 end in addition to dual helical strands, so it is easily-visualized throughout the
3
4 procedure course under X-ray. The LVIS stent is compatible with 0.021 inch
5
6 Headway® microcatheters. To improve wall apposition, conformability, and to
7
8 facilitate stent access, the end of LVIS stent is flared, a design similar to the Enterprise
9
10 and Leo stents. Meanwhile, the similarly-designed LVIS Junior has a 50% larger cell
11
12 (1.5 mm) than the standard LVIS stent, which enables it to be delivered through even
13
14 lower-profile microcatheters (0.017 inch) for parent vessels 2.0-3.5 mm in size. The
15
16 LVIS Junior is a self-expanding Nitinol 12-wire braided device with three radiopaque
17
18 tantalum threads within the body and radiopaque markers on each end of stent. The
19
20 Headway®17 advanced microcatheter and sceptor occlusion balloon catheter are both
21
22 compliant with the LVIS Junior stent. As the LVIS and LVIS JR stent both have a much
23
24 higher metal coverage rate than normal coil-assist stents, it is important to pay
25
26 additional attention during its deployment at tortuous or bifurcated arteries, as there is
27
28 a risk of in-stent thrombosis due to stent kinking or occlusion of the bifurcated arteries
29
30 if it is pushed too much.
31
32
33

34 35 **3.2.7 Apollo™ stent**

36
37
38 The Apollo stent (MicroPort) is a balloon expandable stent designed for the treatment
39
40 of intracranial artery stenosis. The support units of this open-cell stent are shaped like
41
42 sine waves and segments are connected with asymmetrical strengthening rings to
43
44 enhance radial strength and flexibility for navigating tortuous intracranial arteries. The
45
46 stent is laser-cut from medical-grade 316L stainless steel with diameters between 2.0-
47
48 4.0 mm and lengths of 8 to 23 mm. The Apollo stent has a metal coverage rate between
49
50 10.6-15.2% and strut thickness of 0.004 inch. This stent system has a 0.040 inch
51
52 maximum crossing profile and is delivered by a 0.014 inch microwire. The relatively
53
54 low pressure (6 atm) it needs to release decreases the likelihood of vessel tearing or
55
56 rupture. The greatest advantages of the Apollo stent are accurate positioning during
57
58 expansion and good visibility under fluoroscopy. However, despite many stent design
59
60
61
62
63
64
65

1
2 improvements to improve its flexibility, this stent system is still not flexible enough for
3
4 use in tortuous brain vasculature and the balloon dilation is likely to cause arterial wall
5
6 damage or occasionally artery rupture.
7

8 9 **3.2.8 WillisTM stent graft**

10
11 The Willis covered stent or stent graft is a newer stent designed for intracranial
12
13 vasculature applications, including the treatment of cerebral aneurysms or
14
15 arteriovenous fistulas^[10c, 61, 72]. It consists of 3 parts: a bare stent, an expandable
16
17 polytetrafluoroethylene (ePTFE) membrane, and a low-pressure flexible balloon
18
19 catheter. It is produced in diameters from 3 to 5 mm and in lengths from 7 to 19 mm.
20
21 This stent system is very flexible because multiple stent bodies are connected at 2
22
23 asymmetric points between the crest walls. The thin, tubular ePTFE membrane of the
24
25 stent is only 30-50 μm thick, and the balloon has 5 valves (instead of 3) to prevent it
26
27 from climbing the inner wall of the stent when withdrawing. To facilitate precise
28
29 placement, the whole body of the stent is made of a radiopaque cobalt alloy. Similar to
30
31 the Apollo stent, the balloon-expandable stent release method makes this stent system
32
33 slightly stiffer and thus it can only be used in vessels with few curves and in arterial
34
35 segments without important branches or perforators give out.
36
37
38
39
40

41 **3.3 Clinical applications**

42
43 Stent insertion can be applied directly or indirectly to the treatment of different
44
45 cerebrovascular diseases, including hemorrhagic stroke (cerebral aneurysm) and brain
46
47 ischemia (intracranial atherosclerotic stenosis). For cerebral aneurysms, bare stents are
48
49 often used as an assisting tool to increase the coil packing density. The Neuroform and
50
51 Enterprise stents are typical open-cell and closed-cell stents, respectively, with low
52
53 metal coverage, around 10%, to facilitate coiling; in contrast, the Leo and LVIS stents
54
55 are designed not only to facilitate coiling but also to improve coverage at the aneurysm
56
57 neck with around 23% metal coverage^[73]. Covered stents can directly be used to
58
59
60
61
62
63
64
65

1
2 occlude the aneurysm sac while reconstructing the diseased parent artery^[10c, 61]. For
3
4 treatment of atherosclerotic stenoses, stents can be used to remodel the target vessel to
5
6 maintain patency following balloon catheter inflation. Stents used for such procedures
7
8 include the Wingspan and Apollo stents. Stents designed to dilate atherosclerotic
9
10 stenotic arteries often require high radial force compared to stents designed for coiling
11
12 assistance, which is often deployed within normal arterial lumens^[74].
13
14

15 ***3.3.1 Stent used for aneurysm coiling assistance***

16
17
18 Stent assisted coiling (SAC) is an effective technique used in the treatment of wide-
19
20 necked complex aneurysms to stabilize coils inside the aneurysmal sac, which prevents
21
22 herniation back into the parent artery. SAC has been applied to treat a wide range of
23
24 aneurysms and it is considered a feasible technique to decrease the risk of aneurysm
25
26 recurrence. There are two major kinds of SAC techniques: jailed coiling and trans-cell
27
28 coiling. To apply the jailed coiling technique, a microcatheter is first inserted into
29
30 the aneurysm sac and then the stent is semi- or fully released to jail the microcatheter while
31
32 stent struts can seal the aneurysm neck. A great advantage of the jailed coiling technique
33
34 is that the stent can be adjusted or re-sheathed after being partially released.
35
36 Consequently, although any kind of stent can theoretically be used for this technique,
37
38 most operators prefer to use re-sheathable closed-cell stents as they may also allow for
39
40 loose jailing of the microcatheter head to enable better coiling. Frequently used jailing
41
42 stents include laser-cut stents (the Enterprise™ and the Solitaire™ stent) and braided
43
44 stents (the LVIS™ and the LEO™).
45
46
47
48

49
50 Trans-cell coiling is the earliest stent assisted technique used to increase packing in
51
52 the aneurysm sac. After the stent is deployed, the microcatheter advances into the stent
53
54 lumen and its head goes into the aneurysm sac to perform coiling. This technique is
55
56 more complicated to implement than the jailed technique, and often requires that stent
57
58 struts appose well to the vessel wall; otherwise, it is difficult for the microguidewire or
59
60
61
62
63
64
65

1
2 microcatheter to enter the aneurysm sac. In this situation, open-cell stents often perform
3
4 better than closed-cell stents, especially when the parent artery is tortuous. Open-cell
5
6 stents can cover the aneurysm neck better than closed-cell stents as they may gather
7
8 their struts at the neck of the aneurysm and conform to the vessel curvature, which
9
10 induces less vessel straightening. Open-cell stents typically used for the trans-cell
11
12 coiling technique are the Neuroform™ and Neuroform EZ™ stents. A new kind of
13
14 open-cell stent, the Neuroform™ Atlas, has also been applied for assisted embolism in
15
16 vessel lumens sized between 2-4.5 mm.
17
18
19

20
21 Despite complete occlusions occurring less frequently in stented aneurysms
22
23 immediately following the procedure, the complete occlusion rate increases to 73.4%
24
25 at the follow-up angiogram, compared to 54.0% for the no-stent group^[75]. Angiographic
26
27 recurrence occurs in 14.9% of aneurysms after stent assisted coiling compared with
28
29 33.5% for coiling-only aneurysms^[76]. Stent insertion is also likely to cause in-stent
30
31 stenosis approximately 3.5% of the time, but most are asymptomatic^[77]. However,
32
33 permanent neurological procedure-related complications occurred more often in
34
35 procedures with stents than without stents (7.4% vs. 3.8%)^[76]. Compared with the
36
37 balloon remodeling technique, other important factors have to be taken into
38
39 consideration when using a stent, especially the necessity of antiplatelet therapy, which
40
41 brings inherent risks of intracranial bleeding as well as delayed in-stent stenosis and
42
43 parent vessel occlusion. **(Figure 4)**
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




Figure 4. Two different kinds of stent-assisted coiling techniques for aneurysm treatment: jailed coiling and trans-cell coiling^[10b]

3.3.2 Covered stent for aneurysm

A more ideal approach to aneurysm treatment is to shift the treatment target from the aneurysm sac to the diseased parent artery for histological healing of aneurysm. Immediate occlusion promotes thrombus formation, which may in turn further reduce the hemorrhage rate caused by maneuvering within the aneurysm sac. Overlapping deployment of two or three bare stents and flow diverter devices can encourage flow diversion, but these devices cannot fully realize immediate occlusion of an aneurysm. Covered stents, however, can both completely occlude the aneurysm sac and keep the parent artery patent; furthermore, covered stents can greatly reduce the hemorrhage rate after treatment^[72]. Thus, covered stents may be especially suitable for the treatment of

1
2 complex aneurysms such as pseudo-aneurysms, wide aneurysms and large or giant
3 aneurysms. Until recently, the only covered stents available were coronary stents like
4 Jostent (Abbott Vascular, Redwood City, Calif) and Symbiot (Boston Scientific). In
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

complex aneurysms such as pseudo-aneurysms, wide aneurysms and large or giant aneurysms. Until recently, the only covered stents available were coronary stents like Jostent (Abbott Vascular, Redwood City, Calif) and Symbiot (Boston Scientific). In 2002, Islak et al. reported the use of a coronary covered stent to treat giant and fusiform aneurysms^[78]. In 2004, Saatci et al. reported using a coronary stent to treat twenty-five intracranial aneurysms, of which only eight patients had experienced transient endoleaks, which were all handled by post balloon dilation^[79]. No recurrence was found during angiographic follow up. However, the coronary stent system has not been widely adopted since they are very stiff, lacking in longitudinal flexibility, and challenging to navigate. Moreover, they cannot easily adapt to the extreme curves of the intracranial vasculature and can cause damage to the vessel during stent deployment. The Willis™ covered stent improves on coronary stents in different aspects for intracranial applications, including stent structure, membrane thickness and the delivery system. These improvements work together to expand the flexibility of the system and to ease its passage through the tortuous intracranial vasculature. This new kind of intracranial covered stent graft has been used for the treatment of recurrent aneurysm^[80], large or giant aneurysm^[61] and carotid-cavernous sinus fistula (CCF)^[81]. The 3-5 year angiographic follow-up revealed that 87.2% were completely occluded^[10c].

3.3.3 Stenting for atherosclerotic stenosis

Arteriosclerotic vascular disease is a specific form of arteriosclerosis where the artery wall thickens along with the invasion and accumulation of foam cells and the proliferation of intimal smooth-muscle cells. These physiological processes can cause lumen stenosis or even occlusion. In the US, according to Banerjee's statistics, acute ischemic infarctions from intracranial atherosclerotic disease account for about 9~17% of strokes each year^[82]. Balloon dilation and/or stent insertion can restructure the diseased lumen to allow sufficient blood flow for the brain tissue and prevent distal embolisms caused by plaque fall off. Sundt, et al. first reported the utility of

1 percutaneous transluminal angioplasty (PTA) in intracranial vessels in 1980. By using
2 coronary angioplasty catheters after surgical exposure of the vertebral artery at its V3
3 segment, they successfully dilated high-grade basilar artery atherosclerotic stenotic
4 lesions in two patients who had severe symptoms that were progressing despite
5 anticoagulant therapy^[83]. Since their report, PTA and stent insertion (PTAS) has been
6 applied more frequently for atherosclerotic stenosis treatment in selected patients with
7 extracranial and intracranial arteries^[84]. Since the use of a stent led to better
8 angiographic results, less chance of arterial wall dissection, distal embolism, and lower
9 restenosis rate, stent insertion is gradually considered as superior to PTA alone for
10 cerebral artery stenotic diseases. Stents used in intracranial arteries are often self-
11 expanding, either closed-cell or open-cell, and they are made of various metallic
12 materials, but mainly nitinol. Most observational and retrospective single center reports
13 show positive results until the SAMMPRIS trial results were first published^[55b, 56b]. The
14 SAMMPRIS study, a randomized controlled trial (RCT), compared treatment outcomes
15 with or without stenting for patients with severe (70%–99%) symptomatic stenosis of
16 a major intracranial artery^[66]. Unfortunately, this study was aborted at an early stage
17 after only 451 of the planned 764 patients, because at 30 days, a significantly higher
18 rate of stroke and death (14.7%) was observed in the stented patients compared to the
19 patients who received aggressive medical therapy alone (5.8%). This failed study drove
20 the FDA to reduce the recommendations for Wingspan stent usage to patients who had
21 had two or more recurrent strokes despite intensive dual antiplatelet medication and
22 risk factor corrections. Meanwhile, the Vitesse Intracranial Stent Study for Ischemic
23 Stroke Therapy (VISSIT) trial, another multicenter and prospective RCT, was initiated
24 with the goal of evaluating the placement of a Pharos Vitesse balloon-expandable stent
25 to treat intracranial stenosis in patients with cerebral or retinal ischemia symptoms. This
26 study was also stopped early, after 112 of the intended 250 patients had enrolled. Again,
27 the early analysis showed a higher risk of stroke or death in the stented patients within
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 the first 30 days (24.1%) compared to those who only received medical therapy
3
4 (9.4%)^[85]. So far, there is still no significant evidence to show that intracranial stenting
5
6 is more effective than aggressive medication when it comes to preventing strokes in
7
8 patients with intracranial stenosis. However, some important criticisms of the
9
10 SAMMPRIS trial cannot be ignored, including the lack of operator experience,
11
12 treatment in an acute setting following stroke, no strict selection of patients who failed
13
14 intensive medical therapy, stroke caused by perforator occlusion instead of low
15
16 perfusion, and stenting in high-risk perforator rich areas. Further research with
17
18 improved design is required to objectively evaluate intracranial stenting for
19
20 arteriosclerotic vascular disease. In addition, procedure related complications can be
21
22 decreased by conducting the necessary systematic training. The China Angioplasty and
23
24 Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS) trial is a new
25
26 ongoing prospective multicenter RCT that overcomes the shortcomings of previous
27
28 RCTs and aims to redefine the role of stenting in selected patients with symptomatic
29
30 intracranial arterial stenosis^[86]. Intracranial PTAS may further be proven to be safe and
31
32 effective if refinements in patient and device selection or technique innovation occur in
33
34 future studies.
35
36
37
38
39
40
41

4. Flow diverter devices

4.1 Overview

42
43
44
45
46
47
48 Flow diverter devices (FDDs) are breakthrough inventions for intracranial
49
50 aneurysm treatment. The concept developed from the use of overlapping traditional
51
52 stents to obstruct cerebral aneurysms without placing any coils^[87]. Since their first
53
54 application in 2007, FDDs have evolved as endoluminal approaches in the management
55
56 of intracranial aneurysms^[53]. This relatively new method is now rapidly becoming the
57
58 first-line treatment modality for numerous complex cerebral aneurysms since large
59
60 multicenter clinical trials have yielded satisfactory results^[88]. With active development
61
62
63
64
65

1 of such devices, multiple kinds of flow diverters have been ratified for clinical use. To
2 support future device development, it is necessary to review the mechanisms that are
3 responsible for aneurysm closure, the stent design, the delivery of stents, and the stent
4 material^[89].
5
6
7

8
9 Flow diversion involves placement of a semipermeable stent to reshape the parent
10 artery and direct blood flow away from the aneurysm neck while maintaining natural
11 flow through the parent vessel. The efficacy of flow diverters greatly depends on their
12 hemodynamic diversion causing flow stasis within the aneurysm sac leading to gradual
13 thrombosis, which eventually results in occlusion of aneurysm^[90]. Computational
14 hemodynamics studies show that FDDs do attenuate the peak and mean kinetic energy
15 of blood entering the aneurysm. An overall metal coverage rate of 30-50% in FDDs can
16 reduce the maximum flow velocity at the aneurysm neck by about 80%^[91]. In some
17 cases, however, an FDD may generate varying mesh density over the aneurysm orifice
18 during deployment and create inconsistent patterns of intra-aneurysmal flow^[92]. FDDs
19 further promote thrombus formation because once activated platelets pass through the
20 mesh, they have a long residence time in the aneurysm^[93]. The stent material itself can
21 also trigger thrombus formation; small fibrin- and platelet-rich thrombi can be detected
22 at the FDD surface before any observable thrombus forms in the aneurysm^[94]. In
23 parallel, endothelial cells can creep along the FDD surface to occlude the aneurysm
24 neck over 6-12 months^[95]. However, a recent study showed that until the aneurysm is
25 completely sealed, there is a risk of the thrombus escaping out of the aneurysm with
26 blood flow^[96]. Most FDDs are comprised of microfilaments between 30 to 35 μm , and
27 their pore size typically varies between 110 to 250 μm . These characteristics allow
28 small perforators, with a diameter of 100 μm , to still provide sufficient (>55%) blood
29 flow^[97]. **(Table 3) (Figure 3)**
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 3. Detailed information and parameters of flow diverter devices used clinically for the treatment of cerebral aneurysms

Types	Commercial name	Company	Material	Sub-type	Microfilaments	Braid wire diameter	Radiopaque /Marker	Porosity (Pore size/mm ²)	Retrievability	Method of release	of Indications	Occlusion rate	
	Pipeline ^[88, 98]	Covidien/ev3	25% platinum/8% tungsten and nickel-cobalt chromium; synthetic phosphoryl choline polymer	Pipeline, Pipeline Shield	Flex,48/single layer	25400 nm	Every 4th strand is radiopaque/pipeline Resheathing and proximal delivery marker/Pipeline Flex & Shied	65-70% (0.020-0.05)	N/ Resheathable until deployed	Microcatheter	IAs	64%-96%	
	SILK ^[99]	Balt	nickel-titanium	NA	48/single layer	35 um	4 sinusoidal platinum wires	45-65% (0.014-0.063)	Resheathable until deployed	90%	Microcatheter	IAs	70%-86%
Intra-luminal	Surpass ^[53u, 94, 100]	Stryker Neurovascular	Cobalt-chromium	NA	48/72/96 single layer	25/32/36 um	12 platinum (92%) and tungsten (8%) wires	70% (0.031-0.048)	No		Microcatheter	IAs	70%-75%
	FRED ^[101]	MicroVentio n/Terumo	Nitinol	NA	16 outer/48 inner/dual-layer	56 outer/22.5 um inner	2 helical tantalum wires 4 markers each end	53-78% plus outer layer (0.049)	Resheathable until deployed	50-85%	Microcatheter	IAs	73%-87.2%
	Tubrige ^[53v, 102]	Microport	Nitinol/nickel-titanium	NA	46/62 single layer	NA	2 platinum-iridium	65-70% (0.040-0.050)	Resheathable		Microcatheter	IAs	72%-83.3%
	P64 ^[53w, 103]	Phenox	Nitinol	NA	64/single layer	NA	2 helical platinum wire 8 proximal markers	51-60% (NA)	Complete deployment and full recoverability		Microcatheter	IAs	79.6%-88%
Intra-saccular	WEB ^[104]	Sequent Medical	Platinum cored nitinol	Web, Web DL, WEB SLS	108/144/216 per layer	25.4 um (19-38 um, 2 or	3 platinum markers	0-78%, at aneurysm neck	Resheathable	0-	Electrolytic detachment	IAs and other neurovascular abnormalities. Permanently	78%-91%

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

				3 different- diameter wires used)		40%, (Variable (Maximum at 0.1))		obstruct blood flow of cerebral vessels
Luna ^[53z, 105]	NFocus Neuromedica 1	Nitinol	NA	72/ dual- layer	25 um	2 platinum markers -	Resheathable Electrolytic detachment	IAs and other neurovascular abnormalities. Permanently obstruct blood flow of cerebral vessels 77%

FRED = Flow Re-Direction Endoluminal Device; NA.= data not available; P64 = P64 low modulation device; Surpass = Surpass low diverter; WEB = Woven EndoBridge;

4.2 Typical Intra-luminal flow diverters

4.2.1 Pipeline embolization device

4.2.1.1 PED:

The pipeline embolization device (PED; ev3/Covidien, Irvine, CA, USA) is a flexible self-expanding, braided cylindrical device that consists of 48 individual strands made of 25 % platinum, 8% tungsten and 75% nickel-cobalt-chromium alloy. It comes in diameters between 2.5 to 5.0 mm, and in lengths between 10 to 35 mm. The devices have a pore size of 0.020-0.052 mm² with porosity of 65-70% at its nominal diameter^[53]. The device is loaded in a delivery sheath and delivered through a 0.027 inch microcatheter, where it is compressed and elongated to 2.5 times its nominal length. The delivery wire extends 15 mm distal to the PED and sometimes requires a clockwise turn to release the PED distal end. Forward pressure from the delivery wire allows the PED to expand and appose the vessel wall. Multiple PEDs can be telescoped over each other by delivery wire recapture after the previous PED is fully deployed. When a PED is deployed in a vessel less than 2 mm in size, the stent pores may become larger^[98]. (Figure 5)




Figure 5. Photos and schematics of fabricated stent sheets. (a) mesh of the Enterprise stent, (b) mesh of the Silk stent, (c) mesh of the Pipeline FDD, (d,e) mesh of new stent design A and B. (f) Flow velocity inside an aneurysm by CFD simulation at $T = 2.0$ and 6.0 s for control and different kinds of stents, adapted from Kojima et al^[106].

4.2.1.2 PED Flex:

Delivery and deployment of the PED Flex is the same as for the first-generation PED. However, several major modifications have been implemented in the Pipeline Flex: 1) two polytetrafluoroethylene (PTFE) flaps that can rotate 180° were added to the proximal side of the device to facilitate opening and resheathing the device when less than 90% has been deployed; 2) the laser-cut delivery wire is a noticeably stiffer hypotube than its predecessor with improved pushability and device responsiveness; 3) the distal end of the device is no longer constrained on a capture coil and thus it doesn't require any torque to release the device after an initial partial release; 4) the distal tip coil is now 0.012 inches in diameter, compared to 0.014 inches in the first generation, and has a tip angle of 55°^[98b].

The stiffer delivery wire of the PED Flex is also designed to facilitate retracting the microcatheter through the PED after deployment. However, failure to recapture the delivery wire after deployment of the device has been reported, which then requires removal of the delivery wire directly from the lumen of the device^[98c].

Robust intracranial support is required for deployment of the PED Flex. The traditionally-used Marksman microcatheter often fails to provide sufficient support for delivery, deployment or resheathing of the device, particularly in cases of tortuosity. However, the VIA27 microcatheter is reported to provide excellent support for successful PED Flex delivery during procedure^[98i]. Since the Pipeline Flex can be more precisely deployed than the first generation device, fewer devices are needed per case on average^[98b].

4.2.1.3 Pipeline Shield

The third generation Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield), is a surface modified device where a synthetic phosphorylcholine

1
2 polymer (thickness <3 nm) is covalently bonded to its strands to potentially reduce
3 thrombogenicity and the required dose of antithrombotic medication. It has a similar
4 thrombogenicity to devices like Solitaire AB (Covidien-Medtronic, Irvine, California,
5 USA) and LEO plus (Balt Extrusion, Montmorency, France) stents. The Pipeline Shield
6 was approved for clinical application in 2015^[98d]. To date, experimental research
7 has demonstrated that the Pipeline Shield reduces platelet specific thrombogenicity
8 compared with the FRED flow diverter, another device used in similar cases^[98h]. They
9 also reported a high technical success rate of device insertion (98%). The average
10 number of Pipeline Shield devices used was 1.1±0.27 devices per case, comparable to
11 the Pipeline Flex^[107]. The delivery system has not been updated from the previous
12 generation device.
13
14
15
16
17
18
19
20
21
22
23
24

25 26 **4.2.2 Silk flow diverter**

27
28 The Silk flow diverter device (Silk, Balt Extrusion, Montmorency, France) is a braided
29 device comprised of 48 nickel-titanium and 4 platinum microfilaments around 35 µm
30 each. It is a closed-cell mesh cylinder with flared ends that provides 35-55 % metal
31 coverage at its nominal diameter, with a pore size between 110 to 250 µm^[108].
32
33
34
35
36

37 The Silk delivery wire has a 9 mm distal radiopaque tip. The device is deployed via a
38 Vasco 21 (Balt Extrusion, Montmorency, France) microcatheter (0.0236 inch inner
39 diameter) by carefully applying pressure on the delivery wire. Like the PED Flex, an
40 advantage of the Silk device is that it can be resheathed and repositioned up until 90 %
41 deployment^[99c]. The successful deployment rate ranges between 75% and 96% (mean
42 88.6%)^[99b]. Silk flow diverters come in 2-5 mm diameters and 15-40 mm lengths.
43
44
45
46
47
48

49 **4.2.3 Surpass flow diverter**

50
51 The Surpass flow diverter device (Stryker Neurovascular, Fremont, CA, USA) is a
52 single-layer, self-expanding, tube-shaped, braided mesh stent. It has a porosity of 70 %
53 (metal coverage rate 30%) and high pore density of 21-32 pores/mm², with rhomboid
54 shaped pores. The device is available 2.5-5 mm in diameters and 10-35 mm in
55 lengths^[109]. Depending on the device size, the Surpass flow diverter contains different
56
57
58
59
60
61
62
63
64
65

1 numbers of strands: the 2.5 mm device has 48 strands, the 3 and 4 mm devices have 72
2 strands, and the 5 mm device has 96 strands. Twelve marker wires of platinum and
3 tungsten wires are used for radiopacity and the rest are made of cobalt-chromium
4 material. By increasing the strand number in larger devices, the pore configuration,
5 porosity and pore density are all maintained, which should reduce the requirement of
6 additional device implantation^[100]. The Surpass devices foreshorten upon deployment
7 depending on their diameter; 3 mm, 4 mm, and 5 mm diameter devices shorten by 38%
8 42% and 26%, respectively. The delivery of these devices requires a minimum
9 microcatheter inner diameter of 0.040 inches, which is larger than the Pipeline device
10 requirement of 0.027 inches. Because of its size, the Surpass device is not constrained
11 at its delivery push wire, instead its pusher accommodates a standard 0.014-inch
12 microwire. Furthermore, although deployment of the larger device is more difficult, the
13 delivery system is more stable and allows for precise device placement.
14
15
16
17
18
19
20
21
22
23
24
25

26 ***4.2.4 Flow Redirection Endoluminal Device System***

27
28
29 The flow redirection endoluminal device system (FRED; MicroVention, Tustin, CA,
30 USA) is a newer type of paired-stent flow diversion device with a closed-cell design.
31 FRED has a unique stent-in-a-stent design; the outer stent, made of 16 woven nitinol
32 wires, has a high radial force that encourages stent opening while the inner stent is
33 composed of 48 braided nitinol strands that make a low-porosity mesh and create a flow
34 diverting effect. This design means that FRED behaves much more like laser cut stents,
35 with markedly less foreshortening^[101d]. Redirection and attenuation of blood flow are
36 also improved with its 16+48 wires. Taken together, the dual-layer design may provide
37 potential advantages in scaffolding functions, stability, deliverability and occlusion of
38 aneurysms. Currently, the FRED is available in 3.5, 4.0, 4.5, 5.0, and 5.5 mm diameters
39 with a working length ranging from 7 to 56 mm.
40
41
42
43
44
45
46
47
48

49
50 The dual-layer design is localized only to the main tubular body and covers about
51 80% of its total length. The ends of the outer layer are flared approximately 3 mm on
52 each side marked by 4 radiopaque and serve as landing zones during deployment while
53 preserving side branches. An interwoven double helix of tantalum marker strands is
54 used to delineate the working length.
55
56
57
58
59
60
61
62
63
64
65

1 The FRED is contracted onto a 0.027-inch delivery push microwire with a radiopaque
2 distal tip and can be resheathed after up to 80% deployment^[101c]. A recent study
3 suggested that its higher radial force may let deployment much more easier in certain
4 cases^[101b]. However, reports have also been made of the hydrophilic coating scraping
5 off for FRED or its delivery catheter^[101a].
6
7
8
9

10 11 **4.2.5 Tubridge**

12 The Tubridge flow diverter, developed by MicroPort Medical Company (Shanghai,
13 China), is a self-expandable, low-porosity, flow-diverting mesh device with flared ends.
14 Preliminary evidence supports its clinical safety and efficacy for the treatment of
15 complex aneurysms. The size of Tubridge devices ranges from 2.5 to 6.5 mm in
16 diameter and 12 to 45 mm in length^[102].
17
18
19
20
21
22
23

24 Previous studies have reported two kinds of Tubridge devices. Large Tubridge devices
25 (diameter ≥ 3.5 mm) are braided using 62 nickel-titanium microfilaments and 2
26 platinum-iridium radiopaque microfilaments while the small Tubridge devices
27 (diameter < 3.5 mm) are a braid of 46 nitinol microfilaments and 2 platinum-iridium
28 microfilaments. Tubridge flow diverters have a metal coverage rate between 30% and
29 35% when fully deployed and are designed with a gradient in pore size, in which the
30 smallest cell is only 0.040-0.050 mm² in the middle of the device^[53v]. The flared ends
31 with lower metal coverage are designed to avoid perforator infarction and stent
32 migration during deployment.
33
34
35
36
37
38
39
40
41

42 **4.2.6 p64 Flow Modulation Device**

43 The p64 flow modulation device (Phenox, Bochum, Germany) is a fully
44 resheathable, braided tubular implant with controlled mechanical detachment. It is
45 composed of 64 nitinol wires with 2 platinum radiopaque marker wires wrapped around
46 its length. The device can be repositioned or withdrawn until obtaining a satisfactory
47 position, even after completing deployment, a significant advantage^[53w].
48
49
50
51
52
53

54 Wires of the p64 device are grouped into bundles of 8 wires at the proximal end
55 with radio-opaque 0.5-mm markers attached to the end of each bundle. The bundles are
56 attached to a slotted crown shape at the end of a 180 cm stainless steel delivery wire.
57
58
59 The crown is covered by a polymer tube which is locked to the delivery wire by a torque
60
61
62
63
64
65

1 device to prevent unexpected detachment. The device is compatible with a 0.027-inch
2 internal diameter microcatheter. The deployment of p64 is similar to traditional stent
3 release, which fully expands the device through a combination of pushing the delivery
4 wire and retrieving the microcatheter. While the p64 is available with and without a
5 distal wire, the distal wire design may increase flexibility and support during delivery
6 and deployment. The porosity of p64 is relatively low, varying from 51% to 60% at
7 nominal diameters, with a radial force similar to that of the PED Flex^[103b].

8
9
10
11
12
13
14
15 A report showed that the success rate of P64 device placement ranges from 85%-
16 98%. The stiffness of the implant and its friction within the delivery catheter are the
17 main causes of technical failure^[103a]. The P64 device is available between sizes of 2.5-
18 5 mm in diameter with 0.5 mm increment and 9-36 mm length with 3 mm increment.

22 23 **4.2.7 Thin Film Nitinol Flow-Diversion**

24
25
26 In 2009, an animal study demonstrated that pore density (number of pores/mm²),
27 rather than porosity (metal-free area/total area), was an important factor to predict the
28 efficacy of flow-diverting devices. Devices with a high pore density are thought to be
29 more effective^[110]. In contrast to other flow-diverter devices, the flow diverters based
30 on Thin Film Nitinol (TFN) technology attain a very high pore density (70 pores/mm²)
31 but maintain a similar metal coverage rate. TFN Flow-Diversion (NeuroSigma, Los
32 Angeles, California) has a cylindrical TFN micro-mesh that is attached on a laser-cut
33 nitinol stent. The TFN metal sheets are approximately 5 μm thick can be produced in
34 various patterns using techniques commonly used in the microelectronics industry. This
35 device enables high rates of aneurysm occlusion soon after implantation (2 weeks), as
36 observed in preclinical testing^[111].

37
38
39
40
41
42
43
44
45
46
47 Meanwhile, microfabricated TFN membranes show an extreme mechanical
48 bendability (up to 180°) and radial stretchability (>500%) compared with other kinds
49 of flow diverters. However, after the TFN flow-diverter is compressed into a delivery
50 catheter, the TFN membrane undergoes an extreme deformation of 400-500%, which
51 can easily cause mechanical fracture during its delivery within the microcatheter^[112].

4.3 Typical intra-saccular flow diverters

Intra-saccular flow diverter devices represent a different flow diversion approach in which the braided device redirects blood flow at the aneurysm neck after its deployment within the aneurysm sac. These devices are designed to treat bifurcation aneurysms.

4.3.1 Woven EndoBridge device

The Woven EndoBridge device (WEB, Sequent Medical, Aliso Viejo, California, USA) was first marketed in 2011. It is composed of a braided nitinol wire that holds the device in a globular shape. WEB provides a neck metal coverage between 35% and 45% and yields a “stent-like” adherence to the inside of the aneurysm sac^[104b].

The WEB device has three subtypes: the WEB Single Layer (SL) and WEB Single Layer Sphere (SLS) are both single layer devices made of braided nitinol/platinum wires while the WEB Double Layer (DL) is a mesh sphere made of two layers of braided nitinol wires. The device is available in sizes ranging from 4×3 mm and 11×9 mm, and is attached to a flexible delivery wire^[113]. Proximal, distal and/or middle radiopaque platinum markers are used to facilitate accurate positioning of the device, which is delivered through a 0.027 inch microcatheter and detached electrothermally. The device is fully retrievable.

More recently, Asnafi et al. performed a meta-analysis of 588 aneurysms (22% ruptured aneurysms) in 565 patients treated with the WEB device. Treatment failure occurred in 3% of all cases. The initial complete occlusion rate was 59%, and increased to 85% after 7 months^[104a]. Furthermore, the WEB device does not require dual antiplatelet therapy.

4.3.2 The Luna AES device

The Luna aneurysm embolization device (AES; NFocus Neuromedical, Palo Alto, California) is a self-expandable, braided ovoid device made from two layers of nitinol wire mesh. Similar to the WEB device, it is designed to disrupt flow from within the aneurysm, and similarly, there is no need for dual antiplatelet therapy. The device can also be delivered through a standard 0.027 inch inner diameter microcatheter^[53z].

4.3.3 Medina embolization device

The Medina embolization device (MED, Medtronic, Irvine, California, USA) is also designed to be an intra-saccular self-expanding flow diverter, consisting of a core wire and memory alloy outer filaments that are shaped into petals along the axis of the structure. As the device is deployed, the three-dimensional filament petal deforms to fill the aneurysm sac and ostium, creating a spherical shape basket and distributing the forces on the aneurysm wall. The MED is delivered via a smaller 0.021 inch microcatheter. During its deployment within the aneurysm sac it can be easily resheathed, redeployed and finally mechanically detached. This happens in a very similar manner as coil manipulation.

The MED potentially has the following advantages over the WEB device: 1) the delivery microcatheter has a smaller profile (0.021 inch ID for MED vs. 0.027 inch ID for WEB), which makes arrival at the target lesion and entry into the aneurysm sac easier; 2) the ability to place multiple MEDs in a Russian doll fashion or standard coils into the aneurysm is likely to cause an increase of packing density rate and earlier aneurysmal occlusion as compared to WEB device. An extremely rapid occlusion of large aneurysms has already reported in early clinical experience^[53q].

4.3.4 Neck-bridging device

The eCLIPs Bifurcation Remodelling System (eCLIPs, eVasc Neurovascular Enterprises ULC, eVasc Medical Systems Corp, Vancouver, Canada) device is a self-expanding, nickel-titanium, fully retrievable, hemi-stent. The device has a leaf segment with moveable ribs, which can immediately disrupt flow in the aneurysm, while also allowing the placement of detachable coils, thus reducing the chance of aneurysm recurrence. The high density of the leaf segment, 23%-42% metal coverage, also provides a scaffold for endothelial cell creeping and progressive neointimal growth to achieve histological repair at the aneurysm neck^[114].

4.4 Clinical applications

The safety and efficacy of flow-diverting devices have been demonstrated in several well-designed trials and numerous clinical studies. Initially, the Pipeline for Uncoilable and Failed Aneurysms (PUFS) trial prospectively assessed 108 patients with unruptured

1 large and giant wide-necked internal carotid artery aneurysms, and reported a high rate
2 of complete occlusion (78 out of 108, 73.6%) with a low 5.6% rate of major stroke or
3 neurologic death at 180 days. The technique success rate was 99%^[115]. In 2016, the 3-
4 year angiographic follow-up results from the PUFs cohort showed a progressive
5 complete aneurysm obliteration (93.4% cure rate) without delayed aneurysm
6 recanalization and/or growth^[116]. Even more recently, the five-year results of PUFs
7 trial presented a 95.2% (60/63) rate of aneurysm occlusion. Moreover, no new serious
8 device-related events or recanalization were observed^[98e]. In the International
9 Retrospective Study of PED (IntrePED) trial, the largest study on PED for cerebral
10 aneurysms, Kallmes et al. reported on the safety of PED for the treatment of 906
11 aneurysms in 793 patients, and showed that the neurologic morbidity and mortality rate
12 was 8.4%^[88]. Similarly, the prospective Aneurysm Study of Pipeline in an
13 Observational Registry (ASPIRe) reported a combined neurological
14 morbidity/mortality rate of 6.8% (13/191) for patients with unruptured cerebral
15 aneurysms treated with PED, and the complete occlusion rate was 74.8% (77/103) 8
16 months later^[117].

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Similar results are obtained with other commonly used FDDs. A multicenter
32 experience from 24 centers reported that the permanent neurologic morbidity and
33 mortality rates were 6% and 2.7%, respectively, in 186 intracranial aneurysms that
34 received a Surpass flow diverter treatment. Of these, 75% of patients had 100%
35 occlusion after a single Surpass device implant^[94]. For posterior circulation complex
36 aneurysms, a German multicenter study reported a complete aneurysm occlusion rate
37 of 66% with the Surpass flow diverter^[118].

38
39
40
41
42
43
44
45 The most recent experience of 4 Spanish centers of 157 patients treated with a SILK
46 flow-diverter device showed total morbidity and mortality rates of 9.6% (15/157) and
47 3.2% (5/157), respectively, at six months after treatment. Complete occlusion was
48 observed in 78.1% (100/128) of cases within one year of the procedure^[99b]. However,
49 it is possible that the different designs of flow-diverter devices may slightly influence
50 the rate of complications and occlusions^[119].

51
52
53
54
55
56
57 Others studies have also reported safety and efficacy experiences using off-label PED
58 for treating ruptured aneurysms^[120], aneurysms in children^[121], and small aneurysms (\leq
59
60
61
62
63
64
65

1 7 mm)^[122]. However, the indications of FDD for IA treatment need to be fully defined
2 and these kinds of devices have not yet to be shown to be beneficial for all type of
3 patients with cerebral aneurysms. The Flow Diversion in the Treatment of Intracranial
4 Aneurysm Trial (FIAT) trial, conducted in 3 Canadian hospitals, showed that a
5 significantly higher proportion of patients were dead or dependent at 3 or more months
6 when randomized to flow diversion. Based on those results, the authors concluded that
7 FFDs were not as safe and effective as they had originally hypothesized^[123]. Currently,
8 the FIAT trial continues to enroll patients for whom flow diversion appears promising.
9 Clinicians should be judicious when offering patients this novel and promising
10 treatment option. Other trials on flow diversion have already been designed^[124] since
11 further intensive research needs to be conducted to clarify its clinical efficacy in highly
12 selected patients.
13
14
15
16
17
18
19
20
21
22
23

24 **5. Thrombectomy devices**

25 **5.1 Overview**

26 **Stroke is currently** the most common cause of permanent disability and the third most
27 common cause of death in the world, and it is estimated that about 5.7 million people
28 die of strokes each year^[125]. The FDA has approved several devices **for mechanical**
29 thrombectomy to treat acute ischemic stroke (AIS), such as stent retrievers that allow
30 for mechanical thrombectomy at the site of occlusion to immediately restore blood
31 flow^[126]. As opposed to suction devices, stent retrievers are deployed inside the clot to
32 entrap it by exerting continuous radial force on the clot to embed it into the meshed
33 network, which facilitates clot retrieval. The retention force **on the clot by** the device is
34 determined by the stent struts that embed and encase the thrombus^[127]. These devices
35 combine the advantages of temporary reperfusion of the affected territory and
36 mechanical thrombectomy^[128]. The first generation of stent retriever devices (Merci)
37 was approved by FDA in 2004. Since then, the most popular stent retrievers used in
38 clinic are the Solitaire FR revascularization device (EV3 Neurovascular, Irvine,
39 California) and Trevo Provue Retrieval System (Stryker Neurovascular, Kalamazoo,
40 Michigan). Meanwhile, many other promising devices are undergoing clinical trials to
41 evaluate their performance **(Figure 3 and Table 4)**.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 4. Detailed characteristics and parameters of stent retrievers used in thrombectomies for the treatment of acute ischemia stroke

Device Name	Sub-types	Company	Material	Structure design	Micro filaments	Cell size	Diameter/mm	Length/m	Radiopaque /Marker	Radial force/(N/mm)	Retrievability	Compatible microcatheter/deliver system (inch)	Target vessel diameter/mm	Indications	Recanalization rate (TICI 2b-3)
Merci	Merci X ^[129]	Concentric Medical	Nitinol	5 helical tapered nitinol coil loops covered with platinum	0.012-0.014 inch	-	2.5-3.5 mm	Tip /Loop length 7 mm	fully visible	-	Yes	2.4 Fr	NA	AIS	
	Merci L	Concentric Medical	Nitinol	4-6 nontapering helical nitinol coil with prolene filaments	0.012-0.014 inch	-	NA	Tip /Loop length 7 mm	fully visible	-	Yes	2.4 Fr	NA	AIS	43%-69.5%
	Merci V	Concentric Medical	Nitinol	Slight distal narrowing helical nitinol coil with paolene filaments	0.012-0.014 inch	-	2.0-3.0 mm	Loop length 5-7 mm	fully visible	-	Yes	2.4 Fr	2.0–3.5	AIS	
Solitair re	Solitair e TM FR ^[130]	Medtronic	Nitinol	folded architecture of circumferentially overlapping nitinol struts	60 μm	2.6 × 4.5 mm	4-6	15-30	3-4 distal/1 proximal marker	0.0110 N/mm	Yes	0.021-0.027	2.0–4.0(FR 4 mm)/3.0–5.5(FR 6 mm)	AIS	78.3%-100%
	Solitair e TM Platinum ^[131]	Medtronic	Nitinol	with added platinum markers to provide real time procedural feedback	NA	NA	4-6	20-40	3-4 distal/3 body (every 10 mm)/1 proximal marker	NA	Yes	0.021-0.027	2.0–4.0/3.0–5.5	AIS	-
	Mindframe Capture TM LP	Medtronic	Nitinol	with proprietary cell geometry that maximizes entrapment and designed to treat occlusions in arteries of small caliber	~54 μm	~2.5 × 6.4 mm	3-4	20-30	2 gold distal/1 platinum iridium proximal marker	0.005-0.016 N/mm	Yes	0.017	2.0–3.0/2.5–4.0	AIS	-

Trevo device	Trevo provue ^[132]	Stryker	Nitinol	Closed-cell nitinol stent-like retriever with tapered distal end	NA	13.4 mm ² *	4.0	20	Fully visible with distal tip and proximal marker	0.01480 N/mm	Yes	2.4 Fr	1.5-3.5mm	AIS	80%-92%
	Trevo XP ProVue ^[133]	Stryker	Nitinol	Closed-cell nitinol stent-like retriever with tapered distal end	NA	NA	6.0	20	Fully visible with distal tip and proximal marker	0.01480 N/mm	Yes	2.4 Fr	1.5-4mm	AIS	86-91%
	Trevo baby ^[53 aj, 134]	Stryker	Nitinol	Closed-cell nitinol stent-like retriever with tapered distal end	NA	NA	3.0	20	Fully visible with distal tip and proximal marker	0.00600 N/mm	Yes	1.7 Fr	1.5-4mm	AIS	75%-85.7%
Revive	Revive SE ^[53n]	Codman Neuro	Nitinol	Closed-ended basket of nitinol stent	NA	decrease from proximal to distal (3.4 mm ² *)	4.5	30	Radiopaque tip	0.0127 N/mm	Yes	2.4 Fr	1.5-4mm	AIS	79.6%-100%
Embolic Retriever with Interlinked Cages	Embolic Retriever with Interlinked Cages ^[5 3p, 135]	Microvention	Nitinol	3-5 spherical nitinol wire cages	NA	NA	3-6	15-44	Tantalum radiopaque tip (5 mm)	0.01100-0.0185N/mm	Yes	1.7 Fr	NA	AIS	79.4%-86%

Fr = French; NA, -= data not available; * indicated that the data was measured by our lab.

5.2 Typical thrombectomy devices

5.2.1 Merci device

The Merci clot retrieval device (Concentric Medical, Mountain View, CA) is the first FDA cleared embolectomy device for removing clot in AIS patients. It achieved a 69.5% vessel recanalization rate with adjuvant intra-arterial recombinant tissue plasminogen activator (rtPA) usage^[129b]. The Merci Retrieval System includes the Merci retriever device, a microcatheter, and a balloon guide catheter.

The first generation of the nitinol retriever device (models X4, X5 and X6) is a flexible shape-memory wire with 5 helical tapered coil loops at the distal end in a corkscrew shape. The diameter of its distal loops taper from 2.7 mm to 1.1 mm. The device is covered with platinum to improve visibility under fluoroscopy. The X6 is slightly stiffer than the X5. The Merci X series are available in 2.5, 3.0 and 3.5 mm diameters and are inserted through a 2.4F Merci microcatheter^[136]. Once deployed distally to the clot, the device takes on its natural corkscrew shape to ensnare and extract the clot into the Merci balloon catheter, which is placed in the cervical segment of the internal carotid artery.

The L series and V series devices were later introduced in 2006 and 2008, respectively. The Merci second-generation L-series (L4, L5, and L6) devices were redesigned into a non-tapering helical nitinol coil with additional arched prolene filaments from the distal to the proximal end of the helix to increase clot entrapment. The cylindrical helix coil-like design enables optimal vessel wall apposition, and it is at a 90-degree angle with respect to the proximal catheter. The third generation V-series (V 2.0, V 2.5, and V 3.0) device is a hybrid design of the earlier two series. The V retrievers have a linear, non-angular design with a slight distal narrowing, but it is also covered with filaments to increase surface area to facilitate clot extraction. The device

1 is delivered through a Merci microcatheter 18L. Merci devices with a loop diameter of
2 2.0 mm are intended for more distal vessels (M2 segment of MCA), 2.5 mm for
3
4 moderately sized vessels (M1 segment of MCA, vertebral artery), and 3.0 mm for large
5
6 vessels (ICA, basilar artery)^[137].
7
8
9

10
11 One disadvantage of the Merci Retriever is that the curved loops can unwind and
12 slide through the clot rather than tightly engaging the target thrombus during pull
13 back^[138]. Despite differences in design, recanalization rates have not been reported to
14 substantially differ between generations of these retriever devices^[129b]. However,
15 according to the SWIFT and TREVO 2 trials, the Solitaire and Trevo devices
16 introduced next both achieve better blood flow recanalization than the Merci device^{[132b,}
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5.2.2 Solitaire FR device

The Solitaire stent retriever (CE marked since July 2009) is the most regularly used device in recent thrombectomy trials. The device is a laser-cut, self-expandable nitinol stent with an electrically detachable, closed cell design. It is cut from a nitinol sheet into a honeycomb pattern with constant cell dimensions of 2.6×4.5 mm. The device has a folded architecture of circumferentially overlapping struts with a longitudinal split section, which engages and pushes the clot against the vessel wall, with multiple planes of contact^[139].

Currently, four sizes of devices are available: 4 mm diameter with 15 mm or 20 mm working lengths, and 6 mm diameter with 20 mm or 30 mm working lengths. The Solitaire FR 6 mm at any length has a larger radial force than the FR 4 mm. As the working length of Solitaire FR increases, the contact area with the vessel wall also increases^[140]. In general, the working length should be at least the length of the thrombus.

This device is delivered by a 0.021 to 0.027 inch microcatheter via a 180 cm long, 0.016 inch nitinol pusher wire^[141]. The recommended vessel diameter is 2-4 mm for the $4 \times 15/4 \times 20$ mm versions, or 3-5.5 mm for the $6 \times 20/6 \times 30$ mm versions^[130a].

5.2.3 *Trevo device*

The Trevo Retriever (Stryker Neurovascular, Mountain View, CA) is a self-expanding, laser cut, hydrophilic coated, closed-cell nitinol stent-like retriever thrombectomy device which was approved in Europe in 2010. Clinical trials in US first enrolled patients in 2011^[133b].

The distal end has a 4 mm soft and floppy radiopaque tip wire that allows stable deployment and enhances fluoroscopic visualization. The distal end is tapered over a distance of 10 mm, which provides a smooth transition from the radiopaque tip to the active area, which has higher radial force; the taper facilitates release of the device into more distal and smaller vessels^[53ai]. Like other retrieval devices, this device is also deployed by unsheathing the microcatheter, leaving the device directly in the thrombus and allowing it to immediately begin expanding and incorporating into the thrombus. This passive stent opening process may help attenuate potential vascular injury. Its structural design also evenly distributes the radial force of the whole device throughout the **many stent struts along** the device length^[133b]. Flattened stent struts oriented orthogonally to the device promote clot incorporation^[142]. The device is permanently attached to a flexible 0.018-inch pusher wire that is 180 cm at the proximal end with a taper transition to 75 cm, which effectively prevents any accidental detachment while pulling back. The overall length of the Trevo device is 44 mm, with a working length of 20 mm and a diameter of 4 mm. Each Trevo device can be used in 1.5 to 3.5 mm vessels for a maximum of six retrievals^[143].

5.2.3.1 *Trevo ProVue Retriever*

The Trevo ProVue is a fully radiopaque version of the Trevo device that was released in November 2012^[53ai]. The newer generation Trevo device is also constructed of a cylindrical nitinol hypotube with wide cells oriented in a helical way. Platinum is incorporated throughout the entire retriever structure. This fully structurally radiopaque design enables the operator to visualize **strut compression in images, which reflects the progress of clot integration. Furthermore, the strut behavior may indicate the stiffness of the clot,** or whether there may have been an underlying stenosis^[144]. Like the original Trevo, this device also has a perpendicular strut orientation, which, in theory, should improve thrombus integration and extraction^[133b].

1 This device is 4 × 40 mm with a working length of 20 mm. It is recommended for
2 use in intracranial vessels with a diameter between 1.5 mm to 4 mm and the device
3 requires the use of a 0.021 inch or larger microcatheter^[141].
4
5
6

7 8 **5.2.3.2 Trevo XP ProVue Retriever** 9

10 The Trevo XP ProVue 3×20 mm device (Baby Trevo) is the newest generation of the
11 Trevo devices. It is specifically built to retrieve clots from smaller intracranial vessels
12 and has a 36 mm total length that includes a 20 mm clot capture area (working length)
13 and a 3 mm diameter.
14
15
16

17 According to the manufacturer, the Baby Trevo should have a lower radial force
18 than previous models (0.00600 N/mm compared with 0.01480 N/mm), which is
19 supposed to minimize endothelial and arterial wall damage, especially in vessels of
20 smaller caliber (≤ 3 mm)^[132c, 145]. However, clot retriever efficacy is directly
21 proportional to the radial force, so the higher radial force Solitaire device may have a
22 theoretical advantage over the Baby Trevo design by enabling immediate recanalization
23 upon deployment^[146]. An optimized platinum alignment in the device allows for more
24 efficient compression within the catheter to facilitate smooth delivery while a larger
25 cell area improves embolus integration^[144]. Bench test results showed that the Baby
26 Trevo can provide much larger cell sizes than the Trevo device when deployed in small
27 vessels. Cell size was 217% larger when deployed in a 2 mm vessel and 57% larger in
28 a 3 mm vessel than 4×20 mm Trevo device^[53aj, 134].
29
30
31
32
33
34
35
36
37
38
39
40

41 The updated design removes the distal tip and taper of the ProVue Retriever. These
42 design improvements decrease the length of the device that needs to be placed distally
43 to the clot. Its distal end is softer than that of the Solitaire FR 4×20 mm by at least 48%,
44 and the short landing zone may be beneficial while passing through or releasing
45 tortuous anatomies, vessel bifurcations or in small caliber vessels. The stent retriever is
46 fully radiopaque, with one proximal and two distal radiopaque markers to facilitate
47 accurate positioning. It can be delivered through a small 0.017 inch microcatheter^[134].
48 The device has a total length of 190 cm, and pusher wire has been narrowed to 0.015
49 inch to make it compatible with smaller microcatheters than the original device and
50 suitable for distal arteries arrival.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5.2.4 *Revive device*

The Revive device (Codman, Raynham, Massachusetts, USA) is a self-expanding, non-detachable nitinol stent for intracranial thrombectomy. The distal end of this stent has an innovative closed-ended basket with smaller cells to enhance capture of clots and large fragments.

The Revive device has various cell shapes that spiral around the longitudinal axis of the stent. Additionally, it has a high radial force and decreasing cell size from the proximal to the distal retrieval zone. The basket design is optimized for centering within the vessel lumen and preventing further distal embolization during deployment and retrieval. Once device positioned across the occlusion, the displaced clot engages with the basket and is then retracted into the guiding catheter under simultaneous aspiration.

Its narrow and tall strut design provides better penetration and engagement with clots. However, a previous study suggests that the small cell size may be the reason for weak clot engagement between the filaments^[142]. The stent only has one size (4.5 x 22 mm) and is can be delivered by 0.021 or 0.027 inch inner diameter microcatheters^[53n]. The single size design is compatible with most segments of the MCA or Vertebrobasilar artery; however, it is too small to be used in the distal ICA.

5.2.5 *Embolus Retriever with Interlinked Cages device*

The tubular design of typical stent retriever devices has a risk of clot fragmentation, migration or distal embolism. Additionally, a large contact area of metal retriever with the vessel wall may lead to endothelial injuries and/or vessel wall vasospasm during retraction^[147]. The Embolus Retriever with Interlinked Cages (ERIC, MicroVention, Tustin, California) device is a new stent retriever designed to overcome these challenges^[135]. Depending on the size, it consists of 3–5 spherical nitinol wire cages that are linked together in a linear array specifically for reducing clot fragmentation and distal emboli. Meanwhile, the limited vessel wall contact areas may reduce vascular damage.

ERIC is also designed for immediate thrombus retrieval with little or no delay, while other stent retrievers require a 3-5 minute wait for clot integration^[53p]. The device is available in sizes from 3 mm to 6 mm and the number of linked spheres range from

1 3 to 5. The available working lengths range from 15 mm to 44 mm. ERIC can be
2 delivered through a low profile 0.017 inch microcatheter regardless of the device size
3
4 used. The recanalization rate reported for ERIC is about 80% to 85%^[53p].
5
6

7 **5.3 Clinical applications**

8
9
10
11 Acute ischemic stroke is a major cause of death or disability worldwide. Intravenous
12 recombinant tissue plasminogen activator (rtPA) **treatments for occlusion of**
13 **intracranial large vessels often have** a low recanalization rate, with only 10% to 15% of
14
15 ICA occlusions and 25% to 50% of proximal MCA occlusions recanalized, and only
16
17 35% to 40% of patients achieving good clinical functional independence outcomes^[148].
18
19 Mechanical treatment approaches for acute ischemic stroke aim for fast and efficient
20
21 reperfusion with short procedure times. After placing a femoral artery sheath, a
22
23 microcatheter is then inserted into the intracranial vessels and passed through the
24
25 occlusion segment with the support of a guidewire. After using contrast injection to
26
27 confirm its arrival at the distal normal vessel lumen, mechanical thrombectomy devices
28
29 can be introduced via microcatheters, advanced to the affected artery, and then
30
31 deployed under fluoroscopic guidance. Thrombectomy can be performed with or
32
33 without proximal balloon occlusion to **reduce the risk of** distal embolization during the
34
35 procedure.
36
37
38
39
40

41
42 The first generation of thrombectomy devices approved by FDA were the Merci and
43
44 Penumbra (aspiration catheter) devices. These devices had differing mechanisms to
45
46 remove clots: (1) the Merci device is a coil-shaped retriever that can be delivered within
47
48 the microcatheter **as a wire to engage and bind the clot before being pulled back through**
49
50 **the guiding catheter along with the thrombus;** (2) the Penumbra system is a catheter
51
52 **aspiration device that applies** suction to remove the thrombus. The Interventional
53
54 Management of Stroke (IMS) III trial compared IV rtPA with mechanical
55
56 thrombectomy; 45% of the included patients received clot removal using the Merci or
57
58 Penumbra devices^[148b]. However, the results revealed **no significant differences in**
59
60
61
62
63
64
65

1
2 long-term functional outcome between IV rtPA and mechanical thrombectomy
3 treatments. Both sub-groups also had a similar mortality rate at 90 days and a similar
4 proportion of patients with symptomatic intracerebral hemorrhage. The Intra-arterial
5 Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS
6 EXPANSION) trial randomized 362 patients with acute ischemic stroke into either a
7 standard IV rtPA group (n=181) or a mechanical thrombectomy or intra-arterial therapy
8 group (n=181) within 4.5 hours of symptom onset. In this trial, no benefit of
9 endovascular therapy was observed when comparing primary outcomes (vessel
10 recanalization), survival without disability at 90 days, symptomatic intracranial
11 hemorrhage, and mortality^[149]. Thus, early trials using first-generation devices failed to
12 show any clinical benefit to acute stroke patients with regard to mortality and morbidity
13 improvement despite successful recanalization rates in the technique itself. Possible
14 reasons for the discrepancy include: 1) Merci or Penumbra devices were still not able
15 to promise a high rate of recanalization; 2) no strict image selection such as computed
16 tomographic angiography (CTA) or computed tomographic perfusion (CTP) was
17 performed to confirm large vessel occlusion or to identify areas of hyper-perfusion or
18 any collateral circulation compensation; 3) the study did not strictly follow the rule of
19 “time is brain” to select recanalization patients and did not strictly control the time from
20 symptom onset to reperfusion.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 Recently published randomized clinical trials revealed that catheter-based
44 thrombectomy using retrievable stents significantly improves therapeutic outcomes for
45 patients with large vessel occlusion compared to IV rtPA alone^[126f, 150]. The key
46 attribute for success identified in the recent clinical trials is their fast reperfusion time.
47 The time from the onset of symptoms to vessel reperfusion averaged from 4.0 hours to
48 5.5 hours. Clinical success can also be ascribed to the application of stent retriever
49 devices. In most randomized, multi-center clinical trials, the Solitaire stent was the most
50 wildly used stent. Besides the Multicenter Randomized Clinical Trial of Endovascular
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial, which
3
4 didn't specify a particular type of stent to use, the proportion of patients who receive a
5
6 thrombectomy using the Solitaire stent in the Endovascular Treatment for Small Core
7
8 and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to
9
10 Recanalization Times (ESCAPE), the Randomized Trial of Revascularization with
11
12 Solitaire FR® Device vs. Best Medical Therapy in the Treatment of Acute Stroke Due
13
14 to Anterior Circulation Large Vessel Occlusion Presenting within Eight-Hours of
15
16 Symptom Onset (REVASCAT), Solitaire™ FR With the Intention For Thrombectomy
17
18 as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) and
19
20 Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-
21
22 Arterial (EXTEND-IA) trials were 76.9%, 100%, 100% and 100% respectively. The
23
24 total thrombectomy technique success rate can reach up to 72-100% and grade 2 or 3
25
26 reperfusion of Thrombolysis in cerebral infarction (TICI) was achieved in 79.6-94.3%
27
28 of occlusions, while the symptomatic intracranial hemorrhage rate was only 0-6.4%. At
29
30 the 90-day follow up, the rate of good modified Rankin scores of 0-2 was between 53%-
31
32 71%. The TREVO device is the second most popular stent retriever device used for
33
34 thrombectomy in clinic. The Trevo versus Merci retrievers for Thrombectomy
35
36 Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2)
37
38 clinical trial revealed that the technique recanalization rate for Trevo device is 86%,
39
40 and the 90-day good outcome rate with a modified Rankin score 0-2 was 40%, with a
41
42 symptomatic intracranial hemorrhage rate of 7%, which is slightly higher than the
43
44 Solitaire stent^[133b]. The recently-published DWI or CTP Assessment with Clinical
45
46 Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing
47
48 Neurointervention with Trevo (DAWN) and The Endovascular Therapy Following
49
50 Imaging Evaluation for Ischemic Stroke (DEFUSE-3) studies found that if the clinical
51
52 symptom-infarction or hyperperfusion-infarction areas are mismatched, patients can
53
54 benefit from receiving thrombectomy treatment, which has a good (45–49%) functional
55
56
57
58
59
60
61
62
63
64
65

1 independence rate at 90 days compared with 13% to 17% in the control group, where
2
3
4 thrombectomy was performed between 6-16 or 6-24 hours after the onset of ischemic
5
6 stroke^[151]. The REVIVE SE Device is the latest marketed thrombectomy devices and
7
8 it permits a better and faster recanalization in patient with a stroke. The REVIVE SE
9
10 Device is designed to ease navigation through small diameter or tortuous intracranial
11
12 vessels. Presently, several clinical trials are still being undertaken to fully investigate
13
14 its efficacy and safety for clinical application. In 2011, Rohde et al. were the first to
15
16 report that all lesions were successfully recanalized in 10 patients with acute large
17
18 vessel occlusions who received the Revive device treatment. However, two patients had
19
20 symptomatic intracranial hemorrhage and one of them was fatal^[53n]. Overall,
21
22 thrombectomy using stent retriever devices has already evolved as a standard technical
23
24 for the treatment of acute ischemia stroke in strictly selected patients with anterior large
25
26 vessel occlusions in clinic.
27
28
29
30
31
32
33

34 **6. Biosafety for metal device insertion in cerebrovasculature**

35 **6.1 Overview**

36
37 Biosafety is one of the most important issues that needs to be fully investigated after
38
39 metal device insertion. Device related biosafety can be divided into immediate and
40
41 long-term stages based on its different insertion periods. The immediate biosafety stage
42
43 (from immediately post-insertion to a few days after) is mainly affected by the device
44
45 insertion procedure, and the typical risks include arterial wall spasms, thrombosis, distal
46
47 embolism or side branch occlusion. Chances of their occurrence greatly depend on the
48
49 inserted device's mechanical properties, including passing performance, flexibility, and
50
51 the amount of dilation in the vessel lumen. More importantly, proper device selection
52
53 by the operators will minimize the immediate risks. Generally speaking, the better the
54
55 mechanical performance of the device and the better its size matches the vessel
56
57
58
59
60
61
62
63
64
65

1
2 geometry, the less damage is caused by its delivery and insertion. Long-term biosafety
3
4 mainly depends on the body response or biocompatibility of the metal material.
5
6 Considering that metal devices have already been widely used in clinic for a long time,
7
8 their biological response has been proved stable in most cases. However, the local
9
10 disease environment may contribute to the devices' long-term biosafety.
11
12 Endothelization is a standard way to judge if the metal device has become completely
13
14 incorporated into the natural vasculature; any delayed endothelization exposes the
15
16 device surface and increases the risks of thrombosis or intima over-proliferation, which
17
18 can cause lumen restenosis^[152].
19
20

21 22 **6.1 Spasm**

23
24 Cerebral vasospasm is defined as the narrowing of the major cerebral arteries following
25
26 subarachnoid hemorrhage caused by aneurysm rupture, arteriovenous malformation
27
28 rupture, or brain tumor resection^[153]. Vasospasm is detected in 67% of patients with
29
30 subarachnoid hemorrhage (SAH) and is a major cause of morbidity and mortality^[154].
31
32 Vasospasm has a biphasic course after SAH. The acute phase typically begins 3 to 4
33
34 hours after hemorrhage begins, and often rapidly or spontaneously resolves after
35
36 hemorrhage stops. Then, the chronic phase begins 3 to 5 days later and resolves after
37
38 about 14 days, with maximum narrowing typically occurring between days 6 and 8^[155].
39
40 Besides cerebral vasospasm caused by a natural history of the disease, mechanical
41
42 stimulation caused by device insertion can induce cerebral vasospasm in intra- or extra-
43
44 cranial arteries whether or not a patient has SAH. Cerebral artery catheterization,
45
46 balloon dilation, and stent insertion, especially when stent needs to be repositioned in
47
48 the arterial lumen, are all capable of causing damage to the vessel wall that induces
49
50 vasospasm. Vasospasm caused by device insertion belongs to the acute phase of
51
52 response as it typically begins within minutes. Stent retriever devices have been
53
54 confirmed to induce severe vasospasm due to vascular injury and autopsy studies have
55
56 found pathologic inflammation reactions such as fibrin thrombi containing large
57
58
59
60
61
62
63
64
65

1 numbers of neutrophils and neutrophil invasion into the internal elastic lamina^[156].
2
3 Possible vasospasm mechanisms following SAH have already been well-studied. The
4
5 central event of vasospasm is medial vascular smooth muscle contraction caused by an
6
7 increased concentration of intracellular calcium and activated calmodulin and myosin
8
9 light chain kinase (MLCK). Catecholamines, which can be degraded by Catechol-O-
10
11 methyltransferase (COMT) were also found to promote acute vasospasm following
12
13 SAH^[157]. Furthermore, SAH leads to increased phosphorylation of endothelial nitric
14
15 oxide synthase (eNOS), an enzyme that synthesizes NO and plays a protective role
16
17 against vasospasm; phosphorylation decreases NO availability and increases
18
19 superoxide production, which may deplete residual NO even more by further reacting
20
21 to form peroxynitrite^[158]. Inflammation is often considered a factor associated with the
22
23 chronic stage of vasospasm. For example, elevated levels of matrix-metalloproteinase-
24
25 9 (MMP-9) and VEGF following an inflammation reaction are associated with
26
27 vasospasm^[159]. These results were all obtained from studies of vasospasm following
28
29 SAH; however, mechanical injury to arterial walls caused by device insertion might
30
31 induce vasospasm by different mechanisms and further investigation is needed.
32
33
34
35
36

37 Since vasospasm related to metal device implantation has a higher occurrence rate in
38
39 SAH patients, triple “H” therapy (hypertension, hypervolemia, hemodilution) is basic
40
41 conservative treatment to prevent or reduce its occurrence rate in SAH patients.
42
43 Meanwhile, intra-arterial or intravenous injection of vasodilators, like papaverine,
44
45 magnesium sulfate, erythropoietin, fasudil hydrochloride, endothelin-1 antagonists,
46
47 nitric oxide progenitors, sildenafil and nimodipine are currently employed to manage
48
49 device- and/or SAH-related vasospasm^[160]. However, for high risk vasospasm, such as
50
51 vasospasm occurring immediately after stent insertion or stent retriever push, there is a
52
53 high chance of inducing thrombosis if the vasospasm is not resolved immediately. In
54
55 these situations, balloon angioplasty may be applied^[161].
56
57
58
59
60
61
62
63
64
65

6.2 Thrombosis or thromboembolism

Thrombosis or thromboembolism related to device insertion describes the presence of a thrombus or clot that originated in the device and/or fell off into distal vessel lumen. As an exogenous transplant, metal device insertion into cerebral arteries has the problem of blood compatibility. Thus, patients are required to receive dual antiplatelet aggregation or anticoagulant therapy to reduce their risk of thrombosis or thromboembolic events. However, patients who have aspirin or clopidogrel resistance or who are in a hypercoagulable state may have a higher risk of induced thrombosis within devices.

Thrombosis or thromboembolic events can be triggered by the metallic device, or its polymer or drug coatings, varying from benign reactions to excessive inflammation and in-device thrombosis. Depending on when it occurs, thrombosis can be categorized into early (<30 days), late (>30 days) and very late (>1 year) stages, and early thromboembolic events can be further categorized into intraprocedural (during the procedure) and subacute (from the end of the procedure to 30 days thereafter)^[162]. The one-month cumulative incidence of stent thrombosis ranges from 0.4% to 5%^[163]. However, over 80.0% of angiographically confirmed thromboembolic events occur within 2 days of the procedure^[164]. After 30 days, the risk reduces for bare metal stent due to complete endothelialization within this period of time^[165].

Diabetes, chronic kidney disease, hypercoagulable status, small vessels, multiple stents, bifurcation lesions and chronic total occlusion are all potential risk factors for thromboembolic events^[166]. Device factors affecting thromboembolic event may include: 1) characteristics of the device, as its structural design might influence the risk of platelet activation after deployment. Higher metal coverage rates, closed cell designs, and balloon expandable deployment methods can increase the risk of thrombosis or thromboembolism, while lower metal coverage rates, open cell designs, and self-

1 expandable release via microcatheter may reduce the risk. Functional material drug
2 elution coatings or covering material may also increase the risk of thrombosis or
3 thromboembolism. A previous study suggested that both the polymer coating and the
4 medication it contains might influence the propensity for thrombosis^[167]. 2) Anatomic
5 characteristics of cerebral arteries, including their smaller vessel diameter, tortuous
6 shape and arterial wall injuries such as thrombus-containing lesions and dissections^[168]
7 may also increase the risk of thrombosis in the lumen of the segment implanted with a
8 device. 3) In some circumstances, device manipulation, such as using a stent retriever
9 device, can cause arterial wall damage and induce thrombosis via the extrinsic
10 coagulation pathway.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 Basic drugs including dual antiplatelet therapy and anticoagulant therapy are the
25 essential treatments to prevent thromboembolic events. Antiplatelet agents such as GP
26 IIb/IIIa inhibitors play an important role during treatment of thrombosis, as GP IIb/IIIa
27 inhibitor application, either intravenously or intraarterially, is associated with increased
28 reperfusion and decreased recurrence of stent thromboembolism. Both experimental
29 and human autopsy data have revealed that thrombi within the stent contain very little
30 fibrin and instead consist of mostly platelets^[169]. This fact provides a strong argument
31 for treatment with GP IIb/IIIa inhibitors. Some studies show the reperfusion success
32 rate can reach up to around 90% when IIb/IIIa inhibitors are used along with mechanical
33 recanalization^[170]. Moreover, the use of GP IIb/IIIa inhibitors is the only known
34 predictor that decreases the recurrence of in-stent thrombosis after an initially
35 successful recanalization treatment^[171].
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Thrombolytic drugs can directly be applied to dissolve thrombi, and urokinase and
52 rtPA are two of the most frequently used thrombolytic drugs. They are applied via
53 catheter thrombolysis during interventional procedures. However, considering the low
54 rate of fibrin in the stent thrombi, thrombolytic drugs often not very effective at
55 achieving reperfusion in this setting. Instead, mechanical recanalization is often
56
57
58
59
60
61
62
63
64
65

1
2 required and this method includes the use of guide wire mechanical fragmentation,
3 catheter suction, balloon dilation and stent retrievers. For in situ thrombosis within the
4 implanted devices, guide wire mechanical fragmentation and balloon dilation are often
5 applied, and care should be taken to avoid further damage to the arterial wall, which
6 might result in thrombus aggravation. Meanwhile, catheter suction or stent retriever
7 methods are often considered for distal vessel thromboembolism. After restoration of
8 antegrade blood flow, combination therapy with thrombolytic drugs or GP IIb/IIIa
9 inhibitors may prompt residual thrombolysis or prevent thrombus recurrence.
10
11
12
13
14
15
16
17
18
19
20
21
22

23 **6. 3 Side branch occlusions**

24
25 One of the anatomic characteristics of the cerebral artery is its multiple perforator
26 vessels or side branches. These perforator vessels or side branches are ending feeder
27 vessels and once occluded, a brain infarction is likely to occur. After metal devices
28 insertion, vessel wall contact with a high metal coverage or materials coating the
29 outside of the device (as in covered stents), arterial dissection or tearing, and thrombus
30 migration can all cause occlusion of perforator vessels or side branches leading to
31 ischemic stroke. As the metal coverage rate of a conventional stent is only 6-8%, its
32 insertion does not need to consider coverage of perforator or side branches. However,
33 for flow diverters, whose metal coverage goes up to 45-70%, and for covered stents,
34 whose coating material can cover the whole segment of stented artery, the risk of
35 occluding perforator vessels or side branches runs much higher.
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Generally, PEDs are recommended to be inserted into cerebral arteries with branches
51 or perforators. The PED device has a unique risk profile that includes occlusion of both
52 side branches and perforator vessels. Side branch occlusion has been reported at a
53 particularly high rate at the ophthalmic artery^[172]. Another study detected no immediate
54 postoperative occlusions in the 127 arterial branches covered by PEDs, and
55
56
57
58
59
60
61
62
63
64
65

1
2 angiographic follow-up (mean 10 months, range 3–34.7 months) revealed 13 (15.8%)
3
4 arterial side branches that were occluded out of 82 cases, including 2 anterior cerebral
5
6 arteries, 8 ophthalmic arteries, and 3 posterior communicating arteries. However, no
7
8 anterior choroidal artery occlusion was observed and no neurological symptoms were
9
10 experienced in patients with branch occlusions ^[173].

11
12
13 The main issue with the covered stent usage in the cerebrovasculature is the possible
14
15 blockage of side branches or perforating arteries due to the stented segment. Thus,
16
17 covered stents are mostly not considered for intracranial vessels because distal cerebral
18
19 arteries (like middle cerebral artery or basilar artery) have many perforating branches,
20
21 which means they run a high risk of ischemia after a covered stent deployment. Such
22
23 stents can, however, be successfully used to treat intracranial aneurysms located at the
24
25 ICA or VA. Another reason they are not use intracranially may be that the stiffness of
26
27 the covered stent system may not allow it to arrive at distal cerebral arteries. Instead,
28
29 for vessels at the skull, covered stents can be applied if coverage of important side
30
31 branches can be avoided. Important side branches like the anterior choroidal artery, the
32
33 posterior communicating artery, the fetal type posterior cerebral artery, the anterior and
34
35 posterior inferior cerebellar arteries and the primary trigeminal artery should not be
36
37 covered^[174]. In a previous study, covering the ophthalmic artery in one patient resulted
38
39 in acute vision loss, which might be due to insufficient compensation of lateral branches
40
41 by the ipsilateral external carotid artery^[175]. If the ophthalmic artery or posterior
42
43 communicating artery is suspected to be covered, caution is advised when performing
44
45 a balloon occlusion test at the coverage segment.
46
47
48
49
50
51
52
53

54 **6.4 Endothelization, Neointima and Restenosis**

55
56
57 Metal devices inserted into a vessel lumen, such as a stent or flow diver device, will
58
59 experience the progression of neointimal coverage and endothelization. Neointimal
60
61
62
63
64
65

1 hyperplasia refers to thickening of arterial walls due to the migration and proliferation
2 of vascular smooth muscle cells (SMCs), primarily in the media or tunica intima, before
3 endothelization completes. During endothelization, endothelial cells gradually creep
4 and cover the metal struts, which inhibits platelet and leukocyte activation and
5 maintains vascular SMCs in a nonproliferative state^[176]. Active substances in the vessel
6 such as NO and prostaglandin (PGI) are secreted by endothelial cells to regulate and
7 maintain the balance of vessel contraction and dilation, and the coagulative and
8 fibrinolytic systems, as well as control cell proliferation and inflammation reactions.
9 Thus, complete endothelization has a close relationship to biosafety with regards to
10 metal device insertion.

24 ***6.4.1 Problems of neointimal hyperplasia and restenosis***

27 If the inserted devices have a low metal coverage rate and cause little damage to the
28 vessel wall, then neointima proliferation is often mild with a quick normal
29 endothelization and will run a low risk of causing intra-luminal restenosis. However, if
30 the metal devices have a high metal coverage rate and induce severe damage to arterial
31 wall, such as endothelial cell denudation, atherosclerotic plaque disruption, arterial wall
32 dissection, and even stretching of the entire artery, then excessive neointimal
33 hyperplasia or restenosis can occur. Post angioplasty restenosis is thought to mainly be
34 caused by vascular smooth muscle cell (VSMC) migration and proliferation and
35 excessive extracellular matrix production. Other possible reasons include elastic recoil
36 of the vessel, negative remodeling or contraction, and thrombus formation at the site of
37 injury^[177]. In addition, VSMC over-proliferation and migration thickens arterial walls
38 and decreases arterial lumen space^[178]. The in-stent stenosis rate (ISR) is classified into
39 four types based on the length of restenosis compared to the stented arterial length: (i)
40 focal restenosis no more than 10 mm in length, (ii) diffuse lesions with more than 10
41 mm of restenosis within the stent, (iii) proliferative restenosis more than 10 mm in
42 length that extends outside of the stent, and (iv) occlusive lesions longer than 10 mm in
43 length.

1
2 the stent^[179]. These criteria are adopted from the coronary stent standards. Considering
3
4 that the brain vasculature has its own histological features like underdeveloped SMC in
5
6 the media and different lengths of stented arteries, ISR classifications focused on the
7
8 cerebro vasculature to be further developed.
9

10
11 Device-related restenosis or neointimal over-proliferation can be influenced by the
12
13 following factors:

14
15
16 1) Device design: features that seem to have more favorable ISR rates include open
17
18 cell structures, suitable radial force against the arterial wall, shorter device length and
19
20 fewer implanted devices. Meanwhile, stent strut design may also impact the
21
22 endothelization or intimal hyperplasia by altering the stream of blood flow (**Figure 6**).
23

24
25
26 2) Degree of the damage to the vessel wall: intraluminal stenosis related to device
27
28 insertion is a type of arterial wall healing response to arterial injury. VSMC
29
30 proliferation is closely related with rupture of the internal elastic layer. **Experimental**
31
32 **studies of RNA extraction 30 min after arterial wall injury caused by balloon dilation**
33
34 **demonstrated that as inflation pressure increases, c-fos expression, neointimal**
35
36 **formation and proliferation are stimulated**^[180].
37

38
39
40 3) Degree of neointimal proliferation: Such proliferation is proportional to the
41
42 **degree of injury**. Metal device insertion into a normal vessel often induces mild arterial
43
44 wall injury while for a severely stenotic artery, angioplasty by stent insertion often
45
46 needs to dilate the diseased artery and tear the intima, media or even the entire vessel
47
48 wall. In this situation, severe arterial wall injury often results in an aggressive repair
49
50 reaction and over proliferation of SMCs to induce stenosis.
51

52
53 4) **Inflammation reaction: Vascular inflammation, neointimal proliferation, and**
54
55 **restenotic obstruction at the stented lumen induced by endovascular treatment are the**
56
57 **result of complex interactions between vascular cells and the dysregulation of vascular**
58
59 **repair under particular pathological conditions.** Platelets, neutrophils, and monocytes
60

1 play essential roles in inflammatory response^[181]. Platelet and fibrin deposition at the
2 site of injury triggers expression of cell adhesion molecules that recruit leukocytes^[182].
3
4 Leukocytes then attach to platelets through the combination of leukocyte integrin Mac-
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 (CD11b/CD18) with platelet glycoprotein Ib-alpha^[183] or when fibrinogen binds with
platelet glycoprotein IIb/IIIa^[184]. Experimental and clinical studies have revealed that
leukocyte adhesion mediated by Mac-1 and platelets is the main mechanism that results
in vascular inflammation and restenosis after coronary stenting^[185]. Sometimes the
intensity of infiltration by the inflammatory cells can release inflammatory mediators
and cytokines such as platelet-derived growth factor (PDGF) and transforming growth
factor-b (TGF-b) to induce VSMC migration and proliferation^[186]. Previous studies
have already revealed that VSMCs or myofibroblasts in the neointimal migrate from
the media or adventitia in response to PDGF^[187].

5) Anatomic and hemodynamic factors: Considering the extremely tortuous course
of the cerebral vasculature, blood flow in the highly curved vessels often presents
complicated hemodynamic characteristics. When a metal device is inserted into a
curved vessel, the greater and lesser curvature sides of the vessel wall may have
different metal coverage rate. The lesser curvature side is more likely to have higher
metal packing or kinking, especially in open cell stents that further disturb the blood
flow. Deformation of the inserted device in a tortuous artery also makes for unequally
distributed radial force, which can cause differing extents of vessel wall injury and
vessel repair that result in stenosis. The complicated hemodynamics in curved vessels
include an asymmetrical distribution of wall shear stress which will directly affect the
process of endothelial cell coverage and neointimal hyperplasia (**Figure 7**). Previous
research indicated that in the curved vessels, the walls with greater and lesser curvature
are subjected to higher wall shear stress; thus, the creeping of endothelial cells from
adjacent normal arterial walls and the deposition of endothelial progenitor cells were
affected and delayed endothelization progress was observed^[53ag].

6) Disease of the arterial wall: Arterial wall atherosclerosis is another important factor that encourages intimal hyperplasia. The pathology of atherosclerotic plaque includes subintimal lipid deposition, proliferation of SMCs and deposition of ECM, so injury of the atherosclerotic artery caused by metal device insertion has a larger chance of resulting in over intimal hyperplasia and lumen stenosis. 7) Patients with a history of diabetes or restenosis may run a higher risk of ISR^[188]. Meanwhile, patients displaying systemic markers of inflammation, such as midkine, have a higher risk of intimal hyperplasia due to macrophage accumulation caused by stent insertion^[189].




Figure 6. Diagram of the biosafety issues for metal stents insertion into the arterial lumen and the potential solutions and future directions to reduce these risks^[190].




Figure 7. *The complicated hemodynamics in curved vessels. (A) The effect of stenting on vascular anatomy and computational fluid dynamics analysis found good correlation between low WSS areas (orange lines) and the in-stent restenosis after 14 days on histological observation. (B) Histological observation after using a covered stent to treat curved cervical artery aneurysm (a-c) showed at 6 months, endothelial cells (yellow arrows) become tightly arranged to cover the stent strut (red arrows) (B-d) or form a whirlpool in the curved segment (B-e), while at 12 months, the endothelial cells have completely matured and are arranged even more tightly (B-f)^[53ag, 191]*

6.4.2 Mechanism of neointimal hyperplasia

Molecular or genetic mechanisms related to neointimal hyperplasia or in-stent restenosis have been carefully studied since the clinical application of stent insertion. Both the MAPK and the cAMP-protein kinase A (PKA) signaling pathways have been found to inhibit intima proliferation and formation after balloon-induced injury. In particular, cAMP/PKA activation markedly inhibits VSMC proliferation^[192]. Amplifying or stimulating the cAMP/PKA pathway in VSMCs at the molecular level, such as by overexpressing the A kinase anchor protein, resulted in the activation of

cAMP-induced transcription through anchoring the PKA regulatory subunit to subcellular membranes. These biochemical reactions increase levels of p27kip1 and suppress not only VSMC growth *in vitro* but also neointimal hyperplasia *in vivo*^[193]. Meanwhile, inactivating cellular ras proteins, which are key transducers of mitogenic signals, in balloon-injured rats significantly reduced neointima formation (by approximately 55%) 14 days after balloon injury^[194]. (Figure 8a)




Figure 8. Several aspects of the vascular response to injury. (a) Molecular mechanisms of vascular smooth muscle cell proliferation and selected intracellular targets for antiproliferative strategies^[195]. (b) miRNAs expression involved in response to vascular injury. (+): induction; (-): inhibition; SMCs: smooth muscle cells; ECs: endothelial cells. (c) Schematic diagram of the VSMC cycle and its regulatory mediators^[196]. CDK: cyclin-dependent kinase; CKI: cyclin-kinase inhibitor; G1: Gap 1; G2: Gap 2; M: Mitosis; S: Synthesis.

MicroRNAs (miRNAs) also play a key role to regulate the pathophysiological processes of neointimal hyperplasia or restenosis and have largely been investigated for their potential to function as both biomarkers and therapeutic targets^[197]. Since

1 miRNAs mediate communication between endothelial cells (ECs) and vascular SMCs,
2
3
4 monocytes, pericytes, or platelets, they play an important role in modulating the
5
6 vascular response to injury. Generally, repair induced by vascular injury may result in
7
8 the upregulation of a certain group of miRNAs (such as miR-21, miR-146, miR-
9
10 221/222 and miR-424) and downregulation of another group of miRNAs (such as miR-
11
12 145, miR-143, miR-125 and miR-23b), which together regulate the apoptosis,
13
14 proliferation, migration and differentiation of both SMCs and ECs. (Figure 8b) In
15
16 humans, miR-21 is highly expressed in atherosclerotic lesions or after vascular
17
18 injury^[198]. Upregulation of miR-21 also enhances VSMC growth both *in vitro* and *in*
19
20 *vivo* after vascular injury. This effect is mediated by PTEN, a tumor suppressor that is
21
22 a direct target of miR-21. Meanwhile, the miRNA also indirectly targets Bcl-2,
23
24 indicating that it can modulate VSMC growth through different pathways^[198a]. A
25
26 similar regulation effect is seen in miR-146a when it binds the Krüppel-like factor 4
27
28 (KLF-4), which is a key transcription factor that regulates the phenotypic switch of
29
30 VSMCs: they can regulate each other^[199]. High expression of the miR-221/222 cluster
31
32 has also been found to control proliferation, migration, and apoptosis in VSMCs as well
33
34 as in ECs^[200]. Since these miRNAs target p27 and p57, their overexpression results in
35
36 excessive neointimal growth, whereas their downregulation can reduce neointima
37
38 formation by approximately 40% in a rat model^[201]. Furthermore, miR-221/222
39
40 upregulation inhibits EC proliferation by targeting the proto-oncogene c-kit.
41
42
43
44
45 Meanwhile, miR-424 exhibits a completely different way of modulating VSMC
46
47 proliferation than other miRNAs. Despite its increased levels after injury, miR-424
48
49 works by directly targeting cyclin D1 to cause a G1/S transition, and thus arresting
50
51 VSMC proliferation^[202]. The major modulators of SMC phenotype to maintain VSMC
52
53 differentiation are miR-143 and miR-145, and their overexpression prevents neointimal
54
55 hyperplasia^[203]. Their expression can be upregulated by introducing a serum response
56
57 factor such as myocardin or by the jag-1/Notch axis^[204]. Downregulation caused by
58
59
60
61
62
63
64
65

1
2 vascular injury, hemodynamic stress or in atherosclerotic vessels^[205] promote the
3
4 VSMCs to transition from a synthetic phenotype to a contractile phenotype. Like miR-
5
6 146a, miR-145 directly targets KLF-4, but it also interacts with KLF-5, an inhibitor of
7
8 myocardin^[203], calmodulin kinase II δ , and several other factors **involved in** serum
9
10 response factor activity^[206]. **By contrast,** miR-143 functions mainly by targeting Elk-
11
12 1^[204a]. Similar to miR-143 and miR-145, miR-195 is another modulator of VSMC
13
14 phenotypes to prevent VSMC proliferation and migration. **Overexpression of miR-195**
15
16 **decreases cell proliferation and migration by downregulating** Rho-GTPase Cdc42,
17
18 FGF1, and cyclin D1^[207].
19
20
21

22 **6.4.3 Neointimal hyperplasia prevention or treatment**

23
24
25 Despite intimal hyperplasia after metal device insertion being an inevitable pathological
26
27 response, different measures can be taken to minimize the response and to reduce
28
29 restenosis risks caused by intimal hyperplasia. These methods include: 1) Modification
30
31 of the metal surfaces with polymers. A nitinol surface using polyhedral oligomeric
32
33 silsesquioxanes and poly(carbonate-urea) urethane can result in a nanocomposite
34
35 polymer which has antithrombogenic, nonbiodegradable, and in situ endothelialization
36
37 properties^[208]. Surface modification of metal devices to construct a buffer layer is
38
39 important for long-term biocompatibility. 2) Consistent anti-inflammation drug elution
40
41 on the device surface via a polymer carrier. **By releasing drugs that target VSMC**
42
43 **proliferation from the polymer-coated stent struts, drug-eluting stents (DES) have very**
44
45 **successfully** reduced ISR in coronary arteries since they were introduced in 2002^[195].
46
47
48 3) Promotion of the process of re-endothelialization. Stent strut surface modifications
49
50 with thromboresistant biomolecules **encourages the attachment of the vascular cells to**
51
52 **the stent, which is the first step of** endothelialization. Substantially promising bioactive
53
54 materials include heparin, albumin, phosphorylcholine, aptamers, elastin-inspired
55
56 polymers, thrombomodulin and anti-CD34 antibody^[190i]. A heparin/collagen multilayer
57
58 coating functionalized with Anti-CD34 antibody successfully achieves rapid
59
60
61
62
63
64
65

1 endothelialization and prevents restenosis, which indicates that the combination of an
2 EC-specific ligand with a suitable matrix can promote in situ endothelialization and
3 may inhibit ISR. VEGF has also been proven to promote the process of
4 endothelialization. VEGF can be bound on the surface of a stent by static electricity to
5 stimulate EC migration and proliferation. Another method to prompt EC adhesion or
6 proliferation includes integrating adhesion proteins, like collagen, fibronectin, gelatin
7 and nanofibers constructed by fibrin glue, with PLLA-CL on a metal surface to simulate
8 the configuration or chemical environment of the extracellular matrix. Meanwhile, a
9 polypeptide such as heparin and peptides arginine-glycine-aspartic acid (RGD) can also
10 have similar effect to prompt ECs migration and proliferation.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 Intracranial vessel lumen restenosis or reocclusion induced by metal device
25 implantation is a clinical dilemma as no satisfactory methods exist to resolve this issue.
26 For peripheral arterial restenosis, many endovascular treatments such as plain balloons,
27 rotational atherectomy, brachytherapy, drug coated balloons, cutting balloons and drug
28 eluting stents are optional methods associated with of less need for target lesion
29 revascularization and a reduced risk major adverse events compared with treatments
30 using bare metal stents^[209]. However, for intracranial application, a mechanical
31 treatment such as percutaneous transluminal angioplasty dilation is the most commonly
32 applied treatment. Treatment outcomes are associated with vessel lumen size, length of
33 ISR, vessel curvature and whether or not it was completely occluded. Surgical treatment
34 is an option for the treatment of extra-cranial restenosis, as the extra-cranial artery has
35 a larger diameter and an easy access path that allows direct incision to remove the metal
36 device, thrombus, plaque or hyperplastic intima. Sometimes bypass surgery can also be
37 used to restore blood flow reperfusion for distal vessels and brain tissues. However,
38 surgical treatment for intracranial restenosis is often difficult in technique, as the small
39 lumen hinders direct surgical open surgery for cerebrovascular ISR. Moreover, due to
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 its deep location in brain, for most of the diseased artery, there is no proper vessel that
3
4 can be used for bypass surgery.
5
6
7
8
9

10 **7. Future directions of intracranial metal devices**

11
12
13 Devices based on metal materials such as platinum and nitinol alloys have been widely
14 applied in the brain vasculature for the treatment of cerebrovascular diseases. Novel
15 structural designs have mostly focused on enhancing device flexibility and providing
16 better occlusion, isolation or reconstruction performance during treatment for vascular
17 diseases. However, many challenges remain and further investigation is needed to make
18 intracranial devices safer and more effective. Drug elution and 3D printing techniques
19 are well-studied and have been successfully incorporated into the cardiac and peripheral
20 vasculatures; such innovations also have potential value to be applied to
21 cerebrovascular disease treatment^[210].
22
23
24
25
26
27
28
29
30
31
32

33 **7.1 Biodegradable metal materials for intracranial devices**

34
35
36 Compared to biodegradable polymers or synthetic polymers, absorbable metals
37 typically have excellent stiffness and strength, and can often be made into a much
38 smaller size. Thus, they are very attractive for intracranial applications. Current
39 research on metals for vascular applications includes alloys based on magnesium
40 (Mg)^[211], iron (Fe)^[212], and zinc (Zn; Zn-Mg, Zn-Al)^[213]. Magnesium is generally
41 considered a neuro-protective element for acute ischemic stroke. Since magnesium,
42 iron, and zinc all naturally exist in the body, Mg-, Fe- or Zn-based alloys have
43 demonstrated good biocompatibility and non-toxic biodegradation, and are **promising**
44 **metals for absorbable stents**. Mg stents have already been applied in the treatment of
45 atherosclerotic stenosis in the coronary and inferior genicular arteries^[214]. The main
46 limitation of bio-absorbable Mg stents is its fast degradation rate *in vivo*; **it can only**
47 **reliably** provide mechanical support for up to 3 months. Surface modification is one
48 method to increase surface corrosion resistance, which prolongs the stent degradation
49 time. One such modification is a coating of poly (3-hydroxybutyrate-co-3-
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Hydroxyhexanoate) (PHBHHx) or poly (1, 3-trimethylene carbonate) (PTMC)^[215] on
2 Mg alloy. In dynamic degradation tests, the speed of degradation of PHBHHx- or
3 PTMC-coated Mg alloys was found to be reduced by one and three orders of magnitude
4 compared to PCL-coated and bare Mg alloys, respectively. PHBHHx- or PTMC-coated
5 Mg alloys also exhibited less volume loss and generated fewer corrosion products than
6 PCL-coated and bare Mg alloys after 52 weeks in rats. Research also suggests that
7 micro-arc oxidation can reduce the speed of Mg alloy degradation^[216]. Finally, making
8 new alloys that combine different proportions of Mg mixed with other metals is another
9 way to tune the degradation rate and corrosion control while enhancing
10 biocompatibility. Examples of such alloys include Mg ZK60 alloy (Z= Zinc, K=
11 Zirconium)^[217], AZ61 (A= Aluminium, Z= Zirconium)^[218], ZM21 (Z= Zirconium, M=
12 Manganese)^[219], AE21 (A= Aluminium, E= Rare earth)^[220], AZ31^[221].
13
14
15
16
17
18
19
20
21
22
23

24 Other biodegradable metals such as bio-corrodible Fe scaffolds can provide longer
25 term reliable mechanical support (at least 12-18 months), have a slower biodegradation
26 process, and inhibit inflammation reactions compared to Mg stents^[222]. A bio-
27 corrodible iron scaffold is produced by laser cutting a pure Fe (> 99.8%) tube into a
28 design similar to a Nitinol stent under a nitrogen environment to prevent premature
29 corrosion. A mid-term angiographic patient follow up study after 6-18 months indicated
30 that it is a feasible technique with no significant in-stent neointimal hyperplasia or
31 inflammatory reactions around the stent struts, and no iron toxicity^[222a]. Corrosion of
32 the iron-based stent in tissue was observed over 4 weeks^[222b]. Research on Mg- or Fe-
33 based alloys shows mechanical characteristics equal to or higher than stainless steel,
34 but their degradation speed is still an unresolved issue. A study of Mg-based alloys
35 showed that their degradation rate was too fast. In contrast, Fe-based alloys have good
36 mechanical performance but unsatisfactorily slow biodegradation rate. The
37 introduction of Zn and its alloys in 2013 represented a breakthrough in the field of
38 biodegradable metallic stents. Zn alloys, including Zn-Mg and Zn-Al, display slower
39 corrosion and degradation rates of $\sim 0.02 \text{ mm.y}^{-1}$, about half that of standard pure Mg,
40 making them ideal for stent applications^{[223],[224]}. Zn alloys are fabricated with new
41 casting process: First, they are extruded at 250°C followed by homogenization at 350°C
42 for 48h. Then, a Zn alloy tube with a wall thickness of 2.5 mm is made by extrusion at
43 300°C. Hot extrusion is a critical treatment that transforms the corrosion mechanism
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 from localized pitting to a more uniform erosion. Currently, Zn-0.5Mg seems to be the
2 most ideal material for biodegradable stent, as the grain size and orientation do not
3 change during the final cutting process (Table 5).
4
5
6

7
8 Despite the promising research, several important issues need to be clarified before
9 using biodegradable metals in the clinic. One major concern is that the Mg or Fe alloys
10 do not share the self-expandable properties of nitinol alloys, so they can only be
11 assembled on balloon catheters for delivery and release. This is likely to increase the
12 system profile and decrease its flexibility. Furthermore, metal biodegradation and its
13 end products may impart toxic effects to healthy neurons or result in distal vessel
14 embolization. Lastly, the process of metal degradation is likely to cause more severe
15 inflammation, which may result in intimal hyperplasia or delayed endothelization.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 5. Key properties and aspects of potential non-biodegradable and biodegradable metals for medical cerebrovascular device applications

	316L stainless	Co-Cr alloys	Nitinol alloys	Fe alloys	Mg alloys
Radiopaque	Yes	Yes	No	No	No
Self-expandable	No	No	Yes	No	No
Radial force	Good	Excellent	Good	-	-
Flexibility	Good	Good	Excellent	Good	Good
Essential trace element	Yes	Yes	Yes	Yes	Yes
Recommended daily intake	-	60-350ug/day	25-35ug/day	6-20 mg	375-500 mg
Blood serum level	-	0.4 ug/L	26 ug/L	5.0-17.6 g/L	0.73-1.06 mM
In vivo long-term overdose effects	-	Heart failure, shock, goiter, myocarditis.	Skin herpes, erythema, ulceration, hair whitening.	Damage of lipid membranes, proteins and DNA; stimulus for inflammations; increase of free radicals	Excessive Mg leads to nausea; reduction of the excitability of neuromuscular, smooth muscular and cardiac regions
Effect on local pH during degradation	Alkalescent	Acidic	Alkalescent	Alkalescent	Alkalescent
Corrosion mode	Localized corrosion	Mostly localized and piting	Mostly localized and piting	Localized corrosion	Mostly localized and piting
Expected gaseous corrosion products	NA	NA	NA	None	Hydrogen
Expected solid corrosion products	NA	NA	NA	Fe(OH) ₂ , α-FeO(OH), Fe ₃ O ₄	Mg(OH) ₂ , MgO, MgCl ₂ , (Ca _{1-x} Mg _x) ₁₀ (PO ₄) ₆ OH ₂

Fr = French; NA, - = data not available;

7.2 Drug elution techniques for intracranial devices

Devices and designs that are effective in one particular specialty can quickly inspire and prompt innovations in other specialties. For example, the field of neurointerventional surgery has been dramatically influenced by the areas of cardiac and peripheral intervention. At present, drug-eluting stents (DES) have been routinely used in coronary arteries to prevent intimal hyperplasia and restenosis. However, this technique may also have a bright future in intracranial applications, especially when a stent is inserted into arteriosclerotic arteries. Metal device insertion provides a platform to carry polymers that enable the continuous release of drugs. Degradation rate is an effective index to judge drug release performance as it can be affected by polymer itself, passivation, and the fabrication process^[225]. A number of polymers are commonly considered for use, such as polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-D-lactic acid (PDLA), polyglycolic acid (PGA), polyethylene glycol (PEG) and poly(ϵ -caprolactone) (PCL). However, mixtures of two polymers to make a drug carrier for controlled release are more frequently used. For example, devices have been developed using poly(d,l-lactic-co-glycolic acid) (PLGA)^[226], poly-D,L-lactic acid and polycaprolactone (PDLLA-PCL)^[227], poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx)^[215b], poly(1,3-trimethylene carbonate) (PTMC)^[215a], poly(ethylene glycol)-poly(ϵ -caprolactone) (PEG-PCL)^[228], and poly(vinyl alcohol)-g-PLGA (PVA-g-PLGA)^[229]. The drugs used for DESs are mainly anti-cell proliferation drugs including: Sirolimus (Rapamycin), Paclitaxel, and derivatives of Sirolimus (Everolimus, Zotarolimus, Novolimus and Biolimus A9)^[226a]. (Figure 8c) The DESs under clinical investigation or currently in clinical use are listed in Table 6.

Table 6. *The drug-eluting stents in clinical research or use.*

Generation	Polymer type	Stent name	Platform material	Thickness		Drug (concentration)	Drug release	Polymer material	Degradation time
				Strut (μm)	Coating (μm)				
First	Durable	BX velocity ^[230]	Stainless steel	140	5	Sirolimus (140 $\mu\text{g}/\text{cm}^2$)	100% over 15 days	nonerodable polymers	None
		TAXUS NIRx ^[231]	Stainless steel	N/A	N/A	Paclitaxel (1 $\mu\text{g}/\text{cm}^2$)	80% over 48 hours	hydrocarbon-based elastomer	None
Second	Durable	XIENCE V ^[232]	Cobalt-Chromium	87	7.8	Everolimus (100 $\mu\text{g}/\text{cm}^2$)	80% over 30 days	PBMA and PVDF	None
		Endeavour Resolute ^[233]	Cobalt-Chromium	91	6	Zotarolimus (160 $\mu\text{g}/\text{cm}^2$)	85% over 60 days	PBMA, PHMA, PVP, PVA	None
		Promus Element ^[234]	Platinum-Chromium	81	8	Everolimus(100 $\mu\text{g}/\text{cm}^2$)	80% over 30 days	PBMA and PVDF	None
		DESyne ^[235]	Cobalt-Chromium	80	<3	Novolimus (5 $\mu\text{g}/\text{mm}$)	80% over 90 days	PBMA	None
		Resolute Integrity ^[236]	Cobalt alloy	91	5.6	Zotarolimus (1.6 $\mu\text{g}/\text{mm}^2$)	100% after 6 months	BioLinx-Parylene	None
		Partner ^[237]	Stainless steel	90	6	Sirolimus	controlled	PBMA/PEVA	None
		TAXUS Element (ION) ^[238]	Platinum-Chromium	81	7	Paclitaxel (1 $\mu\text{g}/\text{mm}^2$)	80% over 80 days	Translute	None
Third	Biodegradable	BuMA ^[239]	Stainless steel	100	N/A	Sirolimus(1.4 $\mu\text{g}/\text{mm}^2$)	100% over 30 days	PLGA	N/A
		NOYA ^[240]	Cobalt-Chromium	81	6	Sirolimus(8.8 $\mu\text{g}/\text{mm}^2$)	100% over 30 days	PDLLA	N/A
		BioMatrix Flex ^[241]	Stainless steel	112	10	BiolimusA9 (15.6 $\mu\text{g}/\text{mm}$)	45% over 30 days	PDLLA	6-9 months
		Coracto SES ^[242]	Stainless steel	N/A	4	Rapamycin(1.7 $\mu\text{g}/\text{mm}^2$)	Sirolimus(3.9 $\mu\text{g}/\text{mm}^2$)	PLGA	10-12weeks
		Elixir Myolimus ^[243]	Cobalt-Chromium	80	<3	Myolimus (3 $\mu\text{g}/\text{mm}$)	90% over 90 days	PDLLA	6-9months

	NOBORI ^[244]	Stainless steel	112	10	BiolimusA9 (15.6µg/mm)	45% days	over 30	PDLLA	6-9months	
	Axxess ^[245]	Nitinol	152	15	BiolimusA9 (22µg/mm)	45% days	over 30	PLA	6-9months	
	SYNERGY ^[234]	Platinum-Chromium	74	4	Everolimus(6µg/mm)	50% days	over 30	PLGA	3-4months	
	DESyne BD ^[235]	Cobalt-Chromium	81	<3	Novolimus(5µg/mm)	90% days	over 90	PDLLA	6-9months	
	ORSIRO ^[246]	Cobalt-Chromium	60	7	Sirolimus(1.4µg/mm ²)	50% days	over 30	PLLA	> 12months	
	MiStent ^[247]	Cobalt-Chromium	64	9	Cobalt-Chromium	100% days	over 60	PLGA	3-4months	
	EXCEL ^[248]	Stainless steel	119	15	Sirolimus(195-376µg)	45% days	over 30	PDLLA	6-9months	
	Svelte ^[249]	Cobalt-Chromium	81	6	Sirolimus(8.8µg/mm ²)	N/A		Amino-acid-based	12months	
	Ultimaster ^[250]	Cobalt-Chromium	80	15	Sirolimus(3.9µg/mm ²)	100% days	over 3-4months	PDLLA+PCL	3-4months	
Fourth	Polyme r free	BioFreedom ^[251]	Stainless steel	112	N/A	BiolimusA9 (15.6µg/mm)	90% hours	over 5	Polymer free	Polymer free
		Cre8 ^[252]	Cobalt-Chromium	80	N/A	Sirolimus(90µg/cm ²)	100% days	over 90	Polymer free	Polymer free

PBMA: polybutyl methacrylate; PHMA: polyhexyl methacrylate; PDLLA: poly-(D,L)-lactic acid; PLGA: polylactic-co-glycolic acid; PVA: polyvinyl alcohol;

PVDF: polyvinylidene fluoride; PVO: polyvinyl octal; PVP: polyvinyl pyrrolidone; PLC: polymer liquid crystal; PLA: polylactic acid; PLLA: poly-L-lactic acid;

N/A: not applicable.

1 The first-generation of drug eluting stents, such as the Cypher DES, are often made
2 with durable polymer coatings to release paclitaxel or sirolimus^[226a]. (Figure 9a) The
3 first-generation DES significantly reduces neointimal response, but one major limitation
4 is a durable polymer remnant that causes persistent inflammatory response due to the lack
5 of biocompatibility. This often results in late and very late stent thrombosis (ST) rates and
6 an increased risk of late in-stent restenosis (ISR), which is considered a “late catch-up”
7 phenomenon^[253]. Second-generation DESs, such as zotarolimus-eluting and everolimus-
8 eluting stents, are designed to have improved critical components to increase safety and
9 efficacy^[232]. The most distinct changes between first- and second-generation DESs are
10 stent frame design and polymer composition. Several studies show that a thinner stent
11 frame can reduce restenosis, endothelialization and thrombogenicity^[254]. Therefore, the
12 stent materials transitioned from stainless steel to CoCr^[233] and PtCr^[234], which enable
13 the fabrication of thinner stent platforms that preserve the radial strength and recoil
14 properties. For example, the XIENCE V stent uses a Multi-Link Vision’s cobalt-
15 chromium (CoCr) stent platform coated with a thin layer of drug polymer. The
16 thicknesses of the strut and polymer are 87 μm and 7.8 μm , respectively. A more
17 biologically compatible polymer coating reduces the incidence of late ST; however, this
18 technology is limited by the presence of a permanent polymer, which evokes
19 hypersensitivity reactions, chronic inflammation and neo-atherosclerosis.

20 The long-term complications of the first- and second- generation of DES are mostly
21 related to permanent polymeric materials. There are several strategies in development for
22 newer generation DESs, such as biodegradable polymer (BP) DESs, polymer-free (PF)
23 DESs, and fully biodegradable DESs^[255]. Third-generation DESs with biodegradable
24 polymers, such as the BioMatrix Flex stent (Biolimus-eluting stents), have demonstrated
25 less in-stent late lumen loss and neointimal response^[241, 256]. Although BPs are less
26 inflammatory than DPs, they still can induce an inflammatory response. Therefore, the
27 fourth-generation polymer-free DESs (PF-DES) have been promoted as an ideal solution
28 to this problem^[251-252, 257]. The platform material of PF-DES is stainless steel with a
29 microporous surface, and the anti-proliferative drug is released from the struts. Four types
30 of PF-DES are currently under clinical evaluation: microporous DES, DES with reservoir
31 technology, nanoparticle-based DES, and drug filled stents.

1 One alternative to permanent stent insertion, where polymers or stent struts can cause
2 complications, may be to develop completely bio-resorbable vascular scaffolds (BVS).
3 BVSs have some important advantages: (1) they are completely bio-resorbable, leave no
4 residual materials in the vessel wall, and do not damage the integrity of the vascular
5 structure, (2) sufficient mechanical flexibility to adapt to the vessel geometry, which may
6 have favorable effects on blood flow^[258], (3) the vasomotor and physiological function of
7 the scaffold segment is regained within a few months after implantation, and (4) they
8 introduce no imaging artifacts to noninvasive imaging modalities such as MR or CT
9 scans^[259]. Several types of materials are being investigated for BVS^[225b], among which
10 PLLA and magnesium are the most promising. Other materials suitable for BVS may
11 include iron alloys^[222a] and PLLA/PDLA/L-lactic-co-ε-caprolactone^[260].
12
13
14
15
16
17
18
19
20
21
22

23 Drug eluting techniques have already profoundly influenced coronary heart disease
24 treatment, and the use of drug-eluting stents or balloons has become the first line
25 treatment to handle restenosis clinically. In cerebral artery atherosclerosis, the
26 SAMMPRIS trial clearly revealed better outcomes for symptomatic intracranial stenosis
27 with aggressive medical management than with percutaneous angioplasty and metallic
28 stenting^[66a]. As a result, metallic stents to treat intracranial stenosis should only be used
29 for patients who have failed in medical therapy or who have high risk factors^[66b].
30 However, the selection of patients and intervention procedures was considered to be
31 deficient in the SAMMPRIS trial; thus, several additional studies have been carried out
32 to determine if drug eluting stents might bring better treatment outcomes for intracranial
33 atherosclerosis. Although the studies have already revealed that the restenosis rate is
34 significantly reduced compared to the bare metal stent treatment, all drug eluting stents
35 applied in cerebral arteries so far have been coronary stents^[261]. More flexible drug
36 eluting stents need to be developed to improve safety in the cerebrovasculature. Presently,
37 the drug eluting technique is also being applied in flow diverters. The PED 3 flow diverter
38 uses a surface modification of phosphorilcholine. These surface modified flow diverters
39 are reported to cause less thrombus formation than bare FDDs. Additionally, the clot
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

incidence rate for the classic PED is 1.72 times higher than for the Pipeline Flex with Shield Technology^[262].

Nevertheless, safety is still the primary concern about applying drug eluting techniques in brain vasculature. Sustained release of anti-proliferation drugs carried by the metal devices can cause damage to neurons, and moreover, materials can fall off during stent inflation or drug carrier degradation, which may increase the risk of distal vessel embolization to cause a brain infarction. Furthermore, delayed endothelization or suppressed inflammation reaction by drugs runs a high risk of thrombosis and other complications (Figure 9b).




Figure 9. *Controlled drug releasing schematic diagram and endothelization process of the drug eluting stents. (a) Two-stage drug release of the polymer degradation and erosion. Stage 1: slow release by diffusion through the polymer; Stage 2: enhanced release contributed by polymer degradation and erosion. (b) Characteristic images of endothelial coverage were assessed by scanning electron microscopy at 1 and 2 days (A) and 10 days of a paclitaxel-eluting stent (TAXUS) and at 28 days of an anti-ApoA1 coated stent.^[263]*

7.3 Personalized device manufacture for intracranial devices

3D printing is becoming a new option in manufacturing to enable simultaneous customization and enhanced functionality. Increasingly, this technology can help satisfy the great need for patient-specific artificial organs, implants or devices, especially in surgery applications^[264]. Innovation in 3D printing techniques and the development of multifunctional printable materials can drive the future application of 3D printing in many fields. Many medical devices are currently manufactured using metals and/or their alloys. For long-term tissue replacement therapy, they are usually designed as implants or fixtures to undertake loads because of their excellent strength and ductility^[265]. The metals and their alloys that can be 3D printed for medical applications are generally: conventional metals and their alloys, shape memory alloys, and biodegradable metals.

The two commonly used methods of 3D printing are Directed Energy Deposition (DED) and Powder Bed Fusion (PBF). The working principle of DED and PBF differs in one fundamental way: in DED, a continuous stream of metal powder or wire is melted by a high power-density laser as it is deposited onto the substrate, whereas PBF pre-deposits a layer of metal powder and then melts it at the desired location under a focused laser beam with selectively controlled thermal energy^[266]. The quantity directly affects the printing resolution in a DED manufacturing process. Several processes have been created based on PBF technology, including selective laser sintering (SLS) and selective laser melting (SLM), direct metal laser sintering (DMLS), laser cussing and electron beam melting (EBM). DMLS generally uses both metal powder and a high power laser to sinter together a target structure, so it is an additive manufacturing (AM) or rapid prototyping (RP) process. This process can be used to produce dense parts, but post-treatment is often required to make it gas- or pressure-tight. In fact, many tradenames (laser sintering, cussing, etc.) describe the same process with the same technologies^[190a].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3D printed metal devices that can provide anatomically-personalized hemodynamic intervention treatments may have an especially bright future in the treatment of cerebrovascular disease^[267]. Metal devices used in the brain, such as stents and flow diverters, especially stand to benefit from the application of 3D printing techniques. As each cerebral vasculature has its unique tortuous course, different patients or diseases may require the stent to have custom-designed 3D angles or diameters in different stent segments. Thus, 3D printed stents promise improved adaptation to the vascular wall to reduce damage to the arterial wall related to device insertion, which may in turn reduce the risk of thrombosis or late in-stent restenosis. Furthermore, considering that arterial stenosis, occlusion and aneurysms are all hemodynamics-related diseases, enhancing the occlusion rate of a flow diverter or the dilating strength of a stent may improve the treatment outcomes. 3D printing may improve the performance of these metal devices in the following ways: 1) Vascular stents: as intracranial stents often require both mechanical support and high flexibility, we can design and 3D print a patient-specific nitinol alloy stent with an enhanced number or thickness of the stent struts, or increase the diameter in the diseased artery to improve the hemodynamics after stenting; meanwhile, we can adjust the design for a normal artery lumen by reducing the stent diameter or the number or thickness of the stent to enhance its flexibility. These patient-specific stent designs cannot be efficiently manufactured by laser cutting or weaving techniques^[268]. 2) Flow diverters: a flow diverter at the aneurysm neck needs high metal coverage to produce a maximal flow re-direction, while in normal vessel lumens, the metal coverage should be low to maintain the patency of vessel branches. Current designs of flow diverters are braided using nitinol wires, so it is impossible to create different metal coverage rates in different stent segments, while 3D print can easily produce this type of design^[269].

The great advantage of 3D printing technology is that it provides easy customization of implant design to improve functionality. In the surgical fields, 3D printing technology

1
2 promises artificial organs, implants or devices that are patient-specific^[270]. Although
3
4 much progress has already been made, the future of 3D printing technology will require
5
6 continued development in both printing technology and novel printable materials.
7
8
9

10 11 12 **8. Conclusion and future perspectives** 13 14

15
16 In summary, endovascular metal device insertion is already a revolutionary technology
17
18 for the treatment of cerebral vascular diseases, including ischemic or hemorrhagic stroke.
19
20 The wide application of this technology has made it possible to treat previously
21
22 untreatable diseases, and promoted the transition from traditional open surgery to less
23
24 invasive catheter-based interventions. However, some challenges remain when using
25
26 metal devices in the cerebral vasculature. These future directions may lead to potential
27
28 solutions to these problems:
29
30

31
32 i) Devices used in brain vasculature often require excellent mechanical performance,
33
34 such as high flexibility or radial force. The mechanical properties of currently available
35
36 metal materials restrict their application in smaller or distal cerebral vasculature (with
37
38 diameter <2mm). Thus, new metal alloys or novel structural designs must be developed
39
40 to improve the devices' mechanical performance and reduce their profile.
41
42

43
44 ii) Permanent metal device insertion faces challenges of device-related acute
45
46 thrombosis or long-term vessel lumen restenosis. Drug-eluting techniques have been
47
48 widely applied in the coronary or peripheral vasculatures to prevent long-term lumen loss
49
50 after stent insertion, but its safety and efficacy in intracranial vessels still needs further
51
52 investigation. The main concerns about the safety of drug-elution technology center on
53
54 drug neurotoxicity and risks related to the drug carrier when applied in the brain. Thus,
55
56 further research in this area is primarily focused on the following aspects: 1) finding safer
57
58 drugs or other bio-active materials like proteins, polypeptides, molecules or even genes
59
60
61
62
63
64
65

1
2 to prevent device-induced complications and reduce neurotoxicity; 2) optimizing drug
3
4 loading techniques to achieve sustained drug release while minimizing the carrier fall off
5
6 risk. Moreover, the risk of acute thrombosis or inflammation caused by non-
7
8 biodegradable or biodegradable carriers should be fully considered.
9

10
11 iii) As metal device insertion is permanent, risks like restenosis, inflammation and
12
13 thrombus formation cannot be completely avoided. The ideal model is to have a device
14
15 that is inserted to treat the disease, and that completely biodegrades after treatment is
16
17 completed without further interruption to the normal vasculature. Biodegradable
18
19 polymers or metals have already been used in the coronary or peripheral vasculatures in
20
21 the clinic, but too-short or too-long degradation periods, degradation induced by
22
23 inflammation response, and unsatisfactory mechanical performance are major limitations.
24
25 Thus, further research to find more suitable biodegradable materials that have excellent
26
27 mechanical properties and appropriate biodegradation modes is the future direction. Also
28
29 important is to avoid distal vessel embolization or acute thrombosis during the
30
31 biodegradation period; a combination of drug-elution techniques on biodegradable
32
33 material surfaces may be an effective way to reduce inflammation during degradation.
34
35
36
37

38 iv) In view of the unique set of anatomies, vessel lumen diameters, and vessel wall
39
40 structures comprising the cerebral vasculature of each person, individualized devices
41
42 require both flexibility of structure and mechanical strength. Meanwhile, flow dynamics
43
44 and tissue response to devices are also different from person to person, so only a
45
46 personalized device can guarantee maximized treatment outcomes and reduced
47
48 complications. With the development of 3D printing technology, images collected from
49
50 computed tomographic angiography (CTA), magnetic resonance angiography (MRA) or
51
52 digital subtraction angiography (DSA) can be processed to obtain a 3D digital vessel
53
54 model or image that can then be used to design a personalized metal device. These
55
56 technologies will be certainly applied in clinical to enhance treatment outcomes in the
57
58 near future.
59
60
61
62
63
64
65

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (81771943, 81571773 and 51873107), Shanghai Pujiang Program (16PJD036), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No.20152528 and 20171906); Three-year plan program by Shanghai Shen Kang Hospital Development Center (16CR3043A); Shanghai Science and Technology Commission of Shanghai Municipality Program (14DZ1941206 and 18ZR1434200); Shanghai municipal health and Family Planning Commission (201840027). Prof. H. Zhang acknowledges Jane and Aatos Erkkö Foundation (4704010), Academy of Finland (decision no. 297580) and Sigrid Juselius Foundation (grant no. 28001830K1) for financial support. Prof. H. A. Santos acknowledges financial support from the University of Helsinki Research Funds, the HiLIFE Research Funds, the Sigrid Jusélius Foundation (decision no. 4704580), and the European Research Council under the European Union's Seventh Framework Programme (FP/2007–2013, Grant No. 310892).

References

- [1] in *Health, United States, 2016: With Chartbook on Long-term Trends in Health, Hyattsville (MD) 2017*.
- [2] http://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/
- [3] A. S. Go, D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, C. S. Fox, S. Franco, H. J. Fullerton, C. Gillespie, S. M. Hailpern, J. A. Heit, V. J. Howard, M. D. Huffman, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, D. Magid, G. M. Marcus, A. Marelli, D. B. Matchar, D. K. McGuire, E. R. Mohler, C. S. Moy, M. E. Mussolino, G. Nichol, N. P. Paynter, P. J. Schreiner, P. D. Sorlie, J. Stein, T. N. Turan, S. S. Virani, N. D. Wong, D. Woo, M. B. Turner, *Circulation* **2013**, 127, e6.
- [4] A. S. Go, M. Dariush, V. L. Roger, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, D. Shifan, E. S. Ford, C. S. Fox, *Circulation* **2013**, 127, 143.
- [5] J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, M. Zuccarello, *Circulation* **2007**, 116, e391.
- [6] F. A. Serbinenko, *Voprosy Neirokhirurgii* **1971**, 35, 3.
- [7] G. Guglielmi, F. Vinuela, J. Dion, G. Duckwiler, *J Neurosurg* **1991**, 75, 8.
- [8] (a) R. W. Ryan, A. S. Khan, R. Barco, A. Choulakian, *Neurosurg Focus* **2017**, 42, E11; (b) J. B. White, C. G. Ken, H. J. Cloft, D. F. Kallmes, *AJNR Am J Neuroradiol* **2008**, 29, 1242; (c) L. Touma, K. B.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Filion, L. H. Sterling, R. Atallah, S. B. Windle, M. J. Eisenberg, *JAMA Neurol* **2016**, 73, 275.
- [9] (a) C. Y. Lien, C. R. Huang, W. C. Tsai, C. W. Hsu, N. W. Tsai, C. C. Chang, C. H. Lu, C. C. Chien, W. N. Chang, *J Clin Neurosci* **2017**; (b) T. Sorenson, W. Brinjikji, G. Lanzino, *J Neurosurg Sci* **2016**, 60, 116.
- [10] (a) A. K. Wakhloo, M. J. Deleo, 3rd, M. M. Brown, *Stroke* **2009**, 40, e305; (b) M. Pletin, R. Blanc, *Front Neurol* **2014**, 5, 41; (c) Y. Q. Zhu, M. H. Li, F. Lin, D. L. Song, H. Q. Tan, B. X. Gu, H. Q. Zhang, B. Leng, P. L. Zhang, *Eur Radiol* **2013**, 23, 287; (d) M. Zanaty, N. Chalouhi, S. I. Tjoumakaris, R. H. Rosenwasser, L. F. Gonzalez, P. Jabbour, *Front Neurol* **2014**, 5, 21.
- [11] A. Cowley, B. Woodward, *Platin Met Rev* **2011**, 55, 98.
- [12] M. H. Han, O. K. Kwon, C. J. Yoon, B. J. Kwon, S. H. Cha, K. H. Chang, *AJNR Am J Neuroradiol* **2003**, 24, 539.
- [13] B. R. Bendok, R. J. Rahme, G. Complex Registry, *J Neurointerv Surg* **2013**, 5, 54.
- [14] M. T. Koltz, N. Chalouhi, S. Tjoumakaris, L. Fernando Gonzalez, A. Dumont, D. Hasan, R. Rosenwasser, P. Jabbour, *J Clin Neurosci* **2014**, 21, 148.
- [15] D. H. Lee, A. Arat, H. Morsi, L. D. Jou, M. E. Mawad, *Interv Neuroradiol* **2009**, 15, 29.
- [16] C. A. Taschner, L. Thines, M. El-Mahdy, H. Rachdi, J. Y. Gauvrit, J. P. Lejeune, J. P. Pruvo, X. Leclerc, *Neuroradiology* **2009**, 51, 45.
- [17] G. Jindal, T. Miller, M. Iyohe, R. Shivashankar, V. Prasad, D. Gandhi, *J Vasc Interv Neurol* **2016**, 9, 46.
- [18] M. S. Teleb, A. Ver Hage, J. Carter, M. V. Jayaraman, R. A. McTaggart, *J Neurointerv Surg* **2017**, 9, 122.
- [19] G. Dabus, L. Hacin-Bey, B. Varjavand, R. D. Tomalty, P. P. Han, V. Yerokhin, I. Linfante, J. Mocco, T. Oxley, A. Spiotta, M. I. Chaudry, R. D. Turner, A. S. Turk, *J Neurointerv Surg* **2017**, 9, 419.
- [20] C. G. McDougall, S. C. Johnston, A. Gholkar, S. L. Barnwell, J. C. Vazquez Suarez, J. Masso Romero, J. C. Chaloupka, A. Bonafe, A. K. Wakhloo, D. Tampieri, C. F. Dowd, A. J. Fox, S. J. Imm, K. Carroll, A. S. Turk, M. Investigators, *AJNR Am J Neuroradiol* **2014**, 35, 935.
- [21] B. Gory, F. Turjman, *Acta Neurochir (Wien)* **2014**, 156, 831.
- [22] K. M. Fargen, S. Blackburn, E. M. Deshaies, J. S. Carpenter, P. Jabbour, W. J. Mack, A. T. Rai, A. H. Siddiqui, R. D. Turner, J. Mocco, *J Neurointerv Surg* **2015**, 7, 40.
- [23] A. J. Molyneux, A. Clarke, M. Sneade, Z. Mehta, S. Coley, D. Roy, D. F. Kallmes, A. J. Fox, *Stroke* **2012**, 43, 2544.
- [24] B. Waldau, K. M. Fargen, W. J. Mack, N. M. Wilson, A. Khaldi, B. L. Hoh, J. Mocco, *Interv Neuroradiol* **2012**, 18, 200.
- [25] A. Waseem, I. Ahmed, S. Hadeel, *J Stroke Cerebrovasc Dis* **2018**, 20, S1052.
- [26] S. Fujimura, H. Takao, T. Suzuki, C. Dahmani, H. Mamori, M. Yamamoto, Y. Murayama, *Conf Proc IEEE Eng Med Biol Soc* **2016**, 2016, 3298.
- [27] H. W. Jeong, S. C. Jin, *J Cerebrovasc Endovasc Neurosurg* **2015**, 17, 295.
- [28] (a) D. F. Kallmes, N. H. Fujiwara, *AJNR Am J Neuroradiol* **2002**, 23, 1580; (b) H. J. Cloft, *AJNR Am J Neuroradiol* **2006**, 27, 289.
- [29] X. B. Guo, Y. M. Fan, J. N. Zhang, *Eur J Radiol* **2011**, 79, e42.
- [30] C. A. Taschner, R. Chapot, V. Costalat, P. Machi, P. Courtheoux, X. Barreau, J. Berge, L. Pierot, K.

- 1 Kadziolka, B. Jean, R. Blanc, A. Biondi, H. Brunel, S. Gallas, A. Berlis, D. Herbreteau, J. Berkefeld, H.
2 Urbach, S. El Shikh, J. Fiehler, H. Desal, E. Graf, A. Bonafe, *Neuroradiology* **2016**, 58, 777.
- 3 [31] J. W. Speirs, T. H. Burke, S. Y. Lee, B. D. Ala, *J Neurointerv Surg* **2013**, 5 Suppl 3, iii72.
- 4 [32] M. Killer, D. Kallmes, R. Jones, Y. Ding, M. Vestal, T. Hauser, R. Virmani, G. Cruise, *Minim Invasive*
5 *Neurosurg* **2010**, 53, 97.
- 6 [33] G. Guglielmi, F. Vinuela, I. Sepetka, V. Macellari, *J Neurosurg* **1991**, 75, 1.
- 7 [34] (a) A. J. Molyneux, R. S. Kerr, L. M. Yu, M. Clarke, M. Sneade, J. A. Yarnold, P. Sandercock, *Lancet*
8 **2005**, 366, 809; (b) A. J. Molyneux, R. S. Kerr, J. Birks, N. Ramzi, J. Yarnold, M. Sneade, J. Rischmiller,
9 *Lancet Neurol* **2009**, 8, 427.
- 10 [35] (a) F. Vinuela, G. Duckwiler, M. Mawad, *J Neurosurg* **1997**, 86, 475; (b) C. Cognard, A. Weill, L.
11 Castaings, A. Rey, J. Moret, *Radiology* **1998**, 206, 499.
- 12 [36] L. Pierot, L. Spelle, F. Vitry, *Stroke* **2008**, 39, 2497.
- 13 [37] I. S. o. U. I. A. Investigators, *N Engl J Med* **1998**, 339, 1725.
- 14 [38] M. J. Slob, W. J. van Rooij, M. Sluzewski, *AJNR Am J Neuroradiol* **2005**, 26, 901.
- 15 [39] H. J. Cloft, D. F. Kallmes, *AJNR Am J Neuroradiol* **2004**, 25, 60.
- 16 [40] H. J. Cloft, *AJNR Am J Neuroradiol* **2007**, 28, 152.
- 17 [41] P. M. White, S. C. Lewis, A. Gholkar, R. J. Sellar, H. Nahser, C. Cognard, L. Forrester, J. M. Wardlaw,
18 *Lancet* **2011**, 377, 1655.
- 19 [42] C. Taschner, R. Chapot, V. Costalat, P. Courtheoux, X. Barreau, J. Berge, L. Pierot, K. Kadziolka, B.
20 Jean, R. Blanc, A. Biondi, H. Brunel, S. Gallas, A. Berlis, D. Herbreteau, J. Berkefeld, C. Groden, H.
21 Urbach, S. El Shikh, E. Graf, A. Bonafe, *Neuroradiology* **2015**, 57, 599.
- 22 [43] K. M. Fargen, S. Blackburn, J. S. Carpenter, P. Jabbour, W. J. Mack, A. T. Rai, A. H. Siddiqui, R. D.
23 Turner, J. Mocco, *J Neurointerv Surg* **2014**, 6, 495.
- 24 [44] H. S. Kang, M. H. Han, B. J. Kwon, O. K. Kwon, S. H. Kim, S. H. Choi, K. H. Chang, *AJNR Am J*
25 *Neuroradiol* **2005**, 26, 1921.
- 26 [45] (a) A. Vance, B. G. Welch, *Neurol Res* **2014**, 36, 356; (b) I. Rezek, G. Mousan, Z. Wang, M. H. Murad,
27 D. F. Kallmes, *AJNR Am J Neuroradiol* **2013**, 34, 1769.
- 28 [46] J. Moret, C. Cognard, A. Weill, L. Castaings, A. Rey, *Interv Neuroradiol* **1997**, 3, 21.
- 29 [47] B. D. Jagadeesan, F. Siddiq, A. W. Grande, R. P. Tummala, *J Neurointerv Surg* **2014**, 6, 704.
- 30 [48] L. Pierot, C. Cognard, R. Anxionnat, F. Ricolfi, *Radiology* **2011**, 258, 546.
- 31 [49] L. Pierot, L. Spelle, X. Leclerc, C. Cognard, A. Bonafe, J. Moret, *Radiology* **2009**, 251, 846.
- 32 [50] M. Shapiro, J. Babb, T. Beckske, P. K. Nelson, *AJNR Am J Neuroradiol* **2008**, 29, 1777.
- 33 [51] Y. Matsuda, J. Chung, K. Keigher, D. Lopes, *J Neurointerv Surg* **2018**, 10, 274.
- 34 [52] N. Ebrahimi, B. Claus, C. Y. Lee, A. Biondi, G. Benndorf, *AJNR Am J Neuroradiol* **2007**, 28, 823.
- 35 [53] (a) K. J. Becker, T. G. Brott, *Stroke* **2005**, 36, 400; (b) A. M. Spiotta, A. Miranpuri, M. I. Chaudry, R.
36 D. t. Turner, A. S. Turk, *J Neurointerv Surg* **2013**, 5 Suppl 3, iii79; (c) C. Roth, D. Junk, P. Papanagiotou,
37 A. Keuler, H. Korner, M. Schumacher, W. Reith, *AJNR Am J Neuroradiol* **2012**, 33, 1317; (d) D. Fiorella,
38 P. Lylyk, I. Szikora, M. E. Kelly, F. C. Albuquerque, C. G. McDougall, P. K. Nelson, *J Neurointerv Surg*
39 **2009**, 1, 56; (e) H. Henkes, A. Bose, S. Felber, E. Miloslavski, E. Berg-Dammer, D. Kuhne, *Interv*
40 *Neuroradiol* **2002**, 8, 107; (f) K. Kallenberg, L. Solymosi, C. A. Taschner, J. Berkefeld, M. Schlamann,
41 O. Jansen, S. Arnold, B. Tomandl, M. Knauth, B. Turowski, *J Neurointerv Surg* **2016**, 8, 834; (g) D. J.

1
2 Padalino, A. Singla, W. Jacobsen, E. M. Deshaies, *Surg Neurol Int* **2013**, 4, 9; (h) Z. Kulcsar, U.
3 Ernemann, S. G. Wetzel, A. Bock, S. Goericke, V. Panagiotopoulos, M. Forsting, D. A. Ruefenacht, I.
4 Wanke, *Stroke* **2010**, 41, 1690; (i) C. P. Kealey, Y. J. Chun, F. E. Vinuela, K. P. Mohanchandra, G. P.
5 Carman, F. Vinuela, D. S. Levi, *J Biomed Mater Res B Appl Biomater* **2012**, 100, 718; (j) P. Mordasini,
6 N. Frabetti, J. Gralla, G. Schroth, U. Fischer, M. Arnold, C. Brekenfeld, *AJNR Am J Neuroradiol* **2011**,
7 32, 294; (k) R. T. Higashida, V. V. Halbach, C. F. Dowd, L. Juravsky, S. Meagher, *AJNR Am J*
8 *Neuroradiol* **2005**, 26, 1751; (l) T. Liebig, C. Kabbasch, C. Strasilla, A. Berlis, W. Weber, L. Pierot, T.
9 Patankar, X. Barreau, J. Dervin, A. Kursumovic, S. Rath, B. Lubicz, J. Klisch, *AJNR Am J Neuroradiol*
10 **2015**, 36, 1721; (m) R. D. Turner, A. Turk, I. Chaudry, *J Neurointerv Surg* **2013**, 5, 157; (n) S. Rohde,
11 S. Haehnel, C. Herweh, M. Pham, S. Stampfl, P. A. Ringleb, M. Bendszus, *Stroke* **2011**, 42, 2954; (o) T.
12 Kahles, C. Garcia-Esperon, S. Zeller, M. Hlavica, J. Anon, M. Diepers, K. Nedeltchev, L. Remonda,
13 *AJNR Am J Neuroradiol* **2016**, 37, 114; (p) H. Raoult, H. Redjem, R. Bourcier, A. Gaultier-Lintia, B.
14 Daumas-Duport, J. C. Ferre, F. Eugene, R. Fahed, B. Bartolini, M. Piotin, H. Desal, J. Y. Gouvrit, R.
15 Blanc, *J Neurointerv Surg* **2017**, 9, 574; (q) M. Aguilar Perez, P. Bhogal, R. Martinez Moreno, H. Bazner,
16 O. Ganslandt, H. Henkes, *J Neurointerv Surg* **2017**, 9, 77; (r) C. Ulfert, M. Pham, M. Sonnberger, F.
17 Amaya, J. Trenkler, M. Bendszus, M. A. Mohlenbruch, *J Neurointerv Surg* **2018**, 20, pii: neurintsurg;
18 (s) M. H. Li, Y. D. Li, B. L. Gao, C. Fang, Q. Y. Luo, Y. S. Cheng, Z. Y. Xie, Y. L. Wang, J. G. Zhao, Y.
19 Li, W. Wang, B. L. Zhang, M. Li, *AJNR Am J Neuroradiol* **2007**, 28, 1579; (t) D. F. Kallmes, Y. H. Ding,
20 D. Dai, R. Kadirvel, D. A. Lewis, H. J. Cloft, *Stroke* **2007**, 38, 2346; (u) J. De Vries, J. Boogaarts, A.
21 Van Norden, A. K. Wakhloo, *Stroke* **2013**, 44, 1567; (v) Y. Zhou, P. F. Yang, Y. B. Fang, Y. Xu, B. Hong,
22 W. Y. Zhao, Q. Li, R. Zhao, Q. H. Huang, J. M. Liu, *AJNR Am J Neuroradiol* **2014**, 35, 2326; (w) F.
23 Briganti, G. Leone, M. Marseglia, D. Cicala, F. Caranci, F. Maiuri, *J Neurointerv Surg* **2016**, 8, 173; (x)
24 Y. Ding, D. Dai, D. F. Kallmes, D. Schroeder, C. P. Kealey, V. Gupta, A. D. Johnson, R. Kadirvel, *AJNR*
25 *Am J Neuroradiol* **2016**, 37, 497; (y) J. M. Pumar, M. Blanco, F. Vazquez, J. A. Castineira, L.
26 Guimaraens, A. Garcia-Allut, *AJNR Am J Neuroradiol* **2005**, 26, 2573; (z) S. C. Kwon, Y. H. Ding, D.
27 Dai, R. Kadirvel, D. A. Lewis, D. F. Kallmes, *AJNR Am J Neuroradiol* **2011**, 32, 602; (aa) J. Hartman,
28 *J Neurointerv Surg* **2011**, 3, 207; author reply 207; (ab) F. Gao, B. Du, X. T. Xu, Y. J. Wang, W. J. Jiang,
29 *J Endovasc Ther* **2009**, 16, 642; (ac) R. Jahan, *AJNR Am J Neuroradiol* **2010**, 31, 1938; (ad) J. Klisch,
30 C. Eger, V. Sychra, C. Strasilla, S. Basche, J. Weber, *Neurosurgery* **2009**, 65, 258; (ae) R. M. Starke, A.
31 Turk, D. Ding, R. W. Crowley, K. C. Liu, N. Chalouhi, D. M. Hasan, A. S. Dumont, P. Jabbour, C. R.
32 Durst, R. D. Turner, *J Neurointerv Surg* **2016**, 8, 135; (af) O. Diaz, T. L. Gist, G. Manjarez, F. Orozco,
33 R. Almeida, *J Neurointerv Surg* **2014**, 6, 614; (ag) Y. Q. Zhu, M. H. Li, J. Xie, H. Q. Tan, Y. S. Cheng,
34 J. B. Wang, *Eur Radiol* **2010**, 20, 1974; (ah) H. Henkes, E. Miloslavski, S. Lowens, J. Reinartz, T. Liebig,
35 D. Kuhne, *Neuroradiology* **2005**, 47, 222; (ai) R. G. Nogueira, E. I. Levy, M. Gounis, A. H. Siddiqui, *J*
36 *Neurointerv Surg* **2012**, 4, 295; (aj) D. C. Haussen, A. Lima, R. G. Nogueira, *J Neurointerv Surg* **2016**,
37 8, 295; (ak) Y. H. Ding, D. A. Lewis, R. Kadirvel, D. Dai, D. F. Kallmes, *AJNR Am J Neuroradiol* **2011**,
38 32, 607.

39 [54] (a) Y. Kadkhodayan, N. Rhodes, S. Blackburn, C. P. Derdeyn, D. T. Cross, 3rd, C. J. Moran, *AJR Am*
40 *J Roentgenol* **2013**, 200, 872; (b) R. P. Benitez, M. T. Silva, J. Klem, E. Veznedaroglu, R. H.
41 Rosenwasser, *Neurosurgery* **2004**, 54, 1359; (c) Y. Kadkhodayan, C. T. Somogyi, D. T. Cross, 3rd, C. P.
42 Derdeyn, G. J. Zipfel, M. R. Chicoine, K. M. Rich, R. L. Grubb, Jr., R. G. Dacey, Jr., C. J. Moran, *J*

- 1
2 *Neurointerv Surg* **2012**, 4, 368.
- 3 [55] (a) O. O. Zaidat, R. Klucznik, M. J. Alexander, J. Chaloupka, H. Lutsep, S. Barnwell, M. Mawad, B.
4 Lane, M. J. Lynn, M. Chimowitz, N. I. H. M.-c. W. I. S. R. S. Group, *Neurology* **2008**, 70, 1518; (b) W.
5 J. Jiang, W. Yu, B. Du, F. Gao, L. Y. Cui, *Stroke* **2011**, 42, 1971; (c) M. I. Chimowitz, M. J. Lynn, C. P.
6 Derdeyn, T. N. Turan, D. Fiorella, B. F. Lane, L. S. Janis, H. L. Lutsep, S. L. Barnwell, M. F. Waters, B.
7 L. Hoh, J. M. Hourihane, E. I. Levy, A. V. Alexandrov, M. R. Harrigan, D. Chiu, R. P. Klucznik, J. M.
8 Clark, C. G. McDougall, M. D. Johnson, G. L. Pride, Jr., M. T. Torbey, O. O. Zaidat, Z. Rumboldt, H. J.
9 Cloft, S. T. Investigators, *N Engl J Med* **2011**, 365, 993; (d) D. Fiorella, E. I. Levy, A. S. Turk, F. C.
10 Albuquerque, D. B. Niemann, B. Aagaard-Kienitz, R. A. Hanel, H. Woo, P. A. Rasmussen, L. N.
11 Hopkins, T. J. Masaryk, C. G. McDougall, *Stroke* **2007**, 38, 881.
- 12 [56] (a) X. Wang, Z. Wang, C. Wang, Y. Ji, X. Ding, Y. Zang, *Turk Neurosurg* **2016**, 26, 69; (b) Z. Feng, G.
13 Duan, P. Zhang, L. Chen, Y. Xu, B. Hong, W. Zhao, J. Liu, Q. Huang, *BMC Neurol* **2015**, 15, 187; (c)
14 Z. Vajda, E. Schmid, T. Guthe, C. Klotzsch, A. Lindner, L. Niehaus, W. Sperber, J. Peters, G. Arnold, H.
15 Bazner, H. Henkes, *Neurosurgery* **2012**, 70, 91; (d) J. Mocco, K. V. Snyder, F. C. Albuquerque, B. R.
16 Bendok, S. B. Alan, J. S. Carpenter, D. J. Fiorella, B. L. Hoh, J. U. Howington, B. T. Jankowitz, K. M.
17 Liebman, A. T. Rai, R. Rodriguez-Mercado, A. H. Siddiqui, E. Veznedaroglu, L. N. Hopkins, E. I. Levy,
18 *J Neurosurg* **2009**, 110, 35; (e) K. Y. Lee, D. Y. Chen, H. L. Hsu, C. J. Chen, Y. C. Tseng, *Interv*
19 *Neuroradiol* **2016**, 22, 187.
- 20 [57] (a) R. Juszkat, S. Nowak, S. Smol, W. Kociemba, T. Blok, A. Zarzecka, *Interv Neuroradiol* **2007**, 13,
21 255; (b) B. Lubicz, A. Kadou, R. Morais, B. Mine, *Neuroradiology* **2017**, 59, 271; (c) K. Aydin, A. Arat,
22 S. Sencer, M. Barburuglu, S. Men, *AJNR Am J Neuroradiol* **2015**, 36, 1934.
- 23 [58] (a) J. Klisch, C. Clajus, V. Sychra, C. Eger, C. Strasilla, S. Rosahl, R. Gerlach, I. Bar, H. Hoch, U.
24 Herbon, L. Borota, P. Jonasson, T. Liebig, *Neuroradiology* **2010**, 52, 349; (b) H. W. Ye, Y. Q. Liu, Q. J.
25 Wang, T. Zheng, X. B. Cui, Y. Y. Gao, L. F. Lai, X. Zhang, X. F. Li, S. X. Su, X. Y. He, C. Z. Duan, *Exp*
26 *Ther Med* **2015**, 10, 145; (c) H. W. Jeong, W. B. Seung, *J Cerebrovasc Endovasc Neurosurg* **2015**, 17,
27 301; (d) C. Clajus, V. Sychra, C. Strasilla, J. Klisch, *Neuroradiology* **2013**, 55, 629.
- 28 [59] (a) X. Zhang, J. Zhong, H. Gao, F. Xu, N. C. Bambakidis, *J Neurointerv Surg* **2017**, 9, 553; (b) D.
29 Behme, A. Weber, A. Kowoll, A. Berlis, T. H. Burke, W. Weber, *J Neurointerv Surg* **2015**, 7, 281; (c) M.
30 Mohlenbruch, C. Herweh, L. Behrens, L. Jestaedt, H. Amiri, P. A. Ringleb, M. Bendszus, M. Pham,
31 *Neuroradiology* **2014**, 56, 389.
- 32 [60] W. J. Jiang, X. T. Xu, M. Jin, B. Du, K. H. Dong, J. P. Dai, *AJNR Am J Neuroradiol* **2007**, 28, 830.
- 33 [61] M. H. Li, Y. D. Li, H. Q. Tan, Q. Y. Luo, Y. S. Cheng, *Radiology* **2009**, 253, 470.
- 34 [62] B. King, S. Vaziri, A. Singla, K. M. Fargen, J. Mocco, *J Neurointerv Surg* **2015**, 7, 905.
- 35 [63] W. J. Lee, C. S. Cho, *J Cerebrovasc Endovasc Neurosurg* **2012**, 14, 247.
- 36 [64] M. F. M. Ten Brinck, J. de Vries, R. Bartels, J. A. Grotenhuis, H. D. Boogaarts, *Neurosurgery* **2018**.
- 37 [65] (a) T. Zhao, W. Y. Zhu, X. Y. Xiong, J. Li, L. Wang, H. Y. Ding, F. Wei, Y. Zhou, Z. L. Gong, S. Y.
38 Cheng, Y. Liu, J. Shuai, Q. W. Yang, *J Stroke Cerebrovasc Dis* **2016**, 25, 2368; (b) M. Levesque, P.
39 Salami, C. Behr, M. Avoli, *Epilepsia* **2013**, 54, 596.
- 40 [66] (a) C. P. Derdeyn, M. I. Chimowitz, M. J. Lynn, D. Fiorella, T. N. Turan, L. S. Janis, J. Montgomery,
41 A. Nizam, B. F. Lane, H. L. Lutsep, S. L. Barnwell, M. F. Waters, B. L. Hoh, J. M. Hourihane, E. I.
42 Levy, A. V. Alexandrov, M. R. Harrigan, D. Chiu, R. P. Klucznik, J. M. Clark, C. G. McDougall, M. D.

- 1 Johnson, G. L. Pride, Jr., J. R. Lynch, O. O. Zaidat, Z. Rumboldt, H. J. Cloft, *Lancet* **2014**, 383, 333; (b)
2 H. M. Kwon, M. J. Lynn, T. N. Turan, C. P. Derdeyn, D. Fiorella, B. F. Lane, J. Montgomery, L. S. Janis,
3 Z. Rumboldt, M. I. Chimowitz, *JAMA Neurol* **2016**, 73, 36.
4
5 **[67] S. O. Safety, P. Benefit, 2004.**
6
7 [68] A. Liu, T. Peng, Z. Qian, Y. Li, C. Jiang, Z. Wu, X. Yang, *J Neuroradiol* **2015**, 42, 298.
8
9 [69] (a) S. R. Dashti, D. Fiorella, M. M. Toledo, Y. Hu, C. G. McDougall, F. C. Albuquerque, *J Neurointerv*
10 *Surg* **2010**, 2, 356; (b) B. Gao, A. M. Malek, *AJNR Am J Neuroradiol* **2010**, 31, E85.
11
12 [70] S. W. Kim, S. O. Sung, K. S. Chae, H. S. Park, S. H. Lee, *J Cerebrovasc Endovasc Neurosurg* **2015**,
13 17, 149.
14
15 [71] (a) C. C. Wang, W. Li, *AJNR Am J Neuroradiol* **2017**, 38, 1163; (b) J. A. Grossberg, R. A. Hanel, G.
16 Dabus, K. Keigher, D. C. Haussen, E. Sauvageau, I. Linfante, D. Gonsales, P. Aguilar Salinas, M.
17 Bouslama, M. Mayich, R. G. Nogueira, D. K. Lopes, *J Neurointerv Surg* **2017**, 9, 1098.
18
19 [72] H. Q. Tan, M. H. Li, Y. D. Li, C. Fang, J. B. Wang, W. Wang, J. Wang, P. L. Zhang, Y. Q. Zhu,
20 *Cerebrovasc Dis* **2011**, 31, 154.
21
22 [73] (a) B. Kis, W. Weber, P. Berlit, D. Kuhne, *Neurosurgery* **2006**, 58, 443; (b) W. Poncyłjusz, P. Bilinski,
23 K. Safranow, J. Baron, M. Zbrozarczyk, M. Jaworski, S. Bereza, T. H. Burke, *J Neurointerv Surg* **2015**,
24 7, 524.
25
26 [74] A. Bose, M. Hartmann, H. Henkes, H. M. Liu, M. M. Teng, I. Szikora, A. Berlis, J. Reul, S. C. Yu, M.
27 Forsting, M. Lui, W. Lim, S. P. Sit, *Stroke* **2007**, 38, 1531.
28
29 [75] (a) K. M. Fargen, B. L. Hoh, B. G. Welch, G. L. Pride, G. Lanzino, A. S. Boulos, J. S. Carpenter, A.
30 Rai, E. Veznedaroglu, A. Ringer, R. Rodriguez-Mercado, P. Kan, A. Siddiqui, E. I. Levy, J. Mocco,
31 *Neurosurgery* **2012**, 71, 239; (b) I. L. Maldonado, P. Machi, V. Costalat, T. Mura, A. Bonafe, *AJNR Am*
32 *J Neuroradiol* **2011**, 32, 131.
33
34 [76] M. Piotin, R. Blanc, L. Spelle, C. Mounayer, R. Piantino, P. J. Schmidt, J. Moret, *Stroke* **2010**, 41, 110.
35
36 [77] M. Shapiro, T. Becske, D. Sahlein, J. Babb, P. K. Nelson, *AJNR Am J Neuroradiol* **2012**, 33, 159.
37
38 [78] C. Islak, N. Kocer, S. Albayram, O. Kizilkilic, O. Uzma, O. Cokyuksel, *AJNR Am J Neuroradiol* **2002**,
39 23, 1589.
40
41 [79] I. Saatci, H. S. Cekirge, M. H. Ozturk, A. Arat, F. Ergungor, Z. Sekerci, E. Senveli, U. Er, S. Turkoglu,
42 O. E. Ozcan, T. Ozgen, *AJNR Am J Neuroradiol* **2004**, 25, 1742.
43
44 [80] M. H. Li, Y. Q. Zhu, C. Fang, W. Wang, P. L. Zhang, Y. S. Cheng, H. Q. Tan, J. B. Wang, *AJNR Am J*
45 *Neuroradiol* **2008**, 29, 1395.
46
47 [81] W. Wang, M. H. Li, Y. D. Li, B. X. Gu, H. T. Lu, *Neurosurgery* **2016**, 79, 794.
48
49 [82] C. Banerjee, M. I. Chimowitz, *Circ Res* **2017**, 120, 502.
50
51 [83] T. M. Sundt, Jr., H. C. Smith, J. K. Campbell, R. E. Vlietstra, R. F. Cucchiara, A. W. Stanson, *Mayo*
52 *Clin Proc* **1980**, 55, 673.
53
54 [84] (a) P. D. Purdy, M. D. Devous, Sr., D. H. Unwin, C. A. Giller, H. H. Batjer, *AJNR Am J Neuroradiol*
55 **1990**, 11, 878; (b) R. Kachel, G. Endert, S. Basche, K. Grossmann, F. H. Glaser, *Cardiovasc Intervent*
56 *Radiol* **1987**, 10, 142; (c) H. Touho, *J Neurosurg* **1995**, 82, 953; (d) R. L. Feldman, L. Trigg, J. Gaudier,
57 J. Galat, *Cathet Cardiovasc Diagn* **1996**, 38, 316.
58
59 [85] O. O. Zaidat, B. F. Fitzsimmons, B. K. Woodward, Z. Wang, M. Killer-Oberpfalzer, A. Wakhloo, R.
60 Gupta, H. Kirshner, J. T. Megerian, J. Lesko, P. Pitzer, J. Ramos, A. C. Castonguay, S. Barnwell, W. S.
61
62
63
64
65

- 1 Smith, D. R. Gress, *Jama* **2015**, 313, 1240.
- 2
- 3 [86] P. Gao, Z. Zhao, D. Wang, J. Wu, Y. Cai, T. Li, W. Wu, H. Shi, W. He, F. Zhu, L. Jiao, F. Ling, *Interv*
- 4 *Neuroradiol* **2015**, 21, 196.
- 5
- 6 [87] G. Benndorf, U. Herbon, W. P. Sollmann, A. Campi, *AJNR Am J Neuroradiol* **2001**, 22, 1844.
- 7
- 8 [88] D. F. Kallmes, R. Hanel, D. Lopes, E. Boccardi, A. Bonafe, S. Cekirge, D. Fiorella, P. Jabbour, E. Levy,
- 9 C. McDougall, A. Siddiqui, I. Szikora, H. Woo, F. Albuquerque, H. Bozorgchami, S. R. Dashti, J. E.
- 10 Delgado Almandoz, M. E. Kelly, R. t. Turner, B. K. Woodward, W. Brinjikji, G. Lanzino, P. Lylyk,
- 11 *AJNR Am J Neuroradiol* **2015**, 36, 108.
- 12
- 13 [89] B. N. Roszelle, L. F. Gonzalez, M. H. Babiker, J. Ryan, F. C. Albuquerque, D. H. Frakes,
- 14 *Neuroradiology* **2013**, 55, 751.
- 15
- 16 [90] A. C. Tsang, A. Y. Tang, W. C. Chung, G. K. Leung, K. W. Chow, *Clin Neuroradiol* **2016**, 26, 477.
- 17
- 18 [91] T. M. Liou, Y. C. Li, *J Biomech* **2008**, 41, 1174.
- 19
- 20 [92] D. Ma, T. M. Dumont, H. Kosukegawa, M. Ohta, X. Yang, A. H. Siddiqui, H. Meng, *Ann Biomed Eng*
- 21 **2013**, 41, 2143.
- 22
- 23 [93] K. Wang, Q. Huang, B. Hong, Z. Li, X. Fang, J. Liu, *Neuroradiology* **2012**, 54, 607.
- 24
- 25 [94] A. K. Wakhloo, P. Lylyk, J. de Vries, C. Taschner, J. Lundquist, A. Biondi, M. Hartmann, I. Szikora,
- 26 L. Pierot, N. Sakai, H. Imamura, N. Sourour, I. Rennie, M. Skalej, O. Beuing, A. Bonafe, F. Mery, F.
- 27 Turjman, P. Brouwer, E. Boccardi, L. Valvassori, S. Derakhshani, M. W. Litzenberg, M. J. Gounis, *AJNR*
- 28 *Am J Neuroradiol* **2015**, 36, 98.
- 29
- 30 [95] R. Kadirvel, Y. H. Ding, D. Dai, I. Rezek, D. A. Lewis, D. F. Kallmes, *Radiology* **2014**, 270, 394.
- 31
- 32 [96] M. G. Safain, M. Roguski, R. S. Heller, A. M. Malek, *Stroke* **2016**, 47, 789.
- 33
- 34 [97] M. Shapiro, E. Raz, T. Becske, P. K. Nelson, *AJNR Am J Neuroradiol* **2014**, 35, 727.
- 35
- 36 [98] (a) O. Petr, W. Brinjikji, H. Cloft, D. F. Kallmes, G. Lanzino, *AJNR Am J Neuroradiol* **2016**, 37, 1106;
- 37 (b) M. Martinez-Galdamez, S. Perez, A. Vega, P. Ruiz, J. L. Caniego, E. Barcena, P. Saura, J. C. Mendez,
- 38 F. Delgado, S. Ortega-Gutierrez, A. Romance, T. Diaz, E. Gonzalez, A. Gil, E. Murias, P. Vega, *J*
- 39 *Neurointerv Surg* **2016**, 8, 396; (c) M. A. Mooney, K. Moon, B. A. Gross, A. F. Ducruet, F. C.
- 40 Albuquerque, *J Neurointerv Surg* **2017**, 9, 571; (d) G. Girdhar, J. Li, L. Kostousov, J. Wainwright, W.
- 41 L. Chandler, *J Thromb Thrombolysis* **2015**, 40, 437; (e) T. Becske, W. Brinjikji, M. B. Potts, D. F.
- 42 Kallmes, M. Shapiro, C. J. Moran, E. I. Levy, C. G. McDougall, I. Szikora, G. Lanzino, H. H. Woo, D.
- 43 K. Lopes, A. H. Siddiqui, F. C. Albuquerque, D. J. Fiorella, I. Saatci, S. H. Cekirge, A. L. Berez, D. J.
- 44 Cher, Z. Berentei, M. Marosfoi, P. K. Nelson, *Neurosurgery* **2017**, 80, 40; (f) M. Martinez-Galdamez,
- 45 S. M. Lamin, K. G. Lagios, T. Liebig, E. F. Ciceri, R. Chapot, L. Stockx, S. Chavda, C. Kabbasch, G.
- 46 Farago, H. Nordmeyer, T. Boulanger, M. Piano, E. P. Boccardi, *J Neurointerv Surg* **2017**, 9, 772; (g) A.
- 47 S. Puri, F. Massari, T. Asai, M. Marosfoi, P. Kan, S. Y. Hou, M. Howk, M. Perras, C. Brooks, F.
- 48 Clarencon, M. J. Gounis, A. K. Wakhloo, *Neuroradiology* **2016**, 58, 267; (h) M. W. Hagen, G. Girdhar,
- 49 J. Wainwright, M. T. Hinds, *J Neurointerv Surg* **2016**, 9, 1006; (i) L. M. Lin, G. P. Colby, M. T. Bender,
- 50 R. Xu, J. Huang, R. J. Tamargo, A. L. Coon, *J Neurointerv Surg* **2017**, 9, 689.
- 51
- 52 [99] (a) J. J. Shankar, D. Tampieri, D. Iancu, M. Cortes, R. Agid, T. Krings, J. Wong, P. Lavoie, J. Ghostine,
- 53 B. Shettar, K. Ritchie, A. Weill, *J Neurointerv Surg* **2016**, 8, 273; (b) J. M. Pumar, A. Banguero, H.
- 54 Cuellar, L. Guimaraens, J. Masso, S. Miralbes, M. Blanco-Ulla, F. Vazquez-Herrero, M. Souto, M.
- 55 Gelabert-Gonzalez, *Neurosurgery* **2017**, 81, 595; (c) S. Maimon, L. Gonen, E. Nossek, I. Strauss, R.
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

- 1 Levite, Z. Ram, *Acta Neurochir (Wien)* **2012**, 154, 979.
- 2
- 3 [100] G. P. Colby, L. M. Lin, J. M. Caplan, B. Jiang, B. Michniewicz, J. Huang, R. J. Tamargo, A. L. Coon,
4 *J Neurointerv Surg* **2016**, 8, 279.
- 5
- 6 [101] (a) J. P. Cruz, T. Marotta, C. O'Kelly, M. Holtmannspotter, G. Saliou, R. Willinsky, T. Krings, R. Agid,
7 *AJNR Am J Neuroradiol* **2014**, 35, 1954; (b) H. Luecking, T. Engelhorn, *AJNR Am J Neuroradiol* **2017**,
8 38, 596; (c) M. A. Mohlenbruch, C. Herweh, L. Jestaedt, S. Stampfl, S. Schonenberger, P. A. Ringleb,
9 M. Bendszus, M. Pham, *AJNR Am J Neuroradiol* **2015**, 36, 1155; (d) F. Drescher, W. Weber, *AJNR Am*
10 *J Neuroradiol* **2017**, 38, 105.
- 11
- 12 [102] Y. B. Fang, W. L. Wen, P. F. Yang, Y. Zhou, Y. N. Wu, B. Hong, Y. Xu, W. Y. Zhao, J. M. Liu, Q. H.
13 Huang, *Clin Neuroradiol* **2017**, 27, 345.
- 14
- 15 [103] (a) R. Morais, B. Mine, P. J. Bruyere, G. Naeije, B. Lubicz, *Neuroradiology* **2017**, 59, 263; (b) S.
16 Fischer, M. Aguilar-Perez, E. Henkes, W. Kurre, O. Ganslandt, H. Bazner, H. Henkes, *AJNR Am J*
17 *Neuroradiol* **2015**, 36, 2082.
- 18
- 19 [104] (a) S. Asnafi, A. Rouchaud, *AJNR Am J Neuroradiol* **2016**, 37, 2287; (b) L. Pierot, J. Klisch, C.
20 Cognard, I. Szikora, B. Mine, K. Kadziolka, V. Sychra, I. Gubucz, A. C. Januel, B. Lubicz, *Neurosurgery*
21 **2013**, 73, 27; (c) B. Mine, L. Pierot, B. Lubicz, *Expert Rev Med Devices* **2014**, 11, 315; (d) B. Lubicz,
22 B. Mine, L. Collignon, D. Brisbois, G. Duckwiler, C. Strother, *AJNR Am J Neuroradiol* **2013**, 34, 1209.
- 23
- 24 [105] M. Piotin, A. Biondi, N. Sourour, C. Mounayer, M. Söderman, T. Andersson, S. Mangiafico, M.
25 Jaworski, R. Anxionnat, P. Goffette, *J Neurointerv Surg* **2015**, 7, A13.2.
- 26
- 27 [106] M. Kojima, K. Irie, K. Masunaga, Y. Sakai, M. Nakajima, M. Takeuchi, T. Fukuda, F. Arai, M. Negoro,
28 *Med Biol Eng Comput* **2016**, 54, 831.
- 29
- 30 [107] G. P. Colby, L. M. Lin, *J Neurointerv Surg* **2016**, 8, 702.
- 31
- 32 [108] B. A. Gross, K. U. Frerichs, *J Neurol Neurosurg PS* **2013**, 84, 244.
- 33
- 34 [109] B. P. Walcott, C. J. Stapleton, O. Choudhri, A. B. Patel, *JAMA Neurol* **2016**, 73, 1002.
- 35
- 36 [110] C. Sadasivan, L. Cesar, J. Seong, A. Rakian, Q. Hao, F. O. Tio, A. K. Wakhloo, B. B. Lieber, *Stroke*
37 **2009**, 40, 952.
- 38
- 39 [111] Y. Ding, D. Dai, *AJNR Am J Neuroradiol* **2016**, 37, 497.
- 40
- 41 [112] Y. Chen, C. Howe, Y. Lee, S. Cheon, W. H. Yeo, Y. Chun, *Sci Rep* **2016**, 6, 23698.
- 42
- 43 [113] D. Fiorella, A. Molyneux, A. Coon, I. Szikora, I. Saatci, F. Baltacioglu, A. Sultan, A. Arthur, *J*
44 *Neurointerv Surg* **2017**, 9, 1191.
- 45
- 46 [114] A. H. Chiu, J. De Vries, C. J. O'Kelly, H. Riina, I. McDougall, J. Tippett, M. Wan, A. L. de Oliveira
47 Manoel, T. R. Marotta, *J Neurosurg* **2018**, 128, 482.
- 48
- 49 [115] T. Becske, D. F. Kallmes, I. Saatci, C. G. McDougall, I. Szikora, G. Lanzino, C. J. Moran, H. H. Woo,
50 D. K. Lopes, A. L. Berez, D. J. Cher, A. H. Siddiqui, E. I. Levy, F. C. Albuquerque, D. J. Fiorella, Z.
51 Berentei, M. Marosfoi, S. H. Cekirge, P. K. Nelson, *Radiology* **2013**, 267, 858.
- 52
- 53 [116] T. Becske, M. B. Potts, M. Shapiro, D. F. Kallmes, W. Brinjikji, I. Saatci, C. G. McDougall, I. Szikora,
54 G. Lanzino, C. J. Moran, H. H. Woo, D. K. Lopes, A. L. Berez, D. J. Cher, A. H. Siddiqui, E. I. Levy, F.
55 C. Albuquerque, D. J. Fiorella, Z. Berentei, M. Marosfoi, S. H. Cekirge, P. K. Nelson, *J Neurosurg* **2017**,
56 127, 81.
- 57
- 58 [117] D. F. Kallmes, W. Brinjikji, E. Boccardi, E. Ciceri, O. Diaz, R. Tawk, H. Woo, P. Jabbour, F.
59 Albuquerque, R. Chapot, A. Bonafe, S. R. Dashti, J. E. Delgado Almandoz, C. Given, 2nd, M. E. Kelly,
60

- 1 D. T. Cross, 3rd, G. Duckwiler, N. Razack, C. J. Powers, S. Fischer, D. Lopes, M. R. Harrigan, D.
2 Huddle, R. t. Turner, O. O. Zaidat, L. Defreyne, V. M. Pereira, S. Cekirge, D. Fiorella, R. A. Hanel, P.
3 Lylyk, C. McDougall, A. Siddiqui, I. Szikora, E. Levy, *Interv Neurol* **2016**, 5, 89.
- 4
5
6 [118] C. A. Taschner, S. Vedantham, *AJNR Am J Neuroradiol* **2017**, 38, 582.
- 7 [119] G. Zhou, M. Su, Y. L. Yin, M. H. Li, *Neurosurg Focus* **2017**, 42, E17.
- 8
9 [120] J. W. Yoon, A. H. Siddiqui, T. M. Dumont, E. I. Levy, L. N. Hopkins, G. Lanzino, D. K. Lopes, R.
10 Moftakhar, J. T. Billingsley, B. G. Welch, A. S. Boulos, J. Yamamoto, R. G. Tawk, A. J. Ringer, R. A.
11 Hanel, *Neurosurgery* **2014**, 75, 419.
- 12
13 [121] R. Navarro, B. L. Brown, A. Beier, N. Ranalli, P. Aldana, R. A. Hanel, *J Neurosurg Pediatr* **2015**, 15,
14 276.
- 15
16 [122] N. Chalouhi, M. Zanaty, A. Whiting, S. Yang, S. Tjoumakaris, D. Hasan, R. M. Starke, S. Hann, C.
17 Hammer, D. Kung, R. Rosenwasser, P. Jabbour, *J Neurosurg* **2015**, 122, 1498.
- 18 [123] J. Raymond, J. C. Gentric, T. E. Darsaut, D. Iancu, M. Chagnon, A. Weill, D. Roy, *J Neurosurg* **2017**,
19 127, 454.
- 20
21 [124] (a) F. Turjman, O. Levrier, X. Combaz, A. Bonafe, A. Biondi, H. Desal, S. Bracard, C. Mounayer, R.
22 Riva, F. Chapuis, L. Huot, X. Armoiry, B. Gory, *Neuroradiology* **2015**, 57, 49; (b) A. S. Turk, 3rd, R. H.
23 Martin, D. Fiorella, J. Mocco, A. Siddiqui, A. Bonafe, *AJNR Am J Neuroradiol* **2014**, 35, 1341.
- 24
25 [125] P. M. Rothwell, A. J. Coull, L. E. Silver, J. F. Fairhead, M. F. Giles, C. E. Lovelock, J. N. Redgrave,
26 L. M. Bull, S. J. Welch, F. C. Cuthbertson, L. E. Binney, S. A. Gutnikov, P. Anslow, A. P. Banning, D.
27 Mant, Z. Mehta, *Lancet* **2005**, 366, 1773.
- 28
29 [126] (a) P. W. Vinny, V. Y. Vishnu, D. Khurana, *N Engl J Med* **2015**, 372, 2363; (b) B. C. Campbell, G. A.
30 Donnan, S. M. Davis, *N Engl J Med* **2013**, 368, 2431; (c) T. G. Jovin, A. Chamorro, E. Cobo, M. A. de
31 Miquel, C. A. Molina, A. Rovira, L. San Roman, J. Serena, S. Abilleira, M. Ribo, M. Millan, X. Urra,
32 P. Cardona, E. Lopez-Cancio, A. Tomasello, C. Castano, J. Blasco, L. Aja, L. Dorado, H. Quesada, M.
33 Rubiera, M. Hernandez-Perez, M. Goyal, A. M. Demchuk, R. von Kummer, M. Gallofre, A. Davalos, *N*
34 *Engl J Med* **2015**, 372, 2296; (d) J. L. Saver, M. Goyal, A. Bonafe, H. C. Diener, E. I. Levy, V. M.
35 Pereira, G. W. Albers, C. Cognard, D. J. Cohen, W. Hacke, O. Jansen, T. G. Jovin, H. P. Mattle, R. G.
36 Nogueira, A. H. Siddiqui, D. R. Yavagal, B. W. Baxter, T. G. Devlin, D. K. Lopes, V. K. Reddy, R. du
37 Mesnil de Rochemont, O. C. Singer, R. Jahan, *N Engl J Med* **2015**, 372, 2285; (e) S. Bracard, X. Ducrocq,
38 J. L. Mas, M. Soudant, C. Oppenheim, T. Moulin, F. Guillemin, *Lancet Neurol* **2016**, 15, 1138; (f) M.
39 Goyal, A. M. Demchuk, B. K. Menon, M. Eesa, J. L. Rempel, J. Thornton, D. Roy, T. G. Jovin, R. A.
40 Willinsky, B. L. Sapkota, D. Dowlatsahi, D. F. Frei, N. R. Kamal, W. J. Montanera, A. Y. Poppe, K. J.
41 Ryckborst, F. L. Silver, A. Shuaib, D. Tampieri, D. Williams, O. Y. Bang, B. W. Baxter, P. A. Burns, H.
42 Choe, J. H. Heo, C. A. Holmstedt, B. Jankowitz, M. Kelly, G. Linares, J. L. Mandzia, J. Shankar, S. I.
43 Sohn, R. H. Swartz, P. A. Barber, S. B. Coutts, E. E. Smith, W. F. Morrish, A. Weill, S. Subramaniam,
44 A. P. Mitha, J. H. Wong, M. W. Lowerison, T. T. Sajobi, M. D. Hill, *N Engl J Med* **2015**, 372, 1019.
- 45
46 [127] J. Gralla, G. Schroth, L. Remonda, K. Nedeltchev, J. Slotboom, C. Brekenfeld, *Stroke* **2006**, 37, 3019.
- 47
48 [128] P. Papanagiotou, C. Roth, S. Walter, S. Behnke, M. Politi, K. Fassbender, A. Haass, W. Reith,
49 *Circulation* **2010**, 121, 2605.
- 50
51 [129] (a) Y. P. Gobin, S. Starkman, G. R. Duckwiler, T. Grobelny, C. S. Kidwell, R. Jahan, J. Pile-Spellman,
52 A. Segal, F. Vinuela, J. L. Saver, *Stroke* **2004**, 35, 2848; (b) W. S. Smith, G. Sung, J. Saver, R. Budzik,
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 G. Duckwiler, D. S. Liebeskind, H. L. Lutsep, M. M. Rymer, R. T. Higashida, S. Starkman, Y. P. Gobin,
2 D. Frei, T. Grobelny, F. Hellinger, D. Huddle, C. Kidwell, W. Koroshetz, M. Marks, G. Nesbit, I. E.
3 Silverman, *Stroke* **2008**, 39, 1205; (c) W. S. Smith, G. Sung, S. Starkman, J. L. Saver, C. S. Kidwell, Y.
4 P. Gobin, H. L. Lutsep, G. M. Nesbit, T. Grobelny, M. M. Rymer, I. E. Silverman, R. T. Higashida, R. F.
5 Budzik, M. P. Marks, M. T. Investigators, *Stroke* **2005**, 36, 1432.
- 6
7
8
9 [130] (a) F. Miteff, K. C. Faulder, A. C. Goh, B. S. Steinfert, C. Sue, T. J. Harrington, *AJNR Am J*
10 *Neuroradiol* **2011**, 32, 1078; (b) A. Mpotsaris, M. Bussmeyer, C. Loehr, M. Oelerich, H. Buchner, W.
11 Weber, *J Neurol Neurosur PS* **2012**, 83, 117; (c) F. Dorn, S. Stehle, H. Lockau, C. Zimmer, T. Liebig,
12 *Cerebrovasc Dis* **2012**, 34, 70; (d) J. W. Choi, H. G. Roh, W. J. Moon, N. R. Kim, S. G. Moon, C. H.
13 Kang, Y. I. Chun, H. S. Kang, *Korean J Radiol* **2011**, 12, 662.
- 14
15
16 [131] A. G. Chartrain, A. J. Awad, J. R. Mascitelli, H. Shoirah, T. J. Oxley, R. Feng, M. Gallitto, R. De
17 Leacy, J. T. Fifi, C. P. Kellner, *Neurosurg Focus* **2017**, 42, E12.
- 18
19 [132] (a) V. M. Pereira, J. Gralla, A. Davalos, A. Bonafe, C. Castano, R. Chapot, D. S. Liebeskind, R. G.
20 Nogueira, M. Arnold, R. Sztajzel, T. Liebig, M. Goyal, M. Besselmann, A. Moreno, G. Schroth, *Stroke*
21 **2013**, 44, 2802; (b) J. L. Saver, R. Jahan, E. I. Levy, T. G. Jovin, B. Baxter, R. G. Nogueira, W. Clark,
22 R. Budzik, O. O. Zaidat, *Lancet* **2012**, 380, 1241; (c) P. Machi, F. Jourdan, D. Ambard, C. Reynaud, K.
23 Lobotesis, M. Sanchez, A. Bonafe, V. Costalat, *J Neurointerv Surg* **2017**, 9, 257.
- 24
25
26 [133] (a) A. T. Rai, Y. Jhadhav, J. Domico, G. R. Hobbs, *Cardiovasc Inter Rad* **2012**, 35, 1332; (b) R. G.
27 Nogueira, H. L. Lutsep, R. Gupta, T. G. Jovin, G. W. Albers, G. A. Walker, D. S. Liebeskind, W. S.
28 Smith, *Lancet* **2012**, 380, 1231.
- 29
30
31 [134] A. L. Kuhn, A. K. Wakhloo, J. D. Lozano, F. Massari, K. De Macedo Rodrigues, M. G. Marosfoi, M.
32 Perras, C. Brooks, M. Howk, D. E. Rex, M. J. Gounis, A. S. Puri, *J Neurointerv Surg* **2017**, 9, 541.
- 33
34 [135] H. Steglich-Arnholm, D. Kondziella, A. Wagner, M. E. Cronqvist, K. Hansen, T. C. Truelsen, L. H.
35 Krarup, J. L. S. Hojgaard, S. Taudorf, H. K. Iversen, D. W. Krieger, M. Holtmannspotter, *AJNR Am J*
36 *Neuroradiol* **2017**, 38, 1356.
- 37
38 [136] A. Alshekhlee, D. J. Pandya, J. English, O. O. Zaidat, N. Mueller, R. Gupta, R. G. Nogueira,
39 *Neurology* **2012**, 79, S126.
- 40
41 [137] M. S. Tenser, A. P. Amar, W. J. Mack, *World Neurosurg* **2011**, 76, S16.
- 42
43 [138] J. Y. Chueh, A. K. Wakhloo, M. J. Gounis, *AJNR Am J Neuroradiol* **2012**, 33, 1998.
- 44
45 [139] V. M. Pereira, J. Gralla, A. Davalos, A. Bonafé, C. Castaño, R. Chapot, D. S. Liebeskind, R. G.
46 Nogueira, M. Arnold, R. Sztajzel, *Stroke* **2013**, 44, 2802.
- 47
48 [140] B. Gory, D. Bresson, I. Kessler, M. L. Perrin, A. Guillaudeau, K. Durand, S. Ponnsonard, C. Couquet,
49 C. Yardin, C. Mounayer, *AJNR Am J Neuroradiol* **2013**, 34, 2192.
- 50
51 [141] N. C. Beadell, H. Lutsep, *Curr Atheroscler Rep* **2013**, 15, 333.
- 52
53 [142] K. J. Wenger, J. Berkefeld, M. Wagner, *Clin Neuroradiol* **2014**, 24, 251.
- 54
55 [143] O. Jansen, J. M. Macho, M. Killer-Oberpfalzer, D. Liebeskind, N. Wahlgren, *Cerebrovasc Dis* **2013**,
56 36, 218.
- 57
58 [144] H. C. Prince, A. J. Saliba, J. Wheeler, S. Bruder, *Ann N Y Acad Sci* **2014**, 1329, 107.
- 59
60 [145] G. W. Peitz, C. A. Sy, R. Grandhi, *Neurosurg Focus* **2017**, 42, E12.
- 61
62 [146] N. Mendonca, A. Flores, J. Pagola, M. Rubiera, D. Rodriguez-Luna, M. A. De Miquel, P. Cardona,
63 H. Quesada, P. Mora, J. Alvarez-Sabin, C. Molina, M. Ribo, *J Neuroimaging* **2014**, 24, 167.
- 64
65

- 1
2 [147] D. Arai, A. Ishii, H. Chihara, H. Ikeda, S. Miyamoto, *J Neurointerv Surg* **2016**, 8, 992.
- 3 [148] (a) R. G. Gonzalez, K. L. Furie, G. V. Goldmacher, W. S. Smith, S. Kamalian, S. Payabvash, G. J.
4 Harris, E. F. Halpern, W. J. Koroshetz, E. C. Camargo, W. P. Dillon, M. H. Lev, *Stroke* **2013**, 44, 3109;
5 (b) J. P. Broderick, Y. Y. Palesch, A. M. Demchuk, S. D. Yeatts, P. Khatri, M. D. Hill, E. C. Jauch, T. G.
6 Jovin, B. Yan, F. L. Silver, R. von Kummer, C. A. Molina, B. M. Demaerschalk, R. Budzik, W. M. Clark,
7 O. O. Zaidat, T. W. Malisch, M. Goyal, W. J. Schonewille, M. Mazighi, S. T. Engelter, C. Anderson, J.
8 Spilker, J. Carrozzella, K. J. Ryckborst, L. S. Janis, R. H. Martin, L. D. Foster, T. A. Tomsick, *N Engl J*
9 *Med* **2013**, 368, 893; (c) *N Engl J Med* **1995**, 333, 1581; (d) W. Hacke, M. Kaste, E. Bluhmki, M.
10 Brozman, A. Davalos, D. Guidetti, V. Larrue, K. R. Lees, Z. Medeghri, T. Machnig, D. Schneider, R.
11 von Kummer, N. Wahlgren, D. Toni, *N Engl J Med* **2008**, 359, 1317.
- 12 [149] (a) A. Ciccone, L. Valvassori, M. Nichelatti, A. Sgoifo, M. Ponzio, R. Sterzi, E. Boccardi, *N Engl J*
13 *Med* **2013**, 368, 904; (b) A. Ciccone, L. Valvassori, *N Engl J Med* **2013**, 368, 2433.
- 14 [150] (a) O. A. Berkhemer, P. S. Fransen, D. Beumer, L. A. van den Berg, H. F. Lingsma, A. J. Yoo, W. J.
15 Schonewille, J. A. Vos, P. J. Nederkoorn, M. J. Wermer, M. A. van Walderveen, J. Staals, J. Hofmeijer,
16 J. A. van Oostayen, G. J. Lycklama a Nijeholt, J. Boiten, P. A. Brouwer, B. J. Emmer, S. F. de Bruijn, L.
17 C. van Dijk, L. J. Kappelle, R. H. Lo, E. J. van Dijk, J. de Vries, P. L. de Kort, W. J. van Rooij, J. S. van
18 den Berg, B. A. van Hasselt, L. A. Aerden, R. J. Dallinga, M. C. Visser, J. C. Bot, P. C. Vroomen, O.
19 Eshghi, T. H. Schreuder, R. J. Heijboer, K. Keizer, A. V. Tielbeek, H. M. den Hertog, D. G. Gerrits, R.
20 M. van den Berg-Vos, G. B. Karas, E. W. Steyerberg, H. Z. Flach, H. A. Marquering, M. E. Sprengers,
21 S. F. Jenniskens, L. F. Beenen, R. van den Berg, P. J. Koudstaal, W. H. van Zwam, Y. B. Roos, A. van
22 der Lugt, R. J. van Oostenbrugge, C. B. Majoie, D. W. Dippel, M. C. Investigators, *N Engl J Med* **2015**,
23 372, 11; (b) B. C. Campbell, P. J. Mitchell, T. J. Kleinig, H. M. Dewey, L. Churilov, N. Yassi, B. Yan,
24 R. J. Dowling, M. W. Parsons, T. J. Oxley, T. Y. Wu, M. Brooks, M. A. Simpson, F. Miteff, C. R. Levi,
25 M. Krause, T. J. Harrington, K. C. Faulder, B. S. Steinfors, M. Priglinger, T. Ang, R. Scroop, P. A. Barber,
26 B. McGuinness, T. Wijeratne, T. G. Phan, W. Chong, R. V. Chandra, C. F. Bladin, M. Badve, H. Rice,
27 L. de Villiers, H. Ma, P. M. Desmond, G. A. Donnan, S. M. Davis, *N Engl J Med* **2015**, 372, 1009; (c)
28 L. A. van den Berg, M. G. Dijkgraaf, O. A. Berkhemer, P. S. Fransen, D. Beumer, H. F. Lingsma, C. B.
29 Majoie, D. W. Dippel, A. van der Lugt, R. J. van Oostenbrugge, W. H. van Zwam, Y. B. Roos, *N Engl J*
30 *Med* **2017**, 376, 1341.
- 31 [151] (a) R. G. Nogueira, A. P. Jadhav, D. C. Haussen, A. Bonafe, R. F. Budzik, P. Bhuvra, D. R. Yavagal,
32 M. Ribo, C. Cognard, R. A. Hanel, C. A. Sila, A. E. Hassan, M. Millan, E. I. Levy, P. Mitchell, M. Chen,
33 J. D. English, Q. A. Shah, F. L. Silver, V. M. Pereira, B. P. Mehta, B. W. Baxter, M. G. Abraham, P.
34 Cardona, E. Veznedaroglu, F. R. Hellinger, L. Feng, J. F. Kirmani, D. K. Lopes, B. T. Jankowitz, M. R.
35 Frankel, V. Costalat, N. A. Vora, A. J. Yoo, A. M. Malik, A. J. Furlan, M. Rubiera, A. Aghaebrahim, J.
36 M. Olivot, W. G. Tekle, R. Shields, T. Graves, R. J. Lewis, W. S. Smith, D. S. Liebeskind, J. L. Saver,
37 T. G. Jovin, D. T. Investigators, *N Engl J Med* **2018**, 378, 11; (b) G. W. Albers, M. P. Marks, S. Kemp,
38 S. Christensen, J. P. Tsai, S. Ortega-Gutierrez, R. A. McTaggart, M. T. Torbey, M. Kim-Tenser, T. Leslie-
39 Mazwi, A. Sarraj, S. E. Kasner, S. A. Ansari, S. D. Yeatts, S. Hamilton, M. Mlynash, J. J. Heit, G.
40 Zaharchuk, S. Kim, J. Carrozzella, Y. Y. Palesch, A. M. Demchuk, R. Bammer, P. W. Lavori, J. P.
41 Broderick, M. G. Lansberg, D. Investigators, *N Engl J Med* **2018**, 378, 708.
- 42 [152] T. Simard, B. Hibbert, F. D. Ramirez, M. Froeschl, Y. X. Chen, E. R. O'Brien, *Can J Cardiol* **2014**,

- 1 30, 35.
2
3 [153] (a) N. F. Kassell, T. Sasaki, A. R. Colohan, G. Nazar, *Stroke* **1985**, 16, 562; (b) N. M. Alotaibi, G.
4 Lanzino, *J Neurointerv Surg* **2013**, 5, 413; (c) B. A. Gross, R. Du, *World Neurosurg* **2012**, 78, 300.
5
6 [154] N. W. Dorsch, M. T. King, *J Clin Neurosci* **1994**, 1, 19.
7
8 [155] B. Weir, M. Grace, J. Hansen, C. Rothberg, *J Neurosurg* **1978**, 48, 173.
9
10 [156] P. M. Rist, M. C. Jimenez, S. S. Tworoger, F. B. Hu, J. E. Manson, Q. Sun, K. M. Rexrode, *J Stroke*
11 *Cerebrovasc Dis* **2018**, 27, 68.
12
13 [157] A. Dilraj, J. H. Botha, V. Rambiritch, R. Miller, J. R. van Dellen, *Neurosurgery* **1992**, 31, 42.
14
15 [158] M. Sabri, J. Ai, B. Knight, A. Tariq, H. Jeon, X. Shang, P. A. Marsden, R. Loch Macdonald, *J Cereb*
16 *Blood Flow Metab* **2011**, 31, 190.
17
18 [159] M. J. McGirt, J. R. Lynch, R. Blessing, D. S. Warner, A. H. Friedman, D. T. Laskowitz, *Neurosurgery*
19 **2002**, 51, 1128.
20
21 [160] I. Siasios, E. Z. Kapsalaki, K. N. Fountas, *Neurol Res Int* **2013**, 2013, 571328.
22
23 [161] (a) J. C. Durrant, H. E. Hinson, *Curr Neurol Neurosci Rep* **2015**, 15, 521; (b) G. Dabus, R. G.
24 Nogueira, *Interv Neurol* **2013**, 2, 30.
25
26 [162] I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G. M. Sangiorgi, G. Stankovic, F. Airolidi, A. Chieffo,
27 M. Montorfano, M. Carlino, I. Michev, N. Corvaja, C. Briguori, U. Gerckens, E. Grube, A. Colombo,
28 *JAMA* **2005**, 293, 2126.
29
30 [163] G. Lemesle, C. Delhaye, L. Bonello, A. de Labriolle, R. Waksman, A. Pichard, *Arch Cardiovasc Dis*
31 **2008**, 101, 769.
32
33 [164] (a) M. Awata, J. Kotani, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, S. Nanto,
34 M. Hori, S. Nagata, *Circulation* **2007**, 116, 910; (b) D. E. Cutlip, D. S. Baim, K. K. Ho, J. J. Popma, A.
35 J. Lansky, D. J. Cohen, J. P. Carrozza, Jr., M. S. Chauhan, O. Rodriguez, R. E. Kuntz, *Circulation* **2001**,
36 103, 1967.
37
38 [165] A. V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M. C. John, H. K. Gold, R. Virmani,
39 *Circulation* **2007**, 115, 2435.
40
41 [166] D. R. Holmes, Jr., D. J. Kereiakes, S. Garg, P. W. Serruys, G. J. Dehmer, S. G. Ellis, D. O. Williams,
42 T. Kimura, D. J. Moliterno, *J Am Coll Cardiol* **2010**, 56, 1357.
43
44 [167] D. J. Kereiakes, J. K. Choo, J. J. Young, T. M. Broderick, *Rev Cardiovasc Med* **2004**, 5, 9.
45
46 [168] A. Chieffo, E. Bonizzoni, D. Orlic, G. Stankovic, R. Rogacka, F. Airolidi, G. W. Mikhail, M.
47 Montorfano, I. Michev, M. Carlino, A. Colombo, *Circulation* **2004**, 109, 2732.
48
49 [169] M. H. Jeong, W. G. Owen, M. E. Staab, S. S. Srivatsa, G. Sangiorgi, M. Stewart, D. R. Holmes, Jr.,
50 R. S. Schwartz, *Cathet Cardiovasc Diagn* **1996**, 38, 38.
51
52 [170] (a) S. Rinfret, D. E. Cutlip, P. T. Katsiyannis, K. K. Ho, D. J. Cohen, J. P. Carrozza, Jr., R. J. Laham,
53 *Catheter Cardiovasc Interv* **2002**, 57, 24; (b) D. Hasdai, K. N. Garratt, D. R. Holmes, Jr., P. B. Berger,
54 R. S. Schwartz, M. R. Bell, *J Am Coll Cardiol* **1996**, 28, 361.
55
56 [171] P. Wenaweser, C. Rey, F. R. Eberli, M. Togni, D. Tuller, S. Locher, A. Remondino, C. Seiler, O. M.
57 Hess, B. Meier, S. Windecker, *Eur Heart J* **2005**, 26, 1180.
58
59 [172] M. L. Adix, I. A. Kaminsky, I. S. Choi, *J Neurointerv Surg* **2017**, 9, 686.
60
61 [173] L. Rangel-Castilla, S. A. Munich, N. Jaleel, M. C. Cress, C. Krishna, A. Sonig, K. V. Snyder, A. H.
62 Siddiqui, E. I. Levy, *J Neurosurg* **2017**, 126, 1064.
63
64
65

- 1 [174] (a) S. Kawaguchi, T. Sakaki, H. Iwahashi, K. Fujimoto, J. Iida, H. Mishima, N. Nishikawa,
2 *Cerebrovasc Dis* **2006**, 22, 402; (b) R. M. Hupperts, J. Lodder, E. P. Heuts-van Raak, F. Kessels, *Brain*
3 **1994**, 117 (Pt 4), 825; (c) J. H. Yang, H. Y. Choi, H. S. Nam, S. H. Kim, S. W. Han, J. H. Heo,
4 *Cerebrovasc Dis* **2007**, 24, 445.
5
6 [175] Y. Q. Zhu, M. H. Li, C. Fang, H. Q. Tan, W. Wang, P. L. Zhang, Y. S. Cheng, J. B. Wang, L. T. Ma, *J*
7 *Endovasc Ther* **2010**, 17, 55.
8
9 [176] S. Fuke, K. Maekawa, K. Kawamoto, H. Saito, T. Sato, T. Hioka, T. Ohe, *Circ J* **2007**, 71, 220.
10
11 [177] P. R. Moreno, I. F. Palacios, M. N. Leon, J. Rhodes, V. Fuster, J. T. Fallon, *Am J Cardiol* **1999**, 84,
12 462.
13
14 [178] (a) A. Farb, D. K. Weber, F. D. Kolodgie, A. P. Burke, R. Virmani, *Circulation* **2002**, 105, 2974; (b)
15 M. A. Costa, D. I. Simon, *Circulation* **2005**, 111, 2257.
16
17 [179] H. C. Lowe, S. N. Oesterle, L. M. Khachigian, *J Am Coll Cardiol* **2002**, 39, 183.
18
19 [180] C. Indolfi, G. Esposito, E. Di Lorenzo, A. Rapacciuolo, A. Feliciello, A. Porcellini, V. E.
20 Avvedimento, M. Condorelli, M. Chiariello, *Circulation* **1995**, 92, 1230.
21
22 [181] F. G. Welt, C. Rogers, *Arterioscl Throm Vas* **2002**, 22, 1769.
23
24 [182] V. Evangelista, S. Manarini, S. Rotondo, N. Martelli, R. Polischuk, J. L. McGregor, G. de Gaetano,
25 C. Cerletti, *Blood* **1996**, 88, 4183.
26
27 [183] D. I. Simon, Z. Chen, H. Xu, C. Q. Li, J. Dong, L. V. McIntire, C. M. Ballantyne, L. Zhang, M. I.
28 Furman, M. C. Berndt, J. A. Lopez, *J Exp Med* **2000**, 192, 193.
29
30 [184] T. G. Diacovo, S. J. Roth, J. M. Buccola, D. F. Bainton, T. A. Springer, *Blood* **1996**, 88, 146.
31
32 [185] D. I. Simon, Z. Dhen, P. Seifert, E. R. Edelman, C. M. Ballantyne, C. Rogers, *J Clin Invest* **2000**, 105,
33 293.
34
35 [186] N. A. Scott, *Adv Drug Deliv Rev* **2006**, 58, 358.
36
37 [187] (a) P. Libby, S. J. Warner, R. N. Salomon, L. K. Birinyi, *N Engl J Med* **1988**, 318, 1493; (b) N. A.
38 Scott, G. D. Cipolla, C. E. Ross, B. Dunn, F. H. Martin, L. Simonet, J. N. Wilcox, *Circulation* **1996**, 93,
39 2178.
40
41 [188] (a) A. Abizaid, R. Kornowski, G. S. Mintz, M. K. Hong, A. S. Abizaid, R. Mehran, A. D. Pichard, K.
42 M. Kent, L. F. Satler, H. Wu, J. J. Popma, M. B. Leon, *J Am Coll Cardiol* **1998**, 32, 584; (b) S. Mittal,
43 D. L. Weiss, J. W. Hirshfeld, Jr., D. M. Kolansky, H. C. Herrmann, *Am J Cardiol* **1997**, 80, 711.
44
45 [189] H. Narita, S. Chen, K. Komori, K. Kadomatsu, *J Vasc Surg* **2008**, 47, 1322.
46
47 [190] (a) J. H. Martin, B. D. Yahata, J. M. Hundley, J. A. Mayer, T. A. Schaedler, T. M. Pollock, *Nature*
48 **2017**, 549, 365; (b) C. M. Campos, T. Muramatsu, J. Iqbal, Y. J. Zhang, Y. Onuma, H. M. Garcia-Garcia,
49 M. Haude, P. A. Lemos, B. Warnack, P. W. Serruys, *Int J Mol Sci* **2013**, 14, 24492; (c) M. J. Patel, S. S.
50 Patel, N. S. Patel, N. M. Patel, *Acta Pharm* **2012**, 62, 473; (d) H. Li, T. Liu, M. Wang, D. Zhao, A. Qiao,
51 X. Wang, J. Gu, Z. Li, B. Zhu, *Biomed Eng Online* **2017**, 16, 13; (e) K. M. Lekshmi, H. L. Che, C. S.
52 Cho, I. K. Park, *Chonnam Med J* **2017**, 53, 14; (f) R. Waksman, R. Erbel, C. Di Mario, J. Bartunek, B.
53 de Bruyne, F. R. Eberli, P. Erne, M. Haude, M. Horrigan, C. Ilsley, D. Bose, H. Bonnier, J. Koolen, T. F.
54 Luscher, N. J. Weissman, P.-A. Investigators, *JACC Cardiovasc Interv* **2009**, 2, 312; (g) I. Larrabide, A.
55 J. Geers, H. G. Morales, M. L. Aguilar, D. A. Rufenacht, *J Neurointerv Surg* **2015**, 7, 272; (h) J. M.
56 Jimenez, P. F. Davies, *Ann Biomed Eng* **2009**, 37, 1483; (i) Q. Lin, X. Ding, F. Qiu, X. Song, G. Fu, J.
57 Ji, *Biomaterials* **2010**, 31, 4017; (j) Q. K. Guo, Z. Q. Lu, J. Y. Wang, T. Li, *J Mater Sci Mater Med* **2011**,

- 22, 1615; (k) W. Lin, L. Qin, H. Qi, D. Zhang, G. Zhang, R. Gao, H. Qiu, Y. Xia, P. Cao, X. Wang, W. Zheng, *Acta Biomater* **2017**, 54, 454; (l) T. Koppara, K. Sakakura, E. Pacheco, Q. Cheng, X. Zhao, E. Acampado, A. V. Finn, M. Barakat, L. Maillard, J. Ren, M. Deshpande, F. D. Kolodgie, M. Joner, R. Virmani, *Int J Cardiol* **2016**, 222, 217; (m) T. J. Gundert, S. C. Shadden, A. R. Williams, B. K. Koo, J. A. Feinstein, J. F. Ladisa, Jr., *Ann Biomed Eng* **2011**, 39, 1423; (n) R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilesley, D. Bose, J. Koolen, T. F. Luscher, N. Weissman, R. Waksman, P.-A. Investigators, *Lancet* **2007**, 369, 1869; (o) M. W. Hagen, G. Girdhar, J. Wainwright, M. T. Hinds, *J Neurointerv Surg* **2017**, 9, 1006.
- [191] S. Morlacchi, F. Migliavacca, *Ann Biomed Eng* **2013**, 41, 1428.
- [192] C. Indolfi, E. V. Avvedimento, E. Di Lorenzo, G. Esposito, A. Rapacciuolo, P. Giuliano, D. Grieco, L. Cavuto, A. M. Stingone, I. Ciullo, G. Condorelli, M. Chiariello, *Nat Med* **1997**, 3, 775.
- [193] C. Indolfi, E. Stabile, C. Coppola, A. Gallo, C. Perrino, G. Allevato, L. Cavuto, D. Torella, E. Di Lorenzo, G. Troncone, A. Feliciello, E. Avvedimento, M. Chiariello, *Circ Res* **2001**, 88, 319.
- [194] C. Indolfi, E. V. Avvedimento, A. Rapacciuolo, E. Di Lorenzo, G. Esposito, E. Stabile, A. Feliciello, E. Mele, P. Giuliano, G. Condorelli, et al., *Nat Med* **1995**, 1, 541.
- [195] A. Curcio, D. Torella, C. Indolfi, *Circ J* **2011**, 75, 1287.
- [196] R. Wessely, A. Schomig, A. Kastrati, *J Am Coll Cardiol* **2006**, 47, 708.
- [197] C. Gareri, S. De Rosa, C. Indolfi, *Circ Res* **2016**, 118, 1170.
- [198] (a) R. Ji, Y. Cheng, J. Yue, J. Yang, X. Liu, H. Chen, D. B. Dean, C. Zhang, *Circ Res* **2007**, 100, 1579; (b) E. Raitoharju, L. P. Lyytikainen, M. Levula, N. Oksala, A. Mennander, M. Tarkka, N. Klopp, T. Illig, M. Kahonen, P. J. Karhunen, R. Laaksonen, T. Lehtimaki, *Atherosclerosis* **2011**, 219, 211.
- [199] K. E. King, V. P. Iyemere, P. L. Weissberg, C. M. Shanahan, *J Biol Chem* **2003**, 278, 11661.
- [200] X. Liu, Y. Cheng, J. Yang, L. Xu, C. Zhang, *J Mol Cell Cardiol* **2012**, 52, 245.
- [201] X. Liu, Y. Cheng, S. Zhang, Y. Lin, J. Yang, C. Zhang, *Circ Res* **2009**, 104, 476.
- [202] E. Merlet, F. Atassi, R. K. Motiani, N. Mougnot, A. Jacquet, S. Nadaud, T. Capiod, M. Trebak, A. M. Lompre, A. Marchand, *Cardiovasc Res* **2013**, 98, 458.
- [203] Y. Cheng, X. Liu, J. Yang, Y. Lin, D. Z. Xu, Q. Lu, E. A. Deitch, Y. Huo, E. S. Delphin, C. Zhang, *Circ Res* **2009**, 105, 158.
- [204] (a) K. R. Cordes, N. T. Sheehy, M. P. White, E. C. Berry, S. U. Morton, A. N. Muth, T. H. Lee, J. M. Miano, K. N. Ivey, D. Srivastava, *Nature* **2009**, 460, 705; (b) J. M. Boucher, S. M. Peterson, S. Urs, C. Zhang, L. Liaw, *J Biol Chem* **2011**, 286, 28312.
- [205] L. Elia, M. Quintavalle, J. Zhang, R. Contu, L. Cossu, M. V. Latronico, K. L. Peterson, C. Indolfi, D. Catalucci, J. Chen, S. A. Courtneidge, G. Condorelli, *Cell Death Differ* **2009**, 16, 1590.
- [206] M. Xin, E. M. Small, L. B. Sutherland, X. Qi, J. McAnally, C. F. Plato, J. A. Richardson, R. Bassel-Duby, E. N. Olson, *Genes Dev* **2009**, 23, 2166.
- [207] (a) Q. Liu, H. Fu, F. Sun, H. Zhang, Y. Tie, J. Zhu, R. Xing, Z. Sun, X. Zheng, *Nucleic Acids Res* **2008**, 36, 5391; (b) Y. S. Wang, H. Y. Wang, Y. C. Liao, P. C. Tsai, K. C. Chen, H. Y. Cheng, R. T. Lin, S. H. Juo, *Cardiovasc Res* **2012**, 95, 517.
- [208] R. Bakhshi, A. Darbyshire, J. E. Evans, Z. You, J. Lu, A. M. Seifalian, *Colloids Surf B Biointerfaces* **2011**, 86, 93.
- [209] D. Giacoppo, G. Gargiulo, P. Aruta, P. Capranzano, C. Tamburino, D. Capodanno, *BMJ* **2015**, 351,

- 1 h5392.
2
3 [210] Y. Zhu, K. Yang, R. Cheng, Y. Xiang, T. Yuan, Y. Cheng, B. Sarmiento, W. Cui, *Mater Today* **2017**,
4 20, 516.
5
6 [211] G. La Torre, U. Romeo, G. Iarocci, O. Brugnoletti, L. Semyonov, A. Galanakis, E. Barbato, *Ann*
7 *Stomatol (Roma)* **2015**, 5, 131.
8
9 [212] E. Barbato, W. Wijns, *JACC Cardiovasc Interv* **2015**, 8, 280.
10
11 [213] (a) K. Tsuji-Takayama, T. Inoue, Y. Ijiri, T. Otani, R. Motoda, S. Nakamura, K. Orita, *Biochem*
12 *Biophys Res Commun* **2004**, 323, 86; (b) G. G. Toth, A. Ntalianis, Y. Ntarladimas, M. de Booij, O. De
13 Winter, E. Barbato, B. Pilet, C. Van Mieghem, W. Wijns, B. De Bruyne, *Catheter Cardiovasc Interv*
14 **2015**, 85, 1173.
15
16 [214] (a) C. Di Mario, H. Griffiths, O. Goktekin, N. Peeters, J. Verbist, M. Bosiers, K. Deloose, B. Heublein,
17 R. Rohde, V. Kasese, C. Ilsley, R. Erbel, *J Interv Cardiol* **2004**, 17, 391; (b) P. Zartner, R. Cesnjevar, H.
18 Singer, M. Weyand, *Catheter Cardiovasc Interv* **2005**, 66, 590; (c) D. Schranz, P. Zartner, I. Michel-
19 Behnke, H. Akinturk, *Catheter Cardiovasc Interv* **2006**, 67, 671; (d) R. Erbel, C. Di Mario, J. Bartunek,
20 J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilsley, D. Bose,
21 J. Koolen, T. F. Luscher, N. Weissman, R. Waksman, P.-A. Investigators, *Lancet* **2007**, 369, 1869; (e) A.
22 Schomig, A. Dibra, S. Windecker, J. Mehilli, J. Suarez de Lezo, C. Kaiser, S. J. Park, J. J. Goy, J. H.
23 Lee, E. Di Lorenzo, J. Wu, P. Juni, M. E. Pfisterer, B. Meier, A. Kastrati, *J Am Coll Cardiol* **2007**, 50,
24 1373; (f) M. Haude, H. Ince, A. Abizaid, R. Toelg, P. A. Lemos, C. von Birgelen, E. H. Christiansen, W.
25 Wijns, F. J. Neumann, C. Kaiser, E. Eeckhout, S. T. Lim, J. Escaned, H. M. Garcia-Garcia, R. Waksman,
26 *Lancet* **2016**, 387, 31.
27
28 [215] (a) J. Wang, Y. He, M. F. Maitz, B. Collins, K. Xiong, L. Guo, Y. Yun, G. Wan, N. Huang, *Acta*
29 *Biomater* **2013**, 9, 8678; (b) E. Zhang, F. Shen, *Mater Sci Eng C Mater Biol Appl* **2015**, 52, 37.
30
31 [216] (a) S. F. Fischerauer, T. Kraus, X. Wu, S. Tangl, E. Sorantin, A. C. Hanzi, J. F. Loffler, P. J. Uggowitzer,
32 A. M. Weinberg, *Acta Biomater* **2013**, 9, 5411; (b) P. Lu, L. Cao, Y. Liu, X. Xu, X. Wu, *J Biomed Mater*
33 *Res B Appl Biomater* **2011**, 96, 101.
34
35 [217] E. Mostaed, M. Hashempour, A. Fabrizi, D. Dellasega, M. Bestetti, F. Bonollo, M. Vedani, *J Mech*
36 *Behav Biomed Mater* **2014**, 37, 307.
37
38 [218] M. Greger, R. Kocich, L. Cizek, *J Achievements Mat M* **2007**, 20, 447.
39
40 [219] Y. Li, C. Wen, D. Mushahary, R. Sravanthi, N. Harishankar, G. Pande, P. Hodgson, *Acta Biomater*
41 **2012**, 8, 3177.
42
43 [220] G. Song, A. Atrens, X. Wu, B. Zhang, *Corros Sci* **1998**, 40, 1769.
44
45 [221] B. Ratna Sunil, T. S. Sampath Kumar, U. Chakkingal, V. Nandakumar, M. Doble, V. Devi Prasad, M.
46 Raghunath, *Mater Sci Eng C Mater Biol Appl* **2016**, 59, 356.
47
48 [222] (a) M. Peuster, P. Wohlsein, M. Bruggmann, M. Ehlerding, K. Seidler, C. Fink, H. Brauer, A. Fischer,
49 G. Hausdorf, *Heart* **2001**, 86, 563; (b) C. Wu, H. Qiu, X. Y. Hu, Y. M. Ruan, Y. Tian, Y. Chu, X. L. Xu,
50 L. Xu, Y. Tang, R. L. Gao, *Chin Med J (Engl)* **2013**, 126, 4752.
51
52 [223] P. K. Bowen, J. Drelich, J. Goldman, *Adv Mater* **2013**, 25, 2577.
53
54 [224] E. Mostaed, M. Sikora-Jasinska, A. Mostaed, S. Loffredo, A. G. Demir, B. Previtali, D. Mantovani,
55 R. Beanland, M. Vedani, *J Mech Behav Biomed Mater* **2016**, 60, 581.
56
57 [225] (a) H. Takatsuki, S. Komatsu, R. Sano, Y. Takada, T. Tsuji, *Cancer Res* **2004**, 64, 6065; (b) E.
58
59
60
61
62
63
64
65

- 1 Tenekecioglu, C. Bourantas, M. Abdelghani, Y. Zeng, R. C. Silva, H. Tateishi, Y. Sotomi, Y. Onuma, M.
2 Yilmaz, P. W. Serruys, *Expert Rev Med Devices* **2016**, 13, 271.
- 3
4 [226] (a) X. Zhu, R. D. Braatz, *J Biomed Mater Res A* **2015**, 103, 2269; (b) J. B. McClain, W. C. Carlyle,
5 D. J. Donohoe, J. A. Ormiston, *Minerva Cardioangiol* **2016**.
- 6
7 [227] K. Nishimiya, Y. Matsumoto, H. Uzuka, T. Ogata, M. Hirano, T. Shindo, Y. Hasebe, R. Tsuburaya, T.
8 Shiroto, J. Takahashi, K. Ito, H. Shimokawa, *JACC Cardiovasc Interv* **2016**, 9, 281.
- 9
10 [228] C. S. Yang, H. C. Wu, J. S. Sun, H. M. Hsiao, T. W. Wang, *ACS Appl Mater Interfaces* **2013**, 5, 10985.
- 11
12 [229] U. Westedt, M. Wittmar, M. Hellwig, P. Hanefeld, A. Greiner, A. K. Schaper, T. Kissel, *J Control*
13 *Release* **2006**, 111, 235.
- 14
15 [230] T. Tsuji, H. Nakamura, A. Hirata, T. Yamamoto, *Anat Rec A Discov Mol Cell Evol Biol* **2004**, 279,
16 729.
- 17
18 [231] T. Tsuji, M. Yoshinaga, S. Togami, T. Douchi, Y. Nagata, *Acta Obstet Gynecol Scand* **2004**, 83, 586.
- 19
20 [232] M. Joner, G. Nakazawa, A. V. Finn, S. C. Quee, L. Coleman, E. Acampado, P. S. Wilson, K. Skorija,
21 Q. Cheng, X. Xu, H. K. Gold, F. D. Kolodgie, R. Virmani, *J Am Coll Cardiol* **2008**, 52, 333.
- 22
23 [233] G. G. Stefanini, P. W. Serruys, S. Silber, A. A. Khattab, R. J. van Geuns, G. Richardt, P. E. Buszman,
24 H. Kelbaek, A. J. van Boven, S. H. Hofma, A. Linke, V. Klauss, W. Wijns, C. Macaya, P. Garot, C. Di
25 Mario, G. Manoharan, R. Kornowski, T. Ischinger, A. L. Bartorelli, P. Gobbens, S. Windecker, *J Am*
26 *Coll Cardiol* **2011**, 57, 2221.
- 27
28 [234] G. J. Wilson, B. A. Huibregtse, D. E. Pennington, K. D. Dawkins, *EuroIntervention* **2012**, 8, 250.
- 29
30 [235] J. Iqbal, S. Verheye, A. Abizaid, J. Ormiston, T. de Vries, L. Morrison, S. Toyloy, P. Fitzgerald, S.
31 Windecker, P. W. Serruys, *EuroIntervention* **2015**, 11.
- 32
33 [236] S. Banerjee, *Cardiol Ther* **2013**, 2, 17.
- 34
35 [237] Y. Zhang, F. Chen, T. Muramatsu, B. Xu, Z. Li, J. Ge, Q. He, Z. Yang, S. Li, L. Wang, H. Wang, B.
36 He, K. Li, G. Qi, T. Li, H. Zeng, J. Peng, T. Jiang, Q. Zeng, J. Zhu, G. Fu, C. V. Bourantas, P. W. Serruys,
37 Y. Huo, *Chin Med J (Engl)* **2014**, 127, 2153.
- 38
39 [238] D. J. Kereiakes, L. A. Cannon, J. A. Ormiston, M. A. Turco, T. Mann, G. J. Mishkel, T. McGarry, H.
40 Wang, P. Underwood, K. D. Dawkins, *Am J Cardiol* **2011**, 108, 828.
- 41
42 [239] M. Chen, X. G. Wang, B. Zheng, H. Y. Peng, X. Y. Zhang, B. Zhang, Y. Huo, *Chin Med J (Engl)*
43 **2012**, 125, 4083.
- 44
45 [240] B. Xu, K. Dou, Y. Yang, S. Lv, L. Wang, H. Wang, Z. Li, L. Wang, Y. Chen, Y. Huo, W. Li, A. J.
46 Kirtane, R. Gao, *EuroIntervention* **2012**, 8, 796.
- 47
48 [241] B. Chevalier, P. W. Serruys, S. Silber, E. Garcia, H. Suryapranata, K. Hauptmann, W. Wijns, G.
49 Schuler, F. Fath-Ordoubadi, S. Worthley, L. Thuesen, I. Meredith, M. Bressers, H. Nagai, D. Paunovic,
50 *EuroIntervention* **2007**, 2, 426.
- 51
52 [242] N. Reifart, K. E. Hauptmann, A. Rabe, D. Enayat, K. Giokoglu, *EuroIntervention* **2010**, 6, 356.
- 53
54 [243] S. Oikawa, M. Minegishi, K. Endo, W. Kawashima, K. Suzuki, H. Shimizu, *Vox Sang* **2016**, 111, 437.
- 55
56 [244] G. B. Danzi, B. Chevalier, P. Urban, F. Fath-Ordoubadi, D. Carrie, M. Wiemer, A. Serra, W. Wijns,
57 P. Kala, A. Stabile, J. G. Ruigomez, D. Sagic, P. Laanmets, G. Strupp, N. West, D. Paunovic, N.
58 Investigators, *EuroIntervention* **2012**, 8, 109.
- 59
60 [245] I. Buyschaert, E. Sanidas, T. Hasegawa, B. K. Koo, Y. Honda, P. J. Fitzgerald, S. Verheye, *Catheter*
61 *Cardiovasc Interv* **2014**, 84, 1062.
- 62
63
64
65

- 1
2 [246] J. Waltenberger, J. Brachmann, J. van der Heyden, G. Richardt, O. Frobert, M. Seige, A. Erglis, W.
3 Dewilde, M. Winkens, C. Hegeler-Molkewehrum, N. Klein, S. Hoffmann, B.-I. Investigators,
4 *EuroIntervention* **2016**, 11, 1106.
5
6 [247] G. F. Attizzani, H. G. Bezerra, D. Chamie, Y. Fujino, A. M. Spognardi, J. R. Stanley, H. Yamamoto,
7 E. Mehanna, W. Wang, W. C. Carlyle, J. B. McClain, M. A. Costa, *J Invasive Cardiol* **2012**, 24, 560.
8
9 [248] L. Zhang, J. Yuan, G. Liu, J. P. Zhong, Y. H. Yin, Q. She, L. Su, Z. Y. Ling, Y. Q. Chen, *J Interv*
10 *Cardiol* **2012**, 25, 604.
11
12 [249] R. Diletti, H. M. Garcia-Garcia, C. V. Bourantas, R. J. van Geuns, N. M. Van Mieghem, P. Agostoni,
13 T. Muramatsu, V. Farooq, R. Spencer, J. De Schepper, M. Pomeranz, P. Stella, P. W. Serruys,
14 *EuroIntervention* **2013**, 9, 125.
15
16 [250] E. Barbato, S. Salinger-Martinovic, D. Sagic, B. Beleslin, M. Vrolix, A. N. Neskovic, N. Jagic, S.
17 Verheye, Z. Mehmedbegovic, W. Wijns, *EuroIntervention* **2015**, 11, 541.
18
19 [251] P. Urban, A. Abizaid, B. Chevalier, S. Greene, I. Meredith, M. C. Morice, S. Pocock, *Am Heart J*
20 **2013**, 165, 704.
21
22 [252] C. Moretti, V. Lolli, G. Perona, M. C. Vignolini, K. Cabiale, M. Falzone, M. Galloni, *EuroIntervention*
23 **2012**, 7, 1087.
24
25 [253] L. O. Jensen, M. Maeng, A. Kaltoft, P. Thyssen, H. H. Hansen, M. Bottcher, J. F. Lassen, L. R.
26 Krussel, K. Rasmussen, K. N. Hansen, L. Pedersen, S. P. Johnsen, H. T. Soerensen, L. Thuesen, *J Am*
27 *Coll Cardiol* **2007**, 50, 463.
28
29 [254] (a) H. K. Kim, M. H. Jeong, *Chonnam Med J* **2012**, 48, 141; (b) J. Pache, A. Kastrati, J. Mehilli, H.
30 Schuhlen, F. Dotzer, J. Hausleiter, M. Fleckenstein, F. J. Neumann, U. Sattelberger, C. Schmitt, M.
31 Muller, J. Dirschinger, A. Schomig, *J Am Coll Cardiol* **2003**, 41, 1283; (c) A. Kastrati, J. Mehilli, J.
32 Dirschinger, F. Dotzer, H. Schuhlen, F. J. Neumann, M. Fleckenstein, C. Pfafferott, M. Seyfarth, A.
33 Schomig, *Circulation* **2001**, 103, 2816; (d) K. Kolandaivelu, R. Swaminathan, W. J. Gibson, V. B.
34 Kolachalama, K. L. Nguyen-Ehrenreich, V. L. Giddings, L. Coleman, G. K. Wong, E. R. Edelman,
35 *Circulation* **2011**, 123, 1400.
36
37 [255] D. Sun, Y. Zheng, T. Yin, C. Tang, Q. Yu, G. Wang, *J Biomed Mater Res A* **2014**, 102, 1625.
38
39 [256] B. Chevalier, S. Silber, S. J. Park, E. Garcia, G. Schuler, H. Suryapranata, J. Koolen, K. E. Hauptmann,
40 W. Wijns, M. C. Morice, D. Carrie, G. A. van Es, H. Nagai, D. Detiege, D. Paunovic, P. W. Serruys, N.
41 C. Investigators, *Circ Cardiovasc Interv* **2009**, 2, 188.
42
43 [257] (a) J. Legutko, W. Zasada, G. L. Kaluza, G. Heba, L. Rzeszutko, J. Jakala, J. Dragan, A. Klecha, D.
44 Giszterowicz, W. Dobrowolski, L. Partyka, S. Jayaraman, D. Dudek, *Indian Heart J* **2013**, 65, 388; (b)
45 Q. Dang, Y. J. Li, L. Gao, Z. Jin, L. X. Gou, *Chin Med J (Engl)* **2012**, 125, 3393.
46
47 [258] Y. Onuma, P. W. Serruys, L. E. Perkins, T. Okamura, N. Gonzalo, H. M. Garcia-Garcia, E. Regar, M.
48 Kamberi, J. C. Powers, R. Rapoza, H. van Beusekom, W. van der Giessen, R. Virmani, *Circulation* **2010**,
49 122, 2288.
50
51 [259] S. Brugaletta, J. H. Heo, H. M. Garcia-Garcia, V. Farooq, R. J. van Geuns, B. de Bruyne, D. Dudek,
52 P. C. Smits, J. Koolen, D. McClean, C. Dorange, S. Veldhof, R. Rapoza, Y. Onuma, N. Bruining, J. A.
53 Ormiston, P. W. Serruys, *Eur Heart J* **2012**, 33, 1325.
54
55 [260] R. J. Cottone, G. L. Thatcher, S. P. Parker, L. Hanks, D. A. Kujawa, S. M. Rowland, M. Costa, R. S.
56 Schwartz, Y. Onuma, *EuroIntervention* **2009**, 5 Suppl F, F65.
57
58
59
60
61
62
63
64
65



- 1
2 [261] (a) W. Kurre, M. Aguilar-Perez, S. Fischer, G. Arnold, E. Schmid, H. Bazner, H. Henkes, *Cardiovasc*
3 *Intervent Radiol* **2015**, 38, 583; (b) J. H. Lee, S. M. Jo, K. D. Jo, M. K. Kim, S. Y. Lee, S. H. You, *J*
4 *Cerebrovasc Endovasc Neurosurg* **2013**, 15, 85; (c) S. Park, D. G. Lee, W. J. Chung, D. H. Lee, D. C.
5 Suh, *Neurointervention* **2013**, 8, 9.
6
7 [262] M. Marosfoi, F. Clarencon, E. T. Langan, R. M. King, O. W. Brooks, T. Tamura, J. M. Wainwright,
8 M. J. Gounis, S. Vedantham, A. S. Puri, *J Neurointerv Surg* **2018**, 10, 406.
9
10 [263] (a) S. Bailey, P. Seifert, B. Huibregtse, B. Poff, *Cardiovascular Revascularization Medicine* **2006**, 7,
11 90; (b) A. C. Strang, M. L. Knetsch, L. H. Koole, R. J. de Winter, A. C. van der Wal, C. J. de Vries, P. P.
12 Tak, R. J. Bissoendial, E. S. Stroes, J. I. Rotmans, *PLoS One* **2015**, 10, e0122836.
13
14 [264] (a) P. Tack, J. Victor, P. Gemmel, L. Annemans, *Biomed Eng Online* **2016**, 15, 115; (b) U.
15 Jammalamadaka, K. Tappa, *J Funct Biomater* **2018**, 9, pii: E22.
16
17 [265] J. J. Lewandowski, M. Seifi, *Annu Rev Mater Res* **2016**, 46.
18
19 [266] K. V. Venkatesh, V. V. Nandini, *J Indian Prosthodont Soc* **2013**, 13, 389.
20
21 [267] D. Mitsouras, P. Liacouras, A. Imanzadeh, A. A. Giannopoulos, T. Cai, K. K. Kumamaru, E. George,
22 N. Wake, E. J. Caterson, B. Pomahac, V. B. Ho, G. T. Grant, F. J. Rybicki, *Radiographics* **2015**, 35,
23 1965.
24
25 [268] H. W. Kang, S. J. Lee, I. K. Ko, C. Kengla, J. J. Yoo, A. Atala, *Nat Biotechnol* **2016**, 34, 312.
26
27 [269] S. S. G. Kaplas, Munish, *Adv Manufacturing Pr* **2009**, 24, 1405.
28
29 [270] E. MacDonald, R. Wicker, *Science* **2016**, 353, aaf2093.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



[Click here to access/download](#)

Supporting Information

20180919-Review Paper - clear version.docx





Click here to access/download
Supporting Information
All License.zip



















[Click here to access/download](#)

Production Data

Fig 8.tif





Click here to access/download
Production Data
Fig 9.tif





Click here to access/download
Production Data
Graphic abstract.tif

